US20100144603A1 - Methods and uses thereof of prosaposin - Google Patents

Methods and uses thereof of prosaposin Download PDF

Info

Publication number
US20100144603A1
US20100144603A1 US12/640,788 US64078809A US2010144603A1 US 20100144603 A1 US20100144603 A1 US 20100144603A1 US 64078809 A US64078809 A US 64078809A US 2010144603 A1 US2010144603 A1 US 2010144603A1
Authority
US
United States
Prior art keywords
psap
cancer
protein
tsp
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/640,788
Other languages
English (en)
Inventor
Randolph Watnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Medical Center Corp
Original Assignee
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center Corp filed Critical Childrens Medical Center Corp
Priority to US12/640,788 priority Critical patent/US20100144603A1/en
Assigned to CHILDREN'S MEDICAL CENTER CORPORATION reassignment CHILDREN'S MEDICAL CENTER CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WATNICK, RANDOLPH
Publication of US20100144603A1 publication Critical patent/US20100144603A1/en
Priority to EP10842644.6A priority patent/EP2513137B1/fr
Priority to CA2822026A priority patent/CA2822026C/fr
Priority to US13/516,511 priority patent/US10267799B2/en
Priority to EP21170894.6A priority patent/EP3925670A1/fr
Priority to PCT/US2010/061007 priority patent/WO2011084685A2/fr
Priority to AU2010339794A priority patent/AU2010339794B2/en
Priority to EP18153550.1A priority patent/EP3366695B1/fr
Priority to AU2016222333A priority patent/AU2016222333B2/en
Priority to AU2018201649A priority patent/AU2018201649B2/en
Priority to US16/379,193 priority patent/US10670600B2/en
Priority to AU2020200165A priority patent/AU2020200165B2/en
Priority to US16/867,560 priority patent/US20210102945A1/en
Priority to AU2021261975A priority patent/AU2021261975B2/en
Priority to AU2023219929A priority patent/AU2023219929A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Definitions

  • the present invention relates to methods for treating of tumor metastasis, as well as methods for preventing, inhibiting, and predicting tumor metastasis.
  • the invention further relates to treating angiogenesis-dependent diseases and disorders, screening methods for tumor cell derived anti-angiogenic factors and methods for cancer prognosis evaluation.
  • metastasis The spread of cancer cells from a primary tumor site to distant organs is known as metastasis.
  • the progression of human cancer to metastatic disease is the major contributing factor to its lethality. Metastasis has been considered one of the most interesting aspects of the pathogenesis of cancer.
  • Cancer tumor metastasis, or otherwise known as metastatic disease is responsible for most therapeutic failures in treating the disease, as patients succumb to the multiple tumor growth, accounting for more than 90% of human cancer related deaths. See, for example, Cancer, A Comprehensive Treatise, F. F. Becker (editor), Volume 4, Chapter 3, Plenum Press, New York, 1975.
  • a tumor In order for a tumor to form lethal metastases it must acquire the ability to carry out a complex series of steps. These steps include: gaining access to the vasculature or lymphatic system (intravasation), surviving during transit, exiting the vascular or lymphatic channels (extravasation), and proliferating at the metastatic site.
  • steps include: gaining access to the vasculature or lymphatic system (intravasation), surviving during transit, exiting the vascular or lymphatic channels (extravasation), and proliferating at the metastatic site.
  • angiogenesis not only allows tumors to grow beyond the size limitation imposed by the diffusion limit of oxygen, but also provides a conduit through which the tumor cells can travel and colonize distant organs (Brown et al., 1999; MacDougall and Matrisian, 1995). Once the tumor cells arrive at the metastatic site they must also induce neovascularization in order to grow beyond a microscopic size. It has been documented, however, that metastatic colonies can remain in a microscopic or dormant state and not progress beyond this size for months or years following the initial colonization (Fidler, 2003).
  • tumor growth and proliferation is not governed solely by cell-autonomous processes and that the conditions present in the microenvironment that permitted proliferation at the primary site can not exist at the metastatic site.
  • the ability of a tumor to communicate with the surrounding stroma, composed of fibroblasts, immune cells and endothelium must be reestablished upon arrival at the metastatic site.
  • One way in which heterotopic tumor-stromal signaling could affect tumor growth is through the regulation of the production and secretion of pro- and anti-angiogenic proteins by the surrounding stromal fibroblasts and endothelial cells.
  • tumor cells can stimulate the expression of the pro-angiogenic protein VEGF in the surrounding stroma (Dong et al., 2004; Fukumura et al., 1998).
  • VEGF pro-angiogenic protein
  • Tsp-1 Thrombospondin
  • Embodiments of the present invention are based on the discovery that such dormant, non- or weakly metastatic tumor cells secrete a protein, prosaposin (Psap), that stimulates the expression of thrombospondin (Tsp-1) in the surrounding environment of the tumor cells, namely the stroma comprised of fibroblasts and endothelial cells.
  • Tsp-1 is also activated in distant environments such as the lymph nodes.
  • Tsp-1 is a potent endogenous anti-angiogenic factor, and its activation by the tumor-derived protein is via the activation of the tumor suppressor p53.
  • P53 is a transcription activator of Tsp-1.
  • the present discovery is contrary to current scientific literature wherein the prosaposin and its metabolite derivative saposin C is a potent growth factor for promoting prostate cancer.
  • embodiments of the present invention provide methods of treating an angiogenesis-dependent disease or disorder, the method comprises administering to a subject in need of treatment thereof, a therapeutically effective amount of Psap protein or a vector comprising a nucleic acid encoding Psap protein and a pharmaceutically acceptable carrier.
  • a method of inhibiting the recurrence of an angiogenesis-dependent disease or disorder comprises administering to a subject in need thereof, a therapeutically effective amount of a Psap protein or a vector comprising the nucleic acid encoding a Psap protein, and a pharmaceutically acceptable carrier.
  • Angiogenesis-dependent disease or disorder to which the methods described herein are applicable include, for example, cancer, psoriasis, age-related macular degeneration, thyroid hyperplasia, preeclampsia, rheumatoid arthritis, Alzheimer's disease, obesity, pleura effusion, atherosclerosis, endometriosis, diabetic/other retinopathies, neovascular glaucoma, age-related macular degeneration, hemangiomas, and corneal neovascularization.
  • the age-related macular degeneration is wet macular degeneration.
  • the invention provides a method for inhibiting metastasis of cancer in a subject diagnosed with cancer, the method comprises administering to the individual, a therapeutically effective amount of Psap protein or a vector comprising a nucleic acid encoding Psap protein and a pharmaceutically acceptable carrier.
  • the subject can be diagnosed with a benign or malignant cancer.
  • the invention provides a method of inhibiting recurrence of cancer in a subject diagnosed with cancer, the method comprises administering to a subject in need thereof, a therapeutically effective amount of a Psap protein or a vector comprising the nucleic acid encoding a Psap protein, and a pharmaceutically acceptable carrier.
  • the subject can be diagnosed with a benign or malignant cancer.
  • the invention provides for a method of preventing cancer development in a subject at risk of cancer development, the method comprises administering to a subject in need thereof, a therapeutically effective amount of a Psap protein or a vector comprising the nucleic acid encoding a Psap protein, and a pharmaceutically acceptable carrier.
  • the subject can have a family history of cancer, e.g. early on-set colon rectal cancer, and/or carry some gene mutations that are shown to be associated with certain cancers, e.g. BRAC1 and BRAC2 for breast cancer.
  • the invention provides for a method of preventing cancer metastasis in a subject previously diagnosed with cancer, the method comprises administering to a subject in need thereof, a therapeutically effective amount of a Psap protein or a vector comprising the nucleic acid encoding a Psap protein, and a pharmaceutically acceptable carrier.
  • the subject can be diagnosed with a benign or malignant cancer.
  • the invention provides for a method of preventing development of cancer malignancy in a subject previously diagnosed with cancer, the method comprises administering to a subject in need thereof, a therapeutically effective amount of a Psap protein or a vector comprising the nucleic acid encoding a Psap protein, and a pharmaceutically acceptable carrier.
  • the subject can be diagnosed with a benign or malignant cancer.
  • the Psap protein is saposin A (SEQ. ID. No. 13) or smaller functional fragments and variants thereof.
  • the smaller functional fragment or variant of saposin A is at least 10 amino acid residues and is capable of activating p53 and inducing Tsp-1 expression.
  • the smaller functional fragment or variant of saposin A is fused to other protein or portions thereof, or conjugated with a polymer, wherein the fragment or variant can still activate p53 and induce Tsp-1 expression.
  • the other protein or portions thereof or polymer can be transferrin, Fc portion of IgG, albumin, and PEG, for the purpose of improving serum half-life in vivo.
  • Other examples include to thioredoxin and six histidine tag for facilitating recombinant protein expression and purification; and to angiotensin and endostatin for improving anti-angiogenic activity.
  • Psap protein can be administered after the detection and diagnosis of an angiogenesis-dependent disease or disorder, such as cancer.
  • the treatment can be administered in conjunction with chemotherapy, radiation therapy, a cytostatic agent, an anti-VEGF agent and/or a p53 reactivation agent.
  • An embodiment of the invention also provides a method for prognostic evaluation of an individual diagnosed with cancer, the method comprises determining the level of Psap expression in a tumor sample from an individual diagnosed with cancer and comparing the level to a reference Psap level, e.g. from a non-tumor sample from the individual.
  • a level of Psap in the tumor sample lower than a reference Psap level indicates that there is an increased likelihood of cancer metastasis and/or recurrence of neoplastic disease, and thus a poor prognosis.
  • the method described herein further comprises: (a) determining the level of Tsp-1 expression in the tumor stroma, and comparing the level to a reference Tsp-1 level.
  • the level of Tsp-1 in the tumor stroma are lower than the reference Tsp-1 level, there is an increased likelihood of cancer metastasis and/or recurrence of neoplastic disease, and thus a poor prognosis.
  • the invention provides a method of treating an individual diagnosed with cancer, the method comprises: (a) determining a level of Psap in a tumor sample from said individual; (b) comparing the Psap level determined in (a) with a reference Psap level; and (c) when the Psap level determined in (a) is lower than 95% of said reference Psap level, administering a therapeutically effective amount of Psap protein or a vector comprising a nucleic acid encoding Psap protein and a pharmaceutically acceptable carrier.
  • the treatment can be administered in conjunction with chemotherapy, radiation therapy, a cytostatic agent, an anti-VEGF agent, an anti-angiogenesis factor, and/or a p53 reactivation agent.
  • the invention provides a method of screening and identifying tumor secreted factors that promote angiogenesis and metastasis, the method comprises: (a) contacting fibroblasts and/or endothelial cells with a cancer cell derived factor; (b) determining the levels of angiogenic growth factors and/or angiogenesis inhibitors; and (c) comparing with reference levels of angiogenic growth factors and/or angiogenesis inhibitor of fibroblasts and/or endothelial cells not treated with cancer cell derived factors. A decrease in the level of an angiogenesis inhibitor and/or an increase in the level of angiogenic growth factors in comparison to the respective reference levels indicate that the cancer cell derived factor contains factors that promote angiogenesis and metastasis.
  • the invention provides a method of screening for a compound, drug, or small molecule that inhibits angiogenesis and metastasis, the method comprises: (a) contacting fibroblasts and/or endothelial cells with a cancer cell derived factor in the presence of a compound, drug, or small molecule; (b) determining the levels of angiogenic growth factors and angiogenesis inhibitors; and (c) comparing with reference levels of angiogenic growth factors and angiogenesis inhibitors of fibroblasts and/or endothelial cells not treated with a compound, drug, or small molecule.
  • An increase in the level of an angiogenesis inhibitor and/or a decrease in the level of an angiogenic growth factor in comparison to the respective reference levels indicate that the compound, drug, or small molecule can inhibit angiogenesis and metastasis.
  • the invention provides a method of screening for a compound, drug, or small molecule that promotes anti-angiogenic and anti-metastatic activities, the method comprises: (a) contacting fibroblasts and/or endothelial cells with a compound; (b) determining the expression levels of p53 and Tsp-1; and (c) comparing with reference levels of p53 and Tsp-1 not treated with the compound, drug, or small molecule. Increases in the levels of p53 and Tsp-1 expression in the treated cells indicate that the tested compound has anti-angiogenesis and anti-metastatic activity.
  • the invention provides a method of predicting the metastatic tissue specificity of cancer cells in an individual diagnosed with cancer, the method comprises: (a) contacting test fibroblasts and/or endothelial cells with a cancer cell derived factor; (b) determining the levels of Tsp-1, Psap, and/or c-Myc in the fibroblasts and/or endothelial cells; and (c) comparing to the reference levels of Tsp-1, Psap, and c-Myc of fibroblasts and/or endothelial cells not treated with cancer cell derived factors; wherein repression of Tsp-1 and Psap expressions, and/or an activation of c-Myc expression in the tested fibroblasts and/or endothelial cells indicate that the cancer cells are likely to metastasize to the type of tissue from which tested fibroblast and/or endothelial cells had originated.
  • the invention provides a method for determining the likelihood of metastasis an individual diagnosed with cancer, the method comprises: (a) determining the level of Psap expression in a sample from an individual diagnosed with cancer; and (b) comparing to a reference level of Psap.
  • the reference Psap level is that of a Psap expression in a normal individual not diagnosed with any cancer or an average Psap expression level of a group of normal individuals not diagnosed with any cancer.
  • the invention provides a method for prognostic evaluation in an individual diagnosed with cancer, the method comprises: (a) determining the level of Psap expression in a sample from an individual diagnosed with cancer at a first time point; (b) determining the level of Psap expression in a sample from an individual diagnosed with cancer at a second time point, the first time point being before the second time point; and (c) comparing the levels of Psap from the time points with a reference Psap level. When the level of Psap at the second time point becomes lower than the reference Psap level, the cancer has likely spread.
  • the sample is blood, preferably platelet, serum or plasma.
  • the invention provides an isolated chimeric polypeptide comprising a first portion and a second portion, wherein the first portion is saposin A (SEQ. ID. No. 13) or a functional fragment thereof, and the second portion comprises an amino acid sequence or a polymer that enhances the serum half life of the first portion.
  • the second portion is not a Psap protein, and the first portion is capable of activating p53 and inducing Tsp-1 expression.
  • the invention provides an isolated chimeric polypeptide comprising a first portion and a second portion, wherein the first portion is saposin A (SEQ. ID. No. 13) or a functional fragment thereof, and the second portion comprises an amino acid sequence that facilitates protein expression and/or purification of the first portion.
  • the second portion is not a Psap protein, and the first portion is capable of activating p53 and inducing Tsp-1 expression.
  • the invention provides an isolated chimeric polypeptide comprising a first portion and a second portion, wherein the first portion is saposin A (SEQ. ID. No. 13) or a functional fragment thereof, and the second portion is a therapeutic molecule.
  • the second portion is not a Psap protein, and the first portion is capable of activating p53 and inducing Tsp-1 expression.
  • FIG. 1A ELISA of VEGF secretion by PC3 and PC3M-LN4 (LN4) prostate cancer cells and MDA-MB-231 (231) and MDA-MET (MET) breast cancer cells cultured under 20% oxygen (normoxia) or 1% oxygen (hypoxia) Error bars represent SEM (Standard Error of Mean) of 3 independent experiments performed in triplicate).
  • FIG. 1B Western blot analysis of Tsp-1, c-Myc, and ⁇ -Actin expression by PC3, PC3M-LN4 (LN4), MDA-MB-231 (231) and MDA-MET (MET) cells.
  • FIG. 1C Western blot analysis of phosphorylated c-Myc (phospho-Myc) and ⁇ -Actin expression by PC3, PC3M-LN4 (LN4), MDA-MB-231 (231) and MDA-MET (MET) cells.
  • FIG. 1D Western blot analysis of Tsp-1, c-Myc, and ⁇ -Actin expression in prostate tumors formed by PC3 (P1-P5) and PC3M-LN4 (L1-L4).
  • FIG. 1E ELISA of VEGF secretion from murine stromal cells present in PC3 (P1-P5) and PC3M-LN4 (L1-L5) prostate tumors.
  • FIG. 1F Tabular depiction of Tsp-1 expression in primary tumors formed by PC3 and PC3M-LN4 and the incidence of metastases in mice bearing these tumors.
  • FIG. 2A Western blot analyses of Tsp-1, c-Myc, and ⁇ -Actin expression in prostate fibroblasts that were untreated ( ⁇ ) or treated with the conditioned media from PC3, or PC3M-LN4 (LN4) cells.
  • FIG. 2B Western blot analyses of Tsp-1 and ⁇ -Actin expression in normal human mammary fibroblasts that were treated with the conditioned media (CM) from MDA-MB-231 (231) and MDA-MET (MET) cells or co-cultured in transwell apparati (TW) with MDA-MB-231 (231) and MDA-MET (MET) cells.
  • CM conditioned media
  • MET MDA-MET
  • TW transwell apparati
  • FIG. 2C Western blot analyses of ELISA of VEGF secretion from prostate fibroblasts treated with the conditioned media from PC3, PC3M-LN4 (LN4) cells. Error bars represent SEM (Standard Error of Mean) of 3 independent experiments performed in triplicate.
  • FIG. 2D Western blot analyses of Tsp-1 and ⁇ -Actin expression in WI38 lung fibroblasts and bone marrow stromal cells that were untreated ( ⁇ ) or treated with the conditioned media from PC or PC3M-LN4 (LN4) cells.
  • FIG. 2E Western blot analyses of Tsp-1 and ⁇ -Actin expression in WI38 lung fibroblasts and bone marrow stromal cells that were untreated ( ⁇ ) or treated with the conditioned media from MDA-MB-231 (231) or MDA-MET (MET) cells.
  • FIG. 3A Western blot analyses of Tsp-1 and ⁇ -actin expression in prostate fibroblasts treated with fractions of conditioned media from PC3 cells eluted from a Cu2+-heparin column.
  • FIG. 3B Western blot analyses of Tsp-1 and ⁇ -actin expression in WI38 lung fibroblasts treated with fractions of conditioned media from PC3 cells eluted from a Cu2+-heparin column.
  • FIG. 3C Western blot analyses of Psap and ⁇ -actin expression in PC3 and PC3M-LN4 (LN4) cells.
  • FIG. 3D Western blot analyses of Psap and ⁇ -actin expression in MDA-MB-231 (231), MDA-Bone (Bone), MDA-Brain (Brain), MDA-MB-LM2-4 (LM), MDA-MET (MET), MDA-MB-231-1833 (1833) and MDA-MB-231-4175 (4175) cells.
  • FIG. 3E Western blot analyses of Psap, Tsp-1 and ⁇ -actin expression in PC3 cells that were transduced with five shRNA constructs for Psap or an empty pLKO vector (V).
  • FIG. 3F Western blot analyses of Tsp-1 and ⁇ -actin expression in prostate fibroblasts treated with conditioned media (CM) from pLKO vector transduced PC3, and PC3 cells transduced with 5 shRNA sequences specific for Psap.
  • CM conditioned media
  • FIG. 3G Western blot analyses of Tsp-1 and ⁇ -actin expression in WI 38 lung fibroblasts treated with conditioned media (CM) from pLKO vector transduced PC3, and PC3 cells transduced with 5 shRNA sequences specific for Psap.
  • CM conditioned media
  • FIG. 3H Western blot analyses of Psap and ⁇ -actin expression in PC3M-LN4 cells that were uninfected (LN4), infected with control pLNCX vector (V) or pLNCX-Psap (Psap).
  • FIG. 3I Western blot analyses of Tsp-1 and ⁇ -actin expression in untreated prostate fibroblasts ( ⁇ ), or treated with conditioned media from PC3M-LN4 (LN4), PC3M-LN4-pLNCX (V) or PC3M-LN4-Psap (Psap) cells.
  • FIG. 3J Western blot analyses of Tsp-1 and ⁇ -actin expression in untreated prostate fibroblasts ( ⁇ ), or treated with 5 ⁇ g of purified recombinant human Psap.
  • FIG. 4A Western blot analyses of p53 and ⁇ -Actin expression in prostate tissue from non-tumor bearing mice (N), PC3 prostate tumor tissue (P) and PC3M-LN4 tumor tissue (L).
  • FIG. 4B Western blot analyses of p53 and ⁇ -Actin expression in normal lymph node tissue (N), lymph node tissue from PC3 tumor bearing mice (P) and lymph node metastases from PC3M-LN4 tumor bearing mice (L).
  • FIG. 4C Western blot analyses of p53 and ⁇ tilde over ( ⁇ ) ⁇ Actin expression in prostate fibroblasts (PrF) that were untreated ( ⁇ ) or treated with the conditioned media from PC3 or PC3M-LN4 (LN4) cells;
  • FIG. 4D Western blot analyses of Tsp-1, p53 and ⁇ tilde over ( ⁇ ) ⁇ Actin expression in prostate fibroblasts containing empty pLKO vector, (V) or p53 shRNA that were untreated ( ⁇ ) or treated with the conditioned media from PC3 or PC3M-LN4 (LN4) cells.
  • FIG. 4E Western blot analyses of Tsp-1, p53 and ⁇ -Actin expression in WI38 lung fibroblasts containing empty pLKO vector (V) or p53 shRNA that were untreated ( ⁇ ) or treated with the conditioned media from PC3 or PC3M-LN4 (LN4).
  • FIG. 4F Western blot analyses of p53 and ⁇ -actin expression in prostate fibroblasts treated with conditioned media (CM) from pLKO vector transduced PC3, and PC3 cells transduced with 5 shRNA sequences specific for Psap.
  • CM conditioned media
  • FIG. 4G Western blot analyses of p53 and ⁇ -actin expression in WI 38 lung fibroblasts treated with conditioned media (CM) from pLKO vector transduced PC3, and PC3 cells transduced with 5 shRNA sequences specific for Psap.
  • CM conditioned media
  • FIG. 4H Western blot analyses of p53 and ⁇ -actin expression in untreated prostate fibroblasts ( ⁇ ), or treated with conditioned media from PC3M-LN4 (LN4), PC3M-LN4-pLNCX (V) or PC3M-LN4-Psap (Psap) cells.
  • FIG. 4I Western blot analyses of p53 and ⁇ -actin expression in untreated prostate fibroblasts ( ⁇ ), or treated with 5 ⁇ g of purified recombinant human Psap.
  • FIG. 5A Western blot analyses of Psap and ⁇ -actin expression in pBabepuro vector transduced PC3 or PC3-MycER cells that were untreated ( ⁇ ) or treated with 4-HT (+).
  • FIG. 5B Western blot analyses of Tsp-1, p53 and ⁇ -actin expression in prostate fibroblasts and WI 38 lung fibroblasts that were untreated ( ⁇ ), treated with 4-HT alone ( ⁇ /+) or treated with the conditioned media from 4-HT treated PC3-MycER cells (MycER/+).
  • FIG. 5C Western blot analyses of Myc and ⁇ -actin expression in wild-type PC3M-LN4 cells ( ⁇ ), as well as PC3M-LN4 cells transduced with empty pLKO vector (V) or transduced with pLKO lentivirus specifying two different shRNA sequences for Myc (sh1, sh2).
  • FIG. 5D Western blot analyses of Psap and ⁇ -actin expression in PC3M-LN4 cells containing empty pLKO vector (V) or expressing two different shRNA sequences for Myc (sh1, sh2).
  • FIG. 5E Western blot analyses of Tsp-1, p53 and ⁇ -actin expression in prostate fibroblasts and WI 38 lung fibroblasts that were untreated ( ⁇ ) or treated with the conditioned media from PC3M-LN4-shMyc cells (sh1).
  • FIG. 6A Plot of tumor mass of PC3shPsap tumors and PC3pLKO tumors from SCID mice.
  • FIG. 6B Western blot analyses of Tsp-1, p53, Psap and ⁇ -actin expression in normal prostate (N) and prostate tumor formed by PC3pLKO (P) and PC3shPsap (sh) tumor bearing mice.
  • FIG. 6C Western blot analyses of Tsp-1, p53 and ⁇ -actin expression in normal lymph node (N) and lymph node from PC3pLKO (P) or PC3shPsap (sh) tumor bearing mice.
  • FIG. 6D Western blot analyses of Tsp-1, p53 and ⁇ -actin expression in normal lung tissue (N) and lung tissue from PC3pLKO (P) or PC3shPsap (sh) tumor bearing mice.
  • FIG. 7B Relative mRNA expression levels of Psap in localized human prostate tumors and metastatic human prostate tumors. Each bar represents the mean of each group. The difference in Psap expression between localized and metastatic prostate tumors has a p-value ⁇ 0.0001 based on one way ANOVA.
  • FIG. 7C Relative mRNA expression levels of Tsp-1 in localized human prostate tumors and metastatic human prostate tumors. Each bar represents the mean of each group. The difference in Tsp-1 expression between localized and metastatic prostate tumors has a p-value ⁇ 0.0001 based on one way ANOVA.
  • FIG. 8 Western blot analysis of the expression levels of Thrombospondin-2 (Tsp-2), murine endostatin (m-endostatin) and ⁇ -actin protein in normal mouse prostate (N) tumors formed by PC3 cells (P), and tumor formed by PC3shPsap cells (sh).
  • Tsp-2 Thrombospondin-2
  • m-endostatin murine endostatin
  • ⁇ -actin protein in normal mouse prostate
  • N tumors formed by PC3 cells
  • FIG. 9 Western blot analysis of Tsp-1 and ⁇ -Actin expression in normal human dermal fibroblasts (NHDF), normal human astrocytes (NHA), normal human prostate fibroblasts (prostate) and normal human mammary fibroblasts that were untreated ( ⁇ ) or treated with the conditioned media from PC3, PC3M-LN4 (LN4), MDA-MB-231 (231), MDA-MB-231-4175 (MDA-L), MDA-MB-1833 (MDA-B) or MDA-MET (MET) cells as denoted.
  • NHDF normal human dermal fibroblasts
  • NHA normal human astrocytes
  • prostate normal human prostate fibroblasts
  • LN4 normal human mammary fibroblasts
  • FIG. 10 Western blot analysis of murine Tsp-2 and ⁇ -Actin expression in normal lung tissue ( ⁇ ) and lungs of wild-type and tsp-1 ⁇ / ⁇ C57B1/6J mice injected with 1 ⁇ 10 6 Lewis Lung Carcinoma cells and treated with serum free RPMI media (L+M), conditioned media from empty vector containing PC3pLKO (L+P) or PC3shPsap cells (L+S).
  • FIG. 12 Saposin A stimulates Tsp-1.
  • pCMV expression vector
  • FIG. 13 Psap expression in plasma from colorectal cancer patients. Western blot analysis of prosaposin and Tsp-1 protein levels in plasma samples from normal patients, and colon cancer patients with low grade (T1, N0, M0), high grade without metastases (3 T3, 1 T4 N0, M0) and high grade with metastasis (3 T3, 1 T4, N1, M1).
  • FIG. 14A Correlation of endogenous expression of Prosaposin and biochemical failure in patients after radical prostatectomy.
  • FIG. 14B Kaplan Meyer plot of survival of patients from the series of men described above as a function of time elapsed subsequent to radical prostatectomy and endogenous expression of Prosaposin.
  • FIG. 15 Western blot analysis of prosaposin in serum of normal patients (N) and colon cancer patients with low grade carcinoma (L), high grade carcinoma without metastases (H) and high grade carcinoma with metastases (M), loading was normalized to total protein.
  • FIG. 16A Survival curves for endometrial cancer patients with high and low prosaposin expression.
  • FIG. 16B Survival curves for prostate cancer patients with high and low prosaposin expression.
  • FIG. 17A Western blot analysis of Tsp-1 and ⁇ -actin expression in prostate fibroblasts that were untreated ( ⁇ ) or treated with conditioned media from PC3 cells alone or in combination with RAP.
  • FIG. 17B Western blot analysis of Tsp-1, p53 and ⁇ -actin expression in prostate fibroblasts that were untreated ( ⁇ ) or treated with conditioned media from PC3 cells alone or in combination with the PKC inhibitor Gö 6983 (PKCi).
  • FIG. 18 Plot of mRNA levels of LRP1 and LRP2 (relative to GAPDH) in WI-38 lung fibroblasts and WI-38 lung fibroblasts transduced with lentiviral constructs specifying 2 shRNA sequences specific for LRP1 (LRP1a and LRP1b) and LRP2 (LRP2a and LRP2b).
  • FIG. 19 Western blot analysis of Tsp-1 and actin in WI-38 lung fibroblasts silenced for LRP1 (shLRP1) or LRP2 (shLRP2) that were untreated ( ⁇ ) or treated with PC3 conditioned media.
  • FIG. 20 Western blot analysis of Tsp-1 expression in WI-38 lung fibroblasts treated with CM from PC3M-LN4 transduced with empty pLNCX (V) or with pLNCX-saposin A (A), pLNCX-saposin AB (AB), pLNCX-saposin ABC (ABC), and pLNCX-saposin BCD (BCD).
  • V empty pLNCX
  • A pLNCX-saposin A
  • AB pLNCX-saposin AB
  • ABC pLNCX-saposin ABC
  • BCD pLNCX-saposin BCD
  • FIG. 21A Western blot analysis of Tsp-1 and actin expression in WI-38 fibroblasts treated with 7 overlapping 20-amino acid peptides spanning the length of saposin A.
  • FIG. 21B Sequence alignment of saposin A, B, C and D (SEQ. ID. Nos. 33-36, respectively, in order of appearance).
  • FIG. 21C Crystal structures of saposin A (Sap A), saposin C (Sap C) and the superimposition of the two.
  • FIG. 22 Western blot analysis of Tsp-1, MDM2, p53 and actin in WI-38 fibroblasts that were untreated ( ⁇ ) treated with D4476, an inhibitor of casein kinase 1, (CKI) a 13 amino acid cyclic peptide comprising residues 35-47 of saposin A (13mer) (CDWLPKPNMSASC; SEQ. ID. No. 37) and the 13 amino acid peptide plus D4476 (13mer+CKI).
  • CKI casein kinase 1
  • FIG. 23 Migration of lymphatic endothelial cells (LEC) in the absence ( ⁇ ) or presence of wild-type or prostate fibroblasts in which p53 was silenced via shRNA, that were untreated (Fib) or treated with conditioned media from PC3, PC3M-LN4 (LN4), PC3 cells in which Prosaposin was silenced via shRNA (PC3sh), or PC3M-LN4 cells ectopically expressing prosaposin (LN4ps).
  • * denotes statistically significant differences with p values ⁇ 0.001 as determined by one way ANOVA.
  • FIG. 24A Immunohistochemistry of podoplanin expression in PC3M-LN4 and PC3M-LN4-psap tumors.
  • FIG. 24B Graphical depiction of the number of podoplanin positive lymphatic vessels in each tumor type.
  • FIG. 25 mRNA levels of semaphorin 3F, relative to GAPDH, in WI-38 fibroblasts that were untreated (NoTxPrSc) treated with conditioned media from PC3, PC3-shprosaposin (PC3-sh), PC3M-LN4 (LN4) and PC3M-LN4 cells ectopically expressing prosaposin (LN4Psap) as determined by real time RT-PCR.
  • PC3-sh PC3-shprosaposin
  • LN4 PC3M-LN4
  • LN4Psap PC3M-LN4 cells ectopically expressing prosaposin
  • Embodiments of the present invention are based on the discovery that non- or weakly metastatic tumor cells secrete a protein that stimulates the expression of thrombospondin (Tsp-1) in the surrounding environment of the tumor cells, namely the stroma comprised of fibroblasts and endothelial cells. While not wishing to be bound by theory, the increase in expression of Tsp-1 in the stroma keeps the tumor cells from metastasizing. Tsp-1 is a potent endogenous anti-angiogenic factor, and the stimulation of Tsp-1 expression by the tumor-derived protein is via the activation of the tumor suppressor p53. The tumor suppressor p53 is a transcription activator of Tsp-1 expression.
  • This tumor-associated protein secreted by non- or weakly metastatic tumor cells is prosaposin (Psap).
  • metastatic tumor cells express a high amount of Psap and Tsp-1, in addition to stimulating p53 and Tsp-1 expression in the surrounding tumor stroma.
  • metastatic tumor cells express low amounts of Psap and Tsp-1, and metastatic tumor cells also repress the expression of p53 and Tsp-1 in the tumor stroma.
  • metastasis Psap and Tsp-1 expression in the tumor cells
  • Psap and Tsp-1 expression in the tumor stroma there is also a strong correlation between metastasis and the Psap level in the plasma and/or platelets of patients with metastatic cancers.
  • Psap While not wishing to be bound by theory, high expression of Psap from a dormant primary tumor prevents the tumor from metastasis and also prevents the establishment secondary tumors at sites away from the primary tumor site. Conversely, low or no expression Psap in a primary tumor allows the tumor to metastasize and establish secondary tumors at sites far away from the primary tumor site.
  • the Psap secreted by a tumor affects its local and distant environment via paracrine and endocrine signaling mechanisms, affecting whether a tumor cell can grow bigger and/or implant and grow at a different and distant location from the primary tumor site.
  • Psap functions as a repressor of both lymphatic and vascular metastasis by inducing p53 and consequently Tsp-1 expression in stromal fibroblasts via both paracrine and endocrine signaling mechanisms.
  • Prosaposin is the saposin precursor protein made up of approximately 524-527 amino acids which includes a 16 amino acids signal peptide.
  • the full-length precursor 53-kDa polypeptide undergoes co-translational glycosylation and modification in the endoplasmic reticulum and Golgi system to yield a 70-72 kDa precursor protein.
  • cathepsin D participates in its proteolytic processing to yield intermediate molecular forms of 35 to 53 kDa and then to a 13-kDa glycoprotein and finally to the mature 8-11 kDa partially glycosylated forms of individual saposin molecules (O'Brien J.
  • Psap and the individual saposin proteins are expressed by a wide variety of cells types originating from ectodermal, mesodermal, and endodermal germ layers including but not limited to lung, skin, fibroblast, stromal cells, bone, smooth muscle, skeletal muscle, cardiac muscle, placenta, red and white blood cells, pancreas, placenta, lymphoreticular system (spleen, thymus, liver), micro and macrovascular system, genitourinary system (e.g., prostate, testes, seminal vesicle), central and peripheral nervous system.
  • lung skin
  • fibroblast stromal cells
  • bone smooth muscle
  • skeletal muscle cardiac muscle
  • placenta red and white blood cells
  • pancreas, placenta lymphoreticular system (spleen, thymus, liver), micro and macrovascular system
  • genitourinary system e.g., prostate, testes, seminal vesicle
  • Prosaposin and saposins are also present as soluble proteins in extracellular space/fluid including pleural fluid, cerebrospinal fluid, seminal fluid, milk, and serum (Campana W M., et. al., 1999; Kishimoto Y. et. al., 1992).
  • Psap is overexpressed in breast adenocarcinoma cell lines, non small-cell lung adenocarcinoma, neuroblastoma, and schwannoma cell lines, glioma cell lines, adult and pediatric brain tumors (e.g., medulloblastoma-, astrocytoma-, glioblastoma multiforme-cell lines), fibrosarcoma, osteosarcoma, and prostate cancer cell lines, different types of tumors (brain, colon, lung, pancreas, rectum, ovary, parotid, skin, bladder, small intestine, thymus, and uterus), including human prostate cancer cell lines.
  • the overall the expression and bifunctional significances of prosaposin and saposins in cancer are largely unknown (Koochekpour S. March 2006; Koochekpour S. September 2006).
  • prosaposin is a dual function molecule; as the precursor of intracellular lysosomal saposin proteins involved in sphingolipid hydrolysis activity and as a secreted soluble protein with neurotrophic activities, including growth, development, and maintenance of the peripheral and central nervous system, nerve regeneration and plasticity, stimulation of neurite outgrowth, stimulation of neuroblastoma cells proliferation, protection from cell-death or apoptosis, and activation of MAPK- and PI3K/Akt-signaling pathways (Morales and Badran, 2003; Misasi R, et. al., 2001; Campana W M, et. al., 1998; Hiraiwa M, et.
  • stroma or “tumor stroma” refers to the connective tissue framework and non-tumor cells of a tumor. Examples of some non-tumor cells found in a tumor stroma are fibroblasts and endothelial cells.
  • tumor means a mass of transformed cells that are characterized, at least in part, by containing angiogenic vasculature.
  • the transformed cells are characterized by neoplastic uncontrolled cell multiplication which is rapid and continues even after the stimuli that initiated the new growth has ceased.
  • the term “tumor” is used broadly to include the tumor parenchymal cells as well as the supporting stroma, including the angiogenic blood vessels that infiltrate the tumor parenchymal cell mass.
  • a tumor generally is a malignant tumor, i.e., a cancer having the ability to metastasize (i.e. a metastatic tumor)
  • a tumor also can be nonmalignant (i.e. non-metastatic tumor).
  • Tumors are hallmarks of cancer, a neoplastic disease the natural course of which is fatal. Cancer cells exhibit the properties of invasion and metastasis and are highly anaplastic.
  • the term “metastases” or “metastatic tumor” refers to a secondary tumor that grows separately elsewhere in the body from the primary tumor and has arisen from detached, transported cells, wherein the primary tumor is a solid tumor.
  • the primary tumor refers to a tumor that originated in the location or organ in which it is present and did not metastasize to that location from another location.
  • a “malignant tumor” is one having the properties of invasion and metastasis and showing a high degree of anaplasia. Anaplasia is the reversion of cells to an immature or a less differentiated form, and it occurs in most malignant tumors.
  • recurrence of an angiogenic disease or disorder refers to the re-manifestation/re-development of known symptoms associated with the angiogenic disease or disorder after previous successful treatment of the angiogenic disease or disorder.
  • a “recurrence” of a tumor refers to the enlargement of an existing tumor whose growth had stopped or reduced during an anti-cancer therapy, or the emergence of a tumor at the original (primary) site of tumor discovery after the original tumor had been excised or reduced in size.
  • the recurrence of a tumor can also mean new tumor growth(s) of the same tumor type as the original tumor at a site different from the original site of tumor discovery.
  • a recurrence of rheumatoid arthritis can include localized swelling/pain/joint stiffness, and elevated leukocyte ingression after a period of disease remission and symptom free.
  • the term “inhibit” or “inhibition” means the reduction or prevention of tumor growth and/or tumor metastasis in cancers. Inhibition includes slowing the rate of tumor growth and metastasis. The tumor growth rate can be reduced by about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 125%, about 150% or more compared to a control, untreated tumor of the same type. Inhibition also means a reduction in the size of the tumor of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100% or more compared to a control, untreated tumor of the same type.
  • the prevention of tumor growth and/or metastasis means no further increase in the size of the tumors from the time of start of treatment administration. Prevention also means status quo of no new metastatic tumors detected (i.e. no further spread of cancer) and/or an increase amount of tumor markers detected by methods known in the art.
  • the term “therapeutically effective amount” refers to the amount that is safe and sufficient to prevent or delay the development and further spread of metastases in cancer patients. The amount can also cure or cause the cancer to go into remission, slow the course of cancer progression, slow or inhibit tumor growth, slow or inhibit tumor metastasis, slow or inhibit the establishment of secondary tumors at metastatic sites, or inhibit the formation of new tumor metastasis.
  • treat or “treatment” refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent, slow down, and/or halt the development or spread of cancer.
  • beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable.
  • Treatment can also mean prolonging survival as compared to expected survival if not receiving treatment.
  • Those in need of treatment include those already diagnosed with cancer as well as those likely to develop secondary tumors due to metastasis.
  • angiogenesis refers to the sprouting of new blood vessels from pre-existing blood vessels, characterized by endothelial cell proliferation and migration triggered by certain pathological conditions, such as the growth of solid tumors and metastasis.
  • angiogenesis-dependent disease or disorder refers to diseases or disorders that are dependent on a rich blood supply and blood vessel proliferation for the disease pathological progression (e.g. metastatic tumors) or diseases or disorders that are the direct result of aberrant blood vessel proliferation (e.g. diabetic retinopathy and hemangiomas).
  • Examples include abnormal vascular proliferation, ascites formation, psoriasis, age-related macular degeneration, thyroid hyperplasia, preeclampsia, rheumatoid arthritis and osteoarthritis, Alzheimer's disease, obesity, pleura effusion, atherosclerosis, endometriosis, diabetic/other retinopathies, ocular neovascularizations such as neovascular glaucoma and corneal neovascularization.
  • nucleic acid refers to DNA or RNA.
  • the term encompasses sequences that include any of the known base analogs of DNA and RNA.
  • vector refers to a nucleic acid construct comprising the complete or partial cDNA of Psap (SEQ. ID. No. 2, 4, or 6) (Genbank Accession No. NM — 002778, NM — 001042466, or NM — 001042465), wherein the nucleic acid construct is designed for delivery to a host cell, transfer between different host cells, or for the expression of Psap or functional fragments or variants thereof, in cells.
  • a vector can be viral or non-viral.
  • viral vector refers to a nucleic acid vector construct that includes at least one element of viral origin and includes elements sufficient for or permissive of packaging into a viral vector particle.
  • a viral vector can contain the coding sequence for a Psap protein in place of non-essential viral genes.
  • the vector and/or particle can be utilized for the purpose of transferring DNA, RNA or other nucleic acids into cells either in vitro or in vivo. Numerous forms of viral vectors are known in the art.
  • prognosis encompasses predictions and likelihood analysis of disease progression, particularly tumor recurrence, metastatic spread, and disease relapse.
  • the prognosis method described herein is intended for clinical use in making decision concerning treatment modalities, including therapeutic interventions, diagnostic criteria such as disease staging, and disease monitoring and surveillance for metastasis or recurrence of neoplastic disease.
  • tissue sample refers to a portion, piece, part, segment, or fraction of a tissue which is obtained or removed from an intact tissue or organ of a subject, preferably a human subject.
  • a “subject” refers to a mammal, preferably a human.
  • the term “individual”, “subject”, and “patient” are used interchangeably.
  • a tumor sample refers to a portion, piece, part, segment, or fraction of a tumor, for example, a tumor which is obtained or removed from a subject (e.g., removed or extracted from a tissue of a subject), preferably a human subject.
  • the term “functional” refers to the fragments and variants of Psap protein having cellular functions substantially similar to that of the parent full-length Psap. At the minimum, “functional” refers to the capability of stimulating Tsp-1 and/or p53 expressions. Other cellular functions including capability of being glycosylated, of being proteolytically processed to give the smaller saposins which are required for the hydrolysis of glycosphingolipids by lysosomal lysozmes, ability to bind to membrane lipids, and have neurotrophic activities.
  • the term “substantially similar” refers to no change to the course of direction of biological effects resulting from the actions of the fragments and variants of Psap in the cell.
  • the fragment and variant forms of Psap are still capable of stimulating Tsp-1 and p53 expression and activation, and they can still be processed proteolytically to give saposins, and these saposins can be used by the cell in the hydrolysis of glycosphingolipids.
  • a “substantially similar” functional fragment of saposin A has an amino acid sequence differing from SEQ. ID. No. 13 by having one or more conservative amino acid substitution and/or modification but is still capable of stimulating Tsp-1 and p53 expressions and activation, the methods of assaying are described herein and are well known in the art.
  • variant refers the splice variant of Psap protein (also known as isoforms) encoded by the nucleic acids of Psap (Genbank Accession No. NM — 002778, SEQ. ID. No. 2), NM — 001042465 (SEQ. ID. No. 4), or NM — 001042466 (SEQ. ID. No. 6)).
  • Variant also refers to Psap protein or molecule modified at one or more base pairs, codons, introns, exons, or amino acids, respectively, yet still retain the biological activity and cellular functions of a Psap protein.
  • the polypeptide sequence of the variant Psap protein is slightly different from that prescribed by the Psap coding nucleic acid (SEQ. ID. No. 2, 4, and 6).
  • Psap coding nucleic acid SEQ. ID. No. 2, 4, and 6
  • amino acid mutations in the Psap protein.
  • Conservative amino acid substitution can produced variant Psap proteins.
  • the amino acid serine can be substituted for threonine and the amino acid aspartate can be substituted for glutamate.
  • the variant Psap proteins have comparable or greater Tsp-1 and p53 expression stimulation activity than the parent Psap protein.
  • the variant Psap protein can have at least 80%, at least 90%, at least 100%, at least 110%, at least 120%, at least 130%, at least 140%, or at least 150% of the Tsp-1 and p53 expression stimulation activity of the parent Psap protein.
  • Variants can be produced by a number of means including methods such as, for example, error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis, site-specific mutagenesis, gene reassembly, GSSM and any combination thereof.
  • the term “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a side chain with a similar charge.
  • Families of amino acid residues having side chains with similar charges have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryp
  • fragment refers to an amino acid sequence which is shorter than the original polypeptide encoded by the cDNA of Psap (Genbank Accession No. NM — 002778, SEQ. ID. No. 2), NM — 001042465.1 (SEQ. ID. No. 4), or NM — 001042466.1 (SEQ. ID. No. 6) thus presenting an incomplete Psap protein.
  • the Psap protein is shortened or truncated.
  • the term “functional fragment” as used herein refers to the truncated Psap protein that has cellular functions including the stimulation of Tsp-1 and p53 expression.
  • Fragments are at least 10 amino acids but are not the full-length Psap protein. In other words, fragments are 10 amino acids or more but are not the full-length Psap protein. Examples of fragments include fragments consisting of amino acids 1-300, amino acids 1-150, and amino acids 1-490 of the original full length Psap protein. These fragments contain the Saposin A- and Saposin B-domains and can be cleaved to give the smaller saposins or smaller fragments thereof.
  • Saposin A (protein) SLPCDICKDVVTAAGDMLKDNATEEEILVYLEKTCDWLPKPNMSASCKEIVDSYLPVIL DIIKGEMSRPGEVCSALNLCES (SEQ. ID. No.
  • Saposin B (Protein) GDVCQDCIQMVTDIQTAVRTNSTFVQALVEHVKEECDRLGPGMADICKNYISQYSEIAI QMMMHMQPKEICALVGFCDE (SEQ. ID. No. 14); Saposin C (Protein) SDVYCEVCEFLVKEVTKLIDNNKTEKEILDAFDKMCSKLPKSLSEECQEVVDTYGSSILS ILLEEVSPELVCSMLHLCSG (SEQ. ID. No.
  • Saposin D Protein
  • SLPCDICKDVVTAAG SEQ. ID. No. 18
  • VTAAGDMLKDNATEE SEQ. ID. No. 19
  • NATEEEILVYLEKTC SEQ. ID. No. 20
  • LEKTCDWLPKPNMSA SEQ. ID. No. 21
  • PNMSASCKEIVDSYL SEQ. ID. No. 22
  • VDSYLPVILDIIKGE SEQ. ID. No.
  • polypeptide and “peptide” are used interchangeably herein to refer to a polymer of amino acids. These terms do not connote a specific length of a polymer of amino acids. Thus, for example, the term includes oligomeric peptides, made up of two or more physically linked peptides, whether produced using recombinant techniques, chemical or enzymatic synthesis, or naturally occurring. This term also includes polypeptides that have been modified or derivatized, such as by glycosylation, acetylation, phosphorylation, and the like.
  • Psap protein refers to the splice variant full-length human prosaposin isoform A preproprotein (Genbank Accession Nos.: NM — 002778 (SEQ. ID. No. 2), NP — 002769.1 (SEQ. ID. No. 1)); UniProtKB/Swiss-Prot P07602, UniProtKB/TrEMBL Q53Y86), the splice variant full-length human prosaposin isoform B preproprotein (Genbank Accession Nos.: NM — 001042465.1 (SEQ. ID. No. 4), NP — 001035930.1 (SEQ. ID. No.
  • GenPept/UniProtKB/TrEMBL O75905, P07602.2, Q53FJ5, Q59EN5, Q5BJH1, Q5JQ36, and Q5JQ37; the secreted forms of these splice variants, functional fragments and variants thereof that are greater or equal to 10 amino acid residues, the functional fragments and variants of the isoforms that are greater or equal to 10 amino acid residues, differentially glycosylated forms of the full-length splice variant Psap protein, secreted differentially glycosylated forms of the Psap protein, differentially glycosylated functional fragments with less than 524 amino acids and that are greater or equal to 10 amino acid residues, and/or differentially glycosylated functional variants thereof.
  • Psap protein includes substantially similar Psap proteins, saposin A and functional fragments thereof that are greater or equal to 10 amino acid residues.
  • the term “differentially glycosylated” refers to differences in glycosylation at the available glycosylation sites of full-length Psap. There are five glycosylation sites on the full-length protein. Accordingly, a full-length Psap can have anywhere from zero and up to five glycosylated groups. In addition, the term also refers to the presence of different sugar groups on the polypeptide.
  • cancer refers to any of various malignant neoplasms characterized by the proliferation of anaplastic cells that tend to invade surrounding tissue and metastasize to new body sites as well as to the pathological conditions characterized by such malignant neoplastic growths.
  • cancer also refers to cells and tissue with neoplasms characteristics of anaplastic proliferation that are not invasive of surrounding tissue, i.e. anaplastic cells that are benign.
  • promptness refers to any time within one month of positive laboratory test results confirming presence of cancer cells.
  • development of cancer or “cancer development” refers to the development of primary or initial cancer, the development of metastasis from benign and/or malignant tumors, and/or the development of malignancy from benign tumors.
  • fusion protein refers to a protein created by joining two heterologous genes or two heterologous proteins/peptides or portions thereof together.
  • heterologous in reference to genes and proteins means the genes or proteins are two different and not similar entities.
  • two heterologous genes encode for two different and not similar proteins respectively.
  • a “fusion protein” or “fusion polypeptide” is a chimeric protein, made of at least two different types of proteins or portions thereof.
  • “fusion protein” or “fusion polypeptide” is achieved through the creation of a fusion gene which is done through the removal of the stop codon from a DNA sequence of the first protein and then attaching the DNA sequence of the second protein in frame.
  • the resulting DNA sequence can then be expressed by a cell as a single protein.
  • the two heterologous proteins can be joined together with a linker or spacer peptide added between the two proteins.
  • This linker or spacer peptide often contains protease cleavage site(s) to facilitate the separation of the two different proteins after expression and purification.
  • the making of fusion protein as a technique is commonly used for the identification and purification of proteins through the fusion of a GST protein, FLAG peptide or a hexa-His peptide.
  • a peptide linker is a short sequence of amino acids that is not part of the sequence of either of the two peptides being joined to form a fusion protein or fusion polypeptide.
  • a peptide linker is attached on its amino-terminal end to one polypeptide or polypeptide domain and on its carboxyl-terminal end to another polypeptide or polypeptide domain.
  • the peptide linker can be a flexible linker, in that the peptide sequence does not adopt any secondary structures known in proteins, e.g. alpha helices. Such flexible linkers are predominantly made of non-charged, a polar amino acid residues and are hydrophobic. Secondary protein structures can be determined by methods known in the art, for example, circular dichroism.
  • An example of a flexible peptide linker is LGGGGSGGGGSA (SEQ. ID. No. 42).
  • the peptide linker can take the form a monomeric hydrophilic sa-helix, for example, AEAAAKEAAAKEA (SEQ. ID. No. 43).
  • PEGylated is meant the covalent attachment of at least one molecule of polyethylene glycol to a biologically active molecule.
  • the average molecular weight of the reactant PEG is preferably between about 3,000 and about 50,000 daltons, more preferably between about 10,000 and about 40,000 daltons, and most preferably between about 15,000 and about 30,000 daltons. Particularly preferred are PEGs having nominal average sizes of about 20,000 and about 25,000 daltons.
  • the method of attachment is not critical, but preferably does not alter, or only minimally alters, the activity of the biologically active molecule. Preferably the increase in half-life is greater than any decrease in biological activity.
  • a preferred method of attachment is via N-terminal linkage to a polypeptide or peptide.
  • compositions and methods refers to respective component(s) thereof, as essential to the invention, yet open to the inclusion of unspecified elements, essential or not.
  • compositions, methods, and respective components thereof are limited to those that do not materially affect the basic and novel characteristic(s) of the invention. This is referred to using the term “consisting essentially of”. This applies equally to steps within a described method as well as compositions and components therein. In other embodiments, the inventions, compositions, methods, and respective components thereof, described herein are intended to be exclusive of any element not recited with respect to that composition, element, component or method. This is referred to using the term “consisting of”.
  • essential in reference to compositions and methods refers to the “essential” component in the composition or method being the peptide or protein sequence that, at the minimum, has the ability to stimulate Tsp-1 expression in the assays described herein, preferably also stimulate p53 expression.
  • Non essential component in the composition or method would be heterologous protein that is not Psap, fusion portion of the fusion protein that is not Psap, PEG, polymer, immunoglobulin Fc region or conjugates etc.
  • reducing the likelihood in reference to the development of certain conditions refers to a reduction by at least 20% compared to when no treatment or administration of a therapeutically effective amount of a Psap protein or a vector described herein.
  • the reduction can also be at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, including all the percent between 20% and 100%.
  • the invention provides a method of treating an angiogenesis-dependent disease or disorder, the method comprising administering to a subject in need thereof a therapeutically effective amount of a Psap protein or a vector comprising the nucleic acid encoding a Psap protein, and a pharmaceutically acceptable carrier.
  • the invention provides a method of inhibiting the recurrence of an angiogenesis-dependent disease or disorder, the method comprising administering to a subject in need thereof, a therapeutically effective amount of a Psap protein or a vector comprising the nucleic acid encoding a Psap protein, and a pharmaceutically acceptable carrier.
  • the angiogenesis-dependent disease or disorder is selected from, but is not limited to, a group consisting of cancer, ascites formation, psoriasis, age-related macular degeneration, thyroid hyperplasia, preeclampsia, rheumatoid arthritis and osteoarthritis, Alzheimer's disease, obesity, pleura effusion, atherosclerosis, endometriosis, diabetic/other retinopathies, neovascular glaucoma, age-related macular degeneration (ARMD), hemangiomas, and corneal neovascularization.
  • cancer ascites formation, psoriasis, age-related macular degeneration, thyroid hyperplasia, preeclampsia, rheumatoid arthritis and osteoarthritis, Alzheimer's disease, obesity, pleura effusion, atherosclerosis, endometriosis, diabetic/other retinopathies, neovascular glaucoma, age-related macular
  • the angiogenesis-dependent disease or disorder is cancer, where the rapidly dividing neoplastic cancer cells require an efficient blood supply to sustain their continual growth of the tumor.
  • cancer refers to any of various malignant neoplasms characterized by the proliferation of anaplastic cells that tend to invade surrounding tissue and metastasize to new body sites and also refers to the pathological condition characterized by such malignant neoplastic growths.
  • the blood vessels provide conduits to metastasize and spread elsewhere in the body. Upon arrival at the metastatic site, the cancer cells then work on establishing a new blood supply network.
  • embodiments of the invention serve to halt, prevent and limit the progression of the disease. Any solid tumor that requires an efficient blood supply to keep growing is a candidate target.
  • candidates for the treatment described herein include carcinomas and sarcomas found in the anus, bladder, bile duct, bone, brain, breast, cervix, colon/rectum, endometrium, esophagus, eye, gallbladder, head and neck, liver, kidney, larynx, lung, mediastinum (chest), mouth, ovaries, pancreas, penis, prostate, skin, small intestine, stomach, spinal marrow, tailbone, testicles, thyroid and uterus.
  • carcinomas include papilloma/carcinoma, choriocarcinoma, endodermal sinus tumor, teratoma, adenoma/adenocarcinoma, melanoma, fibroma, lipoma, leiomyoma, rhabdomyoma, mesothelioma, angioma, osteoma, chondroma, glioma, lymphoma/leukemia, squamous cell carcinoma, small cell carcinoma, large cell undifferentiated carcinomas, basal cell carcinoma and sinonasal undifferentiated carcinoma.
  • sarcomas include soft tissue sarcoma such as alveolar soft part sarcoma, angiosarcoma, dermatofibrosarcoma, desmoid tumor, desmoplastic small round cell tumor, extraskeletal chondrosarcoma, extraskeletal osteosarcoma, fibrosarcoma, hemangiopericytoma, hemangiosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, lymphosarcoma, malignant fibrous histiocytoma, neurofibrosarcoma, rhabdomyosarcoma, synovial sarcoma, and Askin's tumor, Ewing's sarcoma (primitive neuroectodermal tumor), malignant hemangioendothelioma, malignant schwannoma, osteosarcoma, and chondrosarcoma.
  • the angiogenesis-dependent disease or disorder is age-related macular degeneration.
  • VEGF contributes to abnormal blood vessel growth from the choroid layer of the eye into the retina, similar to what occurs during the wet or neovascular form of age-related macular degeneration.
  • Macular degeneration often called AMD or ARMD (age-related macular degeneration)
  • AMD age-related macular degeneration
  • New blood vessels grow (neovascularization) beneath the retina and leak blood and fluid. This leakage causes permanent damage to light-sensitive retinal cells, which die off and create blind spots in central vision or the macula.
  • the angiogenic disease or disorder is diabetic retinopathy-abnormal blood vessel growth associated with diabetic eye diseases.
  • the activation of Tsp-1 via prosaposin serves to antagonize VEGF, a substance naturally produced in the body that promotes blood vessel formation. Released by the retina (light-sensitive tissue in back of the eye) when normal blood vessels are damaged by tiny blood clots due to diabetes, VEGF turns on its receptor, igniting a chain reaction that culminates in new blood vessel growth.
  • the backup blood vessels are faulty; they leak, bleed and encourage scar tissue that detaches the retina, resulting in severe loss of vision.
  • Such growth is the hallmark of diabetic retinopathy, the leading cause of blindness among young people in developed countries.
  • the subject in need of treatment can be a mammal, such as a dog or a cat, preferably a human.
  • the angiogenesis-dependent disease or disorder is rheumatoid arthritis.
  • Rheumatoid arthritis is characterized by synovial tissue swelling, leucocyte ingress and angiogenesis, or new blood vessel growth. The disease is thought to occur as an immunological response to an as yet unidentified antigen.
  • the expansion of the synovial lining of joints in rheumatoid arthritis (RA) and the subsequent invasion by the pannus of underlying cartilage and bone necessitate an increase in the vascular supply to the synovium, to cope with the increased requirement for oxygen and nutrients.
  • Angiogenesis is now recognised as a key event in the formation and maintenance of the pannus in RA (Paleolog, E. M., 2002).
  • a mononuclear infiltrate characterizes the synovial tissue along with a luxuriant vasculature.
  • Angiogenesis is integral to formation of the inflammatory pannus and without angiogenesis; leukocyte ingress could not occur (Koch, A. E., 2000). Disruption of the formation of new blood vessels would not only prevent delivery of nutrients to the inflammatory site, it could also reduce joint swelling due to the additional activity of VEGF, a potent pro-angiogenic factor in RA, as a vascular permeability factor.
  • the angiogenesis-dependent disease or disorder is Alzheimer's disease.
  • AD Alzheimer's disease
  • AD is the most common cause of dementia worldwide.
  • AD is characterized by an excessive cerebral amyloid deposition leading to degeneration of neurons and eventually to dementia.
  • the exact cause of AD is still unknown. It has been shown by epidemiological studies that long-term use of non-steroidal anti-inflammatory drugs, statins, histamine H2-receptor blockers, or calcium-channel blockers, all of which are cardiovascular drugs with anti-angiogenic effects, seem to prevent Alzheimer's disease and/or influence the outcome of AD patients. Therefore, it has been speculated that in AD angiogenesis in the brain vasculature may play an important role in AD.
  • the brain endothelium secretes the precursor substrate for the beta-amyloid plaque and a neurotoxic peptide that selectively kills cortical neurons.
  • amyloid deposition in the vasculature leads to endothelial cell apoptosis and endothelial cell activation which leads to neovascularization.
  • Vessel formation could be blocked by the VEGF antagonist SU 4312 as well as by statins, indicating that anti-angiogenesis strategies can interfere with endothelial cell activation in AD (Schultheiss C., el. al., 2006; Grammas P., et. al., 1999) and can be used for preventing and/or treating AD.
  • the angiogenesis-dependent disease or disorder is obesity. It has been shown that the angiogenesis inhibitor, TNP-470 was able to prevent diet-induced and genetic obesity in mice (Ebba Br ⁇ kenhielm et. al., Circulation Research, 2004, 94:1579). TNP-470 reduced vascularity in the adipose tissue, thereby inhibiting the rate of growth of the adipose tissue and obesity development.
  • the angiogenesis-dependent disease or disorder is endometriosis.
  • Excessive endometrial angiogenesis is proposed as an important mechanism in the pathogenesis of endometriosis (Healy, D L., et. al., 1998).
  • the endometrium of patients with endometriosis shows enhanced endothelial cell proliferation.
  • Strategies that inhibit angiogenesis can be used to treat endometriosis.
  • the method of treating cancer is applicable to all carcinomas and sarcomas.
  • the method is applicable to cancers selected from the group consisting of papilloma/carcinoma, choriocarcinoma, endodermal sinus tumor, teratoma, adenoma/adenocarcinoma, melanoma, fibroma, lipoma, leiomyoma, rhabdomyoma, mesothelioma, angioma, osteoma, chondroma, glioma, lymphoma/leukemia, squamous cell carcinoma, small cell carcinoma, large cell undifferentiated carcinomas, basal cell carcinoma, sinonasal undifferentiated carcinoma, soft tissue sarcoma such as alveolar soft part sarcoma, angiosarcoma, dermatofibrosarcoma, desmoid tumor, desmoplastic small round cell tumor, extraskeletal chondrosarcoma,
  • the method of treating cancer is administered promptly after the detection of cancer.
  • promptness refers to any time within one month of positive laboratory test results confirming presence of cancer cells. Diagnosis and detection of cancer cells are well known to one skilled in the art. Laboratory tests can be in the form of histology and/or biomarkers that are known in the art but are not limited to these examples.
  • cancer biomarkers such as cancer antigen (CA) 15-3, carcinoembryonic antigen (CEA) and HER-2 for breast cancer, human papillomavirus (HPV) E6 and E7 oncoproteins for cervical cancer, alpha-fetoprotein (AFP), AFP fractions L3, P4/5, and the +II band, and ultrasonography for hepatocellular carcinoma (HCC), prostate-specific antigen (PSA) for prostate cancer, and serum CA-125 for ovarian and HCC.
  • Tissue biopsy and histology are usually performed for confirmation and tissue typing of the original of cancer cell type.
  • the invention provides a method of inhibiting metastasis of cancer in a subject diagnosed with cancer, the method comprising administering to a subject in need thereof, a therapeutically effective amount of a Psap protein or a vector comprising the nucleic acid encoding a Psap protein, and a pharmaceutically acceptable carrier.
  • the subject can be diagnosed with a benign or malignant cancer.
  • Psap protein can be administered to inhibit the establishment of secondary tumor from the initially discovered benign or malignant tumor.
  • the subject is a mammal, such as a dog or a cat, preferably a human, who has previously been diagnosed with cancer.
  • the cancer can be benign or malignant, and it may or may not have metastasized.
  • individual and subject are used interchangeably.
  • the method of treatment is administered promptly after the diagnosis of cancer.
  • the invention provides a method of inhibiting recurrence of cancer in a subject diagnosed with cancer, the method comprises administering to a subject in need thereof, a therapeutically effective amount of a Psap protein or a vector comprising the nucleic acid encoding a Psap protein, and a pharmaceutically acceptable carrier.
  • the subject can be diagnosed with a benign or malignant cancer.
  • Psap protein can be administered to inhibit the re-growth of the primary tumor, development of tumors not related to the primary tumor, and/or establishment of secondary tumors from the initially discovered benign or malignant tumor.
  • the invention provides a method for reducing the likelihood of cancer development in a subject, the method comprising administering to a subject in need thereof, a therapeutically effective amount of a Psap protein or a vector comprising the nucleic acid encoding a Psap protein, and a pharmaceutically acceptable carrier.
  • Psap protein can be administered to prevent the development of cancer, the development of metastasis, and/or the development of malignancy.
  • a subject who is predisposed to, or at risk of developing cancer e.g. family history of early onset colon-rectal cancer, previous exposure to hepatitis B or C, or the subject carries some gene mutations that are associated with certain cancer types, e.g.
  • Psap can be administered to the subject for preventing cancer development in this subject.
  • the benign tumor can be removed by surgery.
  • Psap can be administered to the subject for preventing any remaining existing benign tumor cells from developing into a malignant cancer as well as to prevent the development of metastasis.
  • Psap can be administered to the subject for preventing the malignant tumor from further metastasis.
  • the invention provides a method for reducing the likelihood of the cancer development in a subject at risk of development of cancer, the method comprises administering to a subject in need thereof, a therapeutically effective amount of a Psap protein or a vector comprising the nucleic acid encoding a Psap protein, and a pharmaceutically acceptable carrier.
  • the invention provides a method for reducing the likelihood of the development of cancer malignancy in a subject previously diagnosed with cancer, the method comprises administering to a subject in need thereof, a therapeutically effective amount of a Psap protein or a vector comprising the nucleic acid encoding a Psap protein, and a pharmaceutically acceptable carrier.
  • the invention provides a method for reducing the likelihood of cancer metastasis in a subject previously diagnosed with cancer, the method comprises administering to a subject in need thereof, a therapeutically effective amount of a Psap protein or a vector comprising the nucleic acid encoding a Psap protein, and a pharmaceutically acceptable carrier.
  • the administration is in conjunction with a p53 reactivation agent.
  • the administration is in conjunction with chemotherapy, radiation therapy, and/or a cytostatic agent.
  • the administration is in conjunction with an anti-VEGF agent or an anti-angiogenesis factor.
  • the Psap protein can be the full-length human prosaposin isoform A preproprotein, isoform B preproprotein, isoform C preproprotein, the secreted forms of these splice variants, functional fragments and variants thereof that are greater than or equal to 10 amino acid residues, the functional fragments and variants that are greater than or equal to 10 amino acid residues of the isoforms, differentially glycosylated forms of the full-length splice variant Psap protein, secreted differentially glycosylated forms of the Psap protein, differentially glycosylated functional fragments with less than 524 amino acids and are greater than or equal to 10 amino acid residues, and/or differentially glycosylated functional variants thereof are greater than or equal to 10 amino acid residues.
  • Examples of functional fragments of Psap include Saposin A: SLPCDICKDVVTAAGDMLKDNATEEEILVYLEKTCDWLPKPNMSASCKEIVDSYLPVIL DIIKGEMSRPGEVCSALNLCES (SEQ. ID. No. 13); Saposin B: GDVCQDCIQMVTDIQTAVRTNSTFVQALVEHVKEECDRLGPGMADICKNYISQYSEIAI QMMMHMQPKEICALVGFCDE (SEQ. ID. No. 14); Saposin C SDVYCEVCEFLVKEVTKLIDNNKTEKEILDAFDKMCSKLPKSLSEECQEVVDTYGSSILS ILLEEVSPELVCSMLHLCSG (SEQ. ID. No.
  • SEQ. ID. No. 16 SLPCDICKDVVTAAG (SEQ. ID. No. 18); VTAAGDMLKDNATEE (SEQ. ID. No. 19); NATEEEILVYLEKTC (SEQ. ID. No. 20); LEKTCDWLPKPNMSA (SEQ. ID. No. 21); PNMSASCKEIVDSYL (SEQ. ID. No. 22); VDSYLPVILDIIKGE (SEQ. ID. No. 23); IIKGEMSRPGEVCSA (SEQ. ID. No.
  • SRPGEVCSALNLCES SEQ. ID. No. 25
  • SLPCDICKDVVTAAGDMLKD SEQ. ID. No. 26
  • VTAAGDMLKDNATEEEILVY SEQ. ID. No. 27
  • NATEEEILVYLEKTCDWLPK SEQ. ID. No. 28
  • LEKTCDWLPKPNMSASCKEI SEQ. ID. No. 29
  • PNMSASCKEIVDSYLPVILD SEQ. ID. No. 30
  • VDSYLPVILDIIKGEMSRPG SEQ. ID. No. 31
  • IIKGEMSRPGEVCSALNLCES SEQ. ID. No. 32
  • the functional fragments of saposin A, saposin B, saposin C, or saposin D, and the substantially similar functional fragments thereof described herein are capable of activating p53 and inducing Tsp-1 expression.
  • Short peptides of at least 10 amino acid residues of saposin A, B, C, or D, and their peptidomimetics are also encompassed herein.
  • Such a peptide mimetic can have different amino acids from the peptide that it mimics but retains the p53 and Tsp-1 activation and induction activity of the peptide that it mimics. Conservative amino acid substitution of these Psap proteins are also specifically contemplated.
  • the methods for determining p53 activating activity and Tsp-1 expression induction activity are described herein and are also well known to one skilled in the art.
  • the Psap protein is saposin A: SLPCDICKDVVTAAGDMLKDNATEEEILVYLEKTCDWLPKPNMSASCKEIVDSYLPVIL DIIKGEMSRPGEVCSALNLCES (SEQ. ID. No. 13).
  • the Psap protein is a functional fragment of saposin A that is less than 81 amino acid residues.
  • the functional fragment of saposin A is any of SEQ. ID. No. 18-31. Conservative amino acid substitution of saposin A and of functional fragments thereof are also specifically contemplated.
  • the Psap protein is a functional fragment of saposin A that comprises at least 10 amino acid residues.
  • the Psap protein is a peptidomimetic of a functional fragment of saposin A.
  • the inventors systematically tested smaller fragments of saposin A and have found that two fragments, a 20-mer LEKTCDWLPKPNMSASCKEI (SEQ. ID. No. 38) and a 13-mer CDWLPKPNMSASC (SEQ. ID. No. 37) were able to stimulate and induce Tsp-1 expression (see Example 15, FIGS. 21A and 22 ). It is specifically contemplated that smaller fragments of the 20smer that contain sequence of the 13 mer (SEQ. ID. No. 37) will also function in this regard. Compositions comprising the peptide consisting essentially of either SEQ. ID. No. 37 or 38, and mixtures of the two peptides (SEQ. ID. Nos. 37 and 38) are also contemplated.
  • the invention provides a composition comprising a peptide consisting of the sequence CDWLPKPNMSASC (SEQ. ID. No. 37) and a pharmaceutically acceptable carrier.
  • the invention also provides a composition comprising a peptide consisting essentially of the sequence CDWLPKPNMSASC (SEQ. ID. No. 37) and a pharmaceutically acceptable carrier.
  • the peptide is derived from saposin A.
  • the essential sequence sufficient to stimulate Tsp-1 expression is SEQ. ID. No. 37.
  • the invention provides a composition comprising a peptide consisting of the sequence LEKTCDWLPKPNMSASCKEI (SEQ. ID. No. 38) and a pharmaceutically acceptable carrier.
  • the invention also provides a composition comprising a peptide consisting essentially of the sequence LEKTCDWLPKPNMSASCKEI (SEQ. ID. No. 38) and a pharmaceutically acceptable carrier.
  • the peptide is derived from saposin A.
  • the peptide consists of at least 10 amino acid residues derived form SEQ. ID. Nos. 37 and 38, e.g. DWLPKPNMSA (SEQ. ID. No. 39), CDWLPKPNMS (SEQ. ID. No. 40) or WLPKPNMSAS (SEQ. ID. No. 41) but in no saposin A (SEQ. ID. No. 13).
  • DWLPKPNMSA SEQ. ID. No. 39
  • CDWLPKPNMS SEQ. ID. No. 40
  • WLPKPNMSAS SEQ. ID. No. 41
  • the peptides have conservative amino acid substitution for one. two, three, four or up to five amino acid residues.
  • the compositions comprise a plurality of peptides or fragments, wherein the peptides are not identical.
  • the plurality of peptides is derived from saposin A and the peptides are greater that or equal to 10 amino acid residues long but is not saposin A (SEQ. ID. No. 13).
  • a composition can comprise of CDWLPKPNMSASC (SEQ. ID. No. 37) and WLPKPNMSAS (SEQ. ID. No. 41); CDWLPKPNMSASC (SEQ. ID. No. 37) and LEKTCDWLPKPNMSA (SEQ. ID. No. 21).
  • compositions comprise a multimer of peptides or fragments, wherein the peptides are identical and wherein the plurality of peptides is derived from saposin A.
  • a plurality of CDWLPKPNMSASC SEQ. ID. No. 37
  • LEKTCDWLPKPNMSASCKEI SEQ. ID. No. 38
  • the multimer of peptides are concatamerically linked.
  • the physical joining of a plurality of peptides by a molecular linker results in an oligomer of peptides.
  • the composition can comprise an oligomeric peptide that is a dimer of two peptides, a trimer of three peptides, a tetramer of four peptides, or a pentamer of five peptides.
  • the oligomeric peptide is a dimer of two peptides and/or a trimer of three peptides.
  • the oligomeric peptide is a homo-oligomeric peptide, comprising identical peptides according to the invention disclosed herein. Hetero-oligomeric peptides comprising different peptides, fragments, and/or variants thereof that are greater than or equal to 10 amino acid residues are also contemplated.
  • the molecular linker that joins the peptides to form an oligomeric peptide can be a peptide linker molecule or a chemical linker.
  • the peptide linker molecule can comprise e.g. at least 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acids residues and preferably less that 50 amino acids residues.
  • the composition can also include the monomeric peptide along with oligomeric peptide. It is contemplated that all possible combinations of monomeric, dimeric, trimeric, tetrameric, and pentameric peptides, and homo-oligomeric peptides as well as hetero-oligomeric peptides can be included in the compositions described herein.
  • the molecular linker used for forming the oligomeric polypeptides is a peptide linker molecule.
  • the peptide linking molecule comprises at least one amino acid residue which links at least two peptides according to the invention.
  • the peptide linker comprises, e.g. at least 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acids residues and preferably less that 50 amino acids residues.
  • the peptide linking molecule can couple polypeptides or proteins covalently or non-covalently. Typical amino acid residues used for linking are glycine, tyrosine, cysteine, lysine, glutamic and aspartic acid, or the like.
  • a peptide linker is attached on its amino-terminal end to one peptide, polypeptide or polypeptide domain (e.g., a C-peptide) and on its carboxyl-terminal end to another peptide, polypeptide or polypeptide domain (again, e.g., a C-peptide).
  • G glycine polymers
  • gly4Ser gly4Ser
  • the molecular linker is a chemical linker such as linkages by disulfide bonds between cysteine amino acid residues or by chemical bridges formed by amine crosslinkers, for example, glutaraldehyde, bis(imido ester), bis(succinimidyl esters), diisocyanates and diacid chlorides.
  • amine crosslinkers for example, glutaraldehyde, bis(imido ester), bis(succinimidyl esters), diisocyanates and diacid chlorides.
  • the oligomeric peptide can be made by linking individual isolated peptides.
  • the individual peptides can be made by chemical methods known in the art or by recombinant methods also known in the art.
  • the DNA coding sequence of a peptide can be made by amplification using the polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • Specially designed PCR primers that incorporate restriction enzyme digestion sites and/or extra spacer or tag amino acid residues can be used to facilitate DNA ligation, recombinant protein expression, and protein purification.
  • additional amino acid residues can be added, by way of the DNA coding sequence, to the peptides.
  • the thiol-group containing amino acid cysteine and the amine-group containing amino acid lysine can be added.
  • the thiol-group and the amine group provide reactive groups useful for crosskinking reactions.
  • the additional amino acids are added at the ends of the peptides.
  • the extra amino acids can be engineered into the coding sequence using standard recombinant molecular biology methods that are known in the art.
  • extra amino acids that constitute a tag can be added to facilitate peptide expression and purifications. Examples of such tags include the thioredoxin first 105 amino acids, the tandem six histidine-tag, HA-tag, and the flag-tag. An example of such a peptide with terminally added cysteine groups and histidine (6 ⁇ ) purification tag.
  • the DNA coding sequences of the different individual peptides can be ligated into expression vectors which are then transfected into appropriate expression host cells and induced to express the recombinant peptide. Subsequently, the expressed recombinant peptide can be purified and then used in cross-linking to form the dimeric, trimer, tetrameric, or pentameric oligomeric peptide compositions described herein by methods known in the art.
  • thiol-groups are available for introducing thiol-groups into proteins and peptides, including but not limited to the reduction of intrinsic disulfides, as well as the conversion of amine or carboxylic acid groups to thiol group.
  • Such methods are known to one skilled in the art and there are many commercial kits for that purpose, such as from Molecular Probes division of Invitrogen Inc. and Pierce Biotechnology.
  • the oligomeric peptide can be made by recombinant methods without the need for linking individual isolated peptides by chemical cross linking.
  • Recombinant methods can be use to synthesize a single coding DNA sequence that comprises the several coding sequences of a peptide. For example, two and up to five peptide coding sequences are ligated in tandem. Additional amino acid coding sequences, coding for, e.g. 2-10 amino acids, can be added between each pair of adjoining peptides as spacer sequences.
  • the expressed polypeptide can contain tandem repeats of peptides, each separated by, e.g. 2-10 extra amino acids.
  • Typical amino acid residues used for spacing sequences are glycine, tyrosine, cysteine, lysine, proline, glutamic and aspartic acid, or the like.
  • the oligomeric peptide is expressed in an amino-carboxyl-amino-carboxyl tandem configuration.
  • the oligomeric peptide synthesized can include a tag amino acid sequence for facilitating oligomeric peptide expression, identification and purifications. Such recombinant methods are well known to one skilled in the art.
  • the complex of oligomeric peptides or monomeric peptides are modified by NH 2 -terminal acylation, e.g., acetylation, or thioglycolic acid amidation, by terminal-carboxylamidation, e.g., with ammonia, methylamine, and the like terminal modifications that are known in the art. Terminal modifications are useful to reduce susceptibility by proteinase digestion, and therefore serve to prolong half life of the peptides in solutions, particularly biological fluids where proteases may be present.
  • the peptide e.g. LEKTCDWLPKPNMSASCKEI (SEQ. ID. No. 38) or CDWLPKPNMSASC (SEQ. ID. No. 37) is linked or fused to an amino acid sequence or a polymer that enhances the serum half life.
  • the peptide e.g. LEKTCDWLPKPNMSASCKEI (SEQ. ID. No. 38) or CDWLPKPNMSASC (SEQ. ID. No. 37) is linked or fused to an amino acid sequence that facilitates protein expression and/or purification of the first portion.
  • the peptide e.g. LEKTCDWLPKPNMSASCKEI (SEQ. ID. No. 38) or CDWLPKPNMSASC (SEQ. ID. No. 37) is linked or fused to a therapeutic molecule.
  • Methods of linking a peptide to an amino acid sequence or a polymer can be by chemical cross-linking or by recombinant methods which are well known in the art and are described herein.
  • the peptide e.g. LEKTCDWLPKPNMSASCKEI (SEQ. ID. No. 38) or CDWLPKPNMSASC (SEQ. ID. No. 37) is a cyclic peptide.
  • Cyclic peptides are polypeptide chains whose amino and carboxyl termini are they linked together with a peptide bond or other covalent bond, forming a circular chain.
  • the peptide contains amino and carboxyl terminal cysteine amino acid residues. Cysteines facilitate S-S disulphide bond formation.
  • the peptide contains additional cysteine amino acid residues, wherein the cysteine amino acid residues are near the termini but not necessarily at the very end. In some embodiments, the cysteine amino acid residues are within the five amino acid residues at the termini of the peptide. e.g. LEKTCDWLPKPNMSACA (SEQ. ID. No. 44).
  • Methods of design and synthesis of cyclic peptides are well known in the art, e.g. as described in U.S. Pat. Nos. 5,596,078; 5,990,273; 7,589,170 and U.S. Patent Application No. 20080287649. A skilled artisan would be readily able to modify and apply the methods and techniques for the synthesis of a cyclic saposin A peptide described herein.
  • the peptide is PEGylated.
  • PEGylation is the process of covalent attachment of Polyethylene glycol polymer chains to another molecule, normally a drug or therapeutic protein. PEGylation is routinely achieved by incubation of a reactive derivative of PEG with the target macromolecule.
  • the covalent attachment of PEG to a drug or therapeutic protein can “mask” the agent from the host's immune system (reduced immunogenicity and antigenicity), and increase the hydrodynamic size (size in solution) of the agent which prolongs its circulatory time by reducing renal clearance.
  • PEGylation can also provide water solubility to hydrophobic drugs and proteins.
  • PEGylation by increasing the molecular weight of a molecule, can impart several significant pharmacological advantages over the unmodified form, such as: improved drug solubility, reduced dosage frequency, without diminished efficacy with potentially reduced toxicity, extended circulating life, increased drug stability, and enhanced protection from proteolytic degradation.
  • PEGylated drugs are have wider opportunities for new delivery formats and dosing regimens.
  • Methods of PEGylating molecules, proteins and peptides are well known in the art, e.g. as described in U.S. Pat. Nos. 5,766,897; 7,610,156; 7,256,258 and the International Application No. WO/1998/032466.
  • composition comprising the various peptides described herein are useful for the following: (1) the treatment of an angiogenesis-dependent disease or disorder; (2) the treatment of cancer; (3) the inhibition of the recurrence of an angiogenesis-dependent disease or disorder; (4) the inhibition of the recurrence of cancer; (5) the inhibition of metastasis of cancer in a subject diagnosed with cancer; (6) the inhibition of recurrence of cancer in a subject diagnosed with cancer; (7) the prevention of cancer development in a subject at risk of development of cancer; (8) the prevention of cancer metastasis in a subject previously diagnosed with cancer; and (9) the prevention of the development of cancer malignancy in a subject previously diagnosed with cancer.
  • the invention provides a method of treating an angiogenesis-dependent disease or disorder comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a peptide consisting essentially of the sequence CDWLPKPNMSASC (SEQ. ID. No. 37) and a pharmaceutically acceptable carrier.
  • the invention provides a method of treating an angiogenesis-dependent disease or disorder comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a peptide consisting of the sequence CDWLPKPNMSASC (SEQ. ID. No. 37) and a pharmaceutically acceptable carrier.
  • a method of treating psoriasis comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a peptide consisting essentially of the sequence CDWLPKPNMSASC (SEQ. ID. No. 37) and a pharmaceutically acceptable carrier.
  • a method of treating psoriasis comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a peptide consisting of the sequence CDWLPKPNMSASC (SEQ. ID. No. 37) and a pharmaceutically acceptable carrier.
  • a method of inhibiting the recurrence of an angiogenesis-dependent disease or disorder comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a peptide consisting essentially of the sequence CDWLPKPNMSASC (SEQ. ID. No. 37) and a pharmaceutically acceptable carrier.
  • a method of inhibiting the recurrence of an angiogenesis-dependent disease or disorder comprising administering to a subject in need thereof, a therapeutically effective amount of a composition comprising a peptide consisting of the sequence CDWLPKPNMSASC (SEQ. ID. No. 37) and a pharmaceutically acceptable carrier.
  • a method of inhibiting metastasis of cancer in a subject diagnosed with cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a composition comprising a peptide consisting essentially of the sequence CDWLPKPNMSASC (SEQ. ID. No. 37) and a pharmaceutically acceptable carrier.
  • a method of inhibiting metastasis of cancer in a subject diagnosed with cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a composition comprising a peptide consisting of the sequence CDWLPKPNMSASC (SEQ. ID. No. 37) and a pharmaceutically acceptable carrier.
  • a method of inhibiting recurrence of cancer in a subject diagnosed with cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a composition comprising a peptide consisting essentially of the sequence CDWLPKPNMSASC (SEQ. ID. No. 37) and a pharmaceutically acceptable carrier.
  • a method of inhibiting recurrence of cancer in a subject diagnosed with cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a composition comprising a peptide consisting of the sequence CDWLPKPNMSASC (SEQ. ID. No. 37) and a pharmaceutically acceptable carrier.
  • a method for reducing the likelihood of cancer development in a subject at risk of development of cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a composition comprising a peptide consisting essentially of the sequence CDWLPKPNMSASC (SEQ. ID. No. 37) and a pharmaceutically acceptable carrier.
  • a method for reducing the likelihood of cancer development in a subject at risk of development of cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a composition comprising a peptide consisting of the sequence CDWLPKPNMSASC (SEQ. ID. No. 37) and a pharmaceutically acceptable carrier.
  • a method for reducing the likelihood of cancer metastasis in a subject previously diagnosed with cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a composition comprising a peptide consisting essentially of the sequence CDWLPKPNMSASC (SEQ. ID. No. 37) and a pharmaceutically acceptable carrier.
  • a method for reducing the likelihood of cancer metastasis in a subject previously diagnosed with cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a composition comprising a peptide consisting of the sequence CDWLPKPNMSASC (SEQ. ID. No. 37) and a pharmaceutically acceptable carrier.
  • a method for reducing the likelihood of the development of cancer malignancy in a subject previously diagnosed with cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a composition comprising a peptide consisting essentially of the sequence CDWLPKPNMSASC (SEQ. ID. No. 37) and a pharmaceutically acceptable carrier.
  • a method for reducing the likelihood of the development of cancer malignancy in a subject previously diagnosed with cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a composition comprising a peptide consisting of the sequence CDWLPKPNMSASC (SEQ. ID. No. 37) and a pharmaceutically acceptable carrier.
  • the peptide LEKTCDWLPKPNMSASCKEI (SEQ. ID. No. 38) is also specifically contemplated for the therapeutic methods described herein.
  • the composition comprises of a peptide consisting of the sequence LEKTCDWLPKPNMSASCKEI (SEQ. ID. No. 38) and a pharmaceutically acceptable carrier.
  • the composition comprises of a peptide consisting essentially of the sequence LEKTCDWLPKPNMSASCKEI (SEQ. ID. No. 38) and a pharmaceutically acceptable carrier.
  • the composition comprises of a plurality of peptides or fragments, wherein the peptides are not identical and wherein the peptides are derived from saposin A, are greater than or equal to 10 amino acids long and are not saposin A (SEQ. ID. No. 13).
  • the composition comprises a multimer of peptides or fragments, wherein the peptides are identical and wherein the peptides are derived from saposin A.
  • the composition comprises of a plurality of peptides that are concatamerically linked.
  • the composition comprises of a peptide that linked or fused to an amino acid sequence or a polymer that enhances the serum half life.
  • the composition comprises of a peptide that linked or fused to an amino acid sequence that facilitates protein expression and/or purification
  • the composition comprises of a peptide that is linked or fused to a therapeutic molecule.
  • the composition comprises of a peptide that is PEGylated.
  • the administration is in conjunction with a p53 reactivation agent.
  • the administration is in conjunction with chemotherapy, radiation therapy, and/or a cytostatic agent.
  • the administration is in conjunction with an anti-VEGF agent or an anti-angiogenesis factor.
  • the invention provides an isolated chimeric polypeptide comprising a first portion and a second portion, wherein the first portion is saposin A (SEQ. ID. No. 13) or a functional fragment thereof, and the second portion comprises an amino acid sequence or a polymer that enhances the serum half life of the first portion.
  • the second portion is not a Psap protein, and the first portion, at the minimum, is capable of activating p53 and inducing Tsp-1 expression.
  • the first portion is a conservative amino acid substitution variant of saposin A, a functional fragment of saposin A, or a functional peptide mimetic of a functional fragment of saposin A.
  • Examples of the second portion are serum transferrin or portions thereof, albumin, transthyretin, Fc of IgG (See G. M. Subramanian, (2007), Nature Biotechnology 25, 1411-141), and polymers such as polyethylene glycol for the purpose of enhancing the serum half life.
  • the suitable polymers include, for example, polyethylene glycol (PEG), polyvinyl pyrrolidone, polyvinyl alcohol, polyamino acids, divinylether maleic anhydride, N-(2-Hydroxypropyl)-methacrylamide, dextran, dextran derivatives including dextran sulfate, polypropylene glycol, polyoxyethylated polyol, heparin, heparin fragments, polysaccharides, cellulose and cellulose derivatives, including methylcellulose and carboxymethyl cellulose, starch and starch derivatives, polyalkylene glycol and derivatives thereof, copolymers of polyalkylene glycols and derivatives thereof, polyvinyl ethyl ethers, and ⁇ , ⁇ -Poly[(2-hydroxyethyl)-DL-aspartamide, and the like, or mixtures thereof.
  • PEG polyethylene glycol
  • polyvinyl pyrrolidone polyvinyl alcohol
  • a polymer may or may not have its own biological activity.
  • the polymers can be covalently or non-covalently conjugated to the first portion.
  • Methods of conjugation for increasing serum half life and for radiotherapy are known in the art, for example, in U.S. Pat. Nos. 5,180,816, 6,423,685, 6,884,780, and 7,022,673, which are hereby incorporated by reference in their entirety.
  • the invention provides an isolated chimeric polypeptide comprising a first portion and a second portion, wherein the first portion is saposin A (SEQ. ID. No. 13) or a functional fragment thereof, and the second portion comprises an amino acid sequence that facilitates protein expression and/or purification of the first portion.
  • the second portion is not a Psap protein, and the first portion is capable of activating p53 and inducing Tsp-1 expression.
  • a short peptide of saposin A, a peptidomimetic thereof or conservative amino acid substitution variant thereof can be fused with other proteins or short amino acid residues for the purposes of facilitating protein expression and purification, e.g. thioredoxin and six histidine tags.
  • the invention provides an isolated chimeric polypeptide comprising a first portion and a second portion, wherein the first portion is saposin A (SEQ. ID. No. 13) or a functional fragment thereof, and the second portion is a therapeutic molecule.
  • the second portion is not a Psap protein, and the first portion is capable of activating p53 and inducing Tsp-1 expression.
  • the first portion is conjugated to a therapeutic molecule.
  • the therapeutic molecule is an anti-angiogenic therapeutic molecule, e.g. angiostatin and endostatin.
  • the therapeutic molecule can be a toxin or a radiotherapy molecule.
  • the functional fragment of Psap for example, a short peptide of saposin A, a peptidomimetic thereof, or conservative amino acid substitution variant thereof can be fused with other anti-angiogenic factors, e.g. angiostatin and endostatin to enhance anti-angiogenic potency. Fusions or conjugates of such Psap peptides have dual functions: activate p53 and induce Tsp-1 expression as well as anti-angiogenic activity. Methods of determining p53 activating activity and Tsp-1 expression inducing activity are described herein. Determining anti-angiogenic activities are well known to one skilled in the art, for example by, a chick chorioallantoic membrane assay.
  • the Psap proteins, peptides, peptidomimetics, fusion protein of saposin A or conservative amino acid substitution variant thereof include modification within the sequence, such as, modification by terminal-NH 2 acylation, e.g., acetylation, or thioglycolic acid amidation, by terminal-carboxylamidation, e.g., with ammonia, methylamine, and the like terminal modifications. Terminal modifications are useful, and are well known, to reduce susceptibility to proteinase digestion, and therefore serve to prolong half life of the polypeptides in solutions, particularly biological fluids where proteases may be present.
  • the methods described herein can be used in combination with other treatment options available for the angiogenesis-dependent disease or disorder.
  • the treatment methods described herein can be administered in conjunction with chemotherapy, radiation therapy, and/or a cytostatic agent.
  • the treatment methods described herein are administered in conjunction with anti-VEGF or anti-angiogenic factor, and/or p53 reactivation agent.
  • cancer chemotherapeutic agents include, but are not limited to, irinotecan (CPT-11); erlotinib; oxalipatin; anthracyclins-idarubicin and daunorubicin; doxorubicin; alkylating agents such as melphalan and chlorambucil; cis-platinum, methotrexate, and alkaloids such as vindesine and vinblastine.
  • a cytostatic agent is any agent capable of inhibiting or suppressing cellular growth and multiplication. Examples of cytostatic agents used in the treatment of cancer are paclitaxel, 5-fluorouracil, 5-fluorouridine, mitomycin-C, doxorubicin, and zotarolimus.
  • Other cancer therapeutics includes inhibitors of matrix metalloproteinases such as marimastat, growth factor antagonists, signal transduction inhibitors and protein kinase C inhibitors.
  • anti-VEGF agents include bevacizumab (AvastinTM), VEGF Trap, CP-547,632, AG13736, AG28262, SU5416, SU11248, SU6668, ZD-6474, ZD4190, CEP-7055, PKC 412, AEE788, AZD-2171, sorafenib, vatalanib, pegaptanib octasodium, IM862, DC101, angiozyme, Sirna-027, caplostatin, neovastat, ranibizumab, thalidomide, and AGA-1470, a synthetic analog of fumagillin (alternate names: Amebacilin, Fugillin, Fumadil B, Fumadil) (A. G. Scientific, catalog #F1028), an angio-inhibitory compound secreted by Aspergillus fumigates
  • anti-VEGF agent refers to any compound or agent that produces a direct effect on the signaling pathways that promote growth, proliferation and survival of a cell by inhibiting the function of the VEGF protein, including inhibiting the function of VEGF receptor proteins.
  • agent or “compound” as used herein means any organic or inorganic molecule, including modified and unmodified nucleic acids such as antisense nucleic acids, RNAi agents such as siRNA or shRNA, peptides, peptidomimetics, receptors, ligands, and antibodies.
  • Preferred VEGF inhibitors include for example, AVASTIN® (bevacizumab), an anti-VEGF monoclonal antibody of Genentech, Inc.
  • VEGF Trap (Regeneron/Aventis). Additional VEGF inhibitors include CP-547,632 (3-(4-Bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin 1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide hydrochloride; Pfizer Inc., NY), AG13736, AG28262 (Pfizer Inc.), SU5416, SU11248, & SU6668 (formerly Sugen Inc., now Pfizer, New York, N.Y.), ZD-6474 (AstraZeneca), ZD4190 which inhibits VEGF-R2 and -R1 (AstraZeneca), CEP-7055 (Cephalon Inc., Frazer, Pa.), PKC 412 (Novartis), AEE788 (Novartis), AZD-2171), NEXAVAR®
  • VEGFR2-selective monoclonal antibody DC101 ImClone Systems, Inc.
  • angiozyme a synthetic ribozyme from Ribozyme (Boulder, Colo.) and Chiron (Emeryville, Calif.)
  • Sirna-027 an siRNA-based VEGFR1 inhibitor, Sirna Therapeutics, San Francisco, Calif.
  • Neovastat IEterna Zentaris Inc; Quebec City, Calif.
  • Anti-angiogenesis factors include any agent that directly or indirectly inhibits, prevents, and stops angiogenesis and/or neovascularization.
  • Anti-angiogenesis factors include anti-VEGF agent.
  • Other anti-angiogenesis factors include, but are not limited to angiostatin, endostatin and cleaved antithrombin III, alpha-2 antiplasmin (fragment), angiostatin (plasminogen fragment), antiangiogenic antithrombin III, cartilage-derived inhibitor (CDI), CD59 complement fragment, endostatin (collagen XVIII fragment), fibronectin fragment, gro-beta (a C-X-C chemokine), heparinases heparin hexasaccharide fragment, human chorionic gonadotropin (hCG), interferon alpha/beta/gamma, interferon inducible protein (IP-10), interleukin-12, kringle 5 (plasminogen fragment), beta-thromboglobulin, EGF (frag
  • bombesin/gastrin-releasing peptide (GRP) antagonists such as RC-3095 and RC-3940-II (Bajol A M, et. al., British Journal of Cancer (2004) 90, 245-252), monoclonal antibody therapies directed against specific pro-angiogenic growth factors and/or their receptors: example: bevacizumab (Avastin®), cetuximab (Erbitux®), panitumumab (VectibixTM), and trastuzumab (Herceptin®); small molecule tyrosine kinase inhibitors (TKIs) of multiple pro-angiogenic growth factor receptors.
  • GRP bombesin/gastrin-releasing peptide
  • TKIs small molecule tyrosine kinase inhibitors
  • TKIs that are currently approved as anti-cancer therapies are erlotinib (Tarceva®), sorafenib (Nexavar®), and sunitinib (Sutent®); and inhibitors of mTOR (mammalian target of rapamycin) such as temsirolimus (ToricelTM) and bortezomib (Velcade®). thalidomide (Thalomid®). Doxycyclin,
  • determining anti-VEGF activity and/or anti-angiogenesis activity are well known to one skilled in the art.
  • the human umbilical vein endothelial cell phosphorylation assay and the VEGF-induced proliferation assay as described by Holash et. al., 2002, in Proc. Natl. Acad. Sci. USA, 99:11393-98 can be used to determine the anti-VEGF inhibitory activity of an anti-VEGF agent and are hereby explicitly incorporated by reference.
  • the human VEGF 165 can be used as the positive control in the cell phosphorylation and proliferation assays.
  • the cell phosphorylation assay detects tyrosine phosphorylation which is an indicator of the activation of the VEGF signaling pathway.
  • the proliferation assay detects cell proliferation induced by the activation of the VEGF signaling pathway.
  • An anti-VEGF agent that blocks the activation of the VEGF signaling pathway will give reduced tyrosine phosphorylation and reduced cell proliferation in these assays compared to the results when the human VEGF 165 is used as a positive control.
  • the methods described herein are administered in conjunction with a p53 reactivation agent.
  • a p53 reactivation agent Around half of all human tumors carry p53 mutations, mostly point mutations that abrogate p53′ s specific DNA binding and transactivation activity. p53 mutation is associated with poor therapeutic response and prognosis. Tumors that carry wild type p53 often have other alterations in the p53 pathway that ablate the p53 tumor suppression response.
  • Several strategies have been designed to restore p53 function in human tumors, including p53 gene therapy, reactivation of mutant p53, and activation of wild type p53 by inhibition of the p53 antagonist MDM2. In all cases, the aim is to eliminate the tumor through induction of massive apoptosis (Bykov VJ and Wiman KG. 2003).
  • a p53 reactivation agent is any organic or inorganic chemical, compound, including protein and nucleic acid molecule that can restore the p53 response of a tumor cell.
  • the p53 reactivation agent can be a gene therapy agent, such as a vector, carrying a wild-type p53 gene for reconstitution into tumor cells with deletions in the p53 gene, that is, introduction of an intact cDNA copy of the p53 gene using a suitable viral vector, typically one based on adenovirus (Adp53) (Wiman, 2006) or ADVEXIN (Introgen Inc.).
  • Adp53 adenovirus
  • Adp53 Adp53
  • ADVEXIN Introgen Inc.
  • P53 reactivation agents that activate p53 by blocking the p53/MDM2 and the p53/HDM-2 protein-protein interactions to prevent p53 degradation are MDM-2 inhibitors and HDM-2 inhibitors.
  • Some examples include a group of imidazoline compounds dubbed Nutlins (Vassilev L T et al., 2004) which fit neatly into the small pocket where MDM-2 contacts p53 and prevent the interaction between the two proteins.
  • Mutant p53 proteins have point mutations that abrogate p53′ s specific DNA binding and transactivation activity. These mutant p53 often fold abnormally and thus lose the ability to regulate their target genes. New small molecules that help these mutant p53 proteins fold more normally have been successful in reactivating the mutant p53 protein. Examples are the novel compounds RITA (Issaeva N., et. al., 2004; Espinoza-Fonseca LM. 2005), the related PRIMA-1 and MIRA-1 (Rehman, A. 2005), and CP-31398 (Tanner S and Barberis A., 2004; Ho C K and Li G., 2005).
  • RITA Issaeva N., et. al., 2004; Espinoza-Fonseca LM. 2005
  • PRIMA-1 and MIRA-1 Rehman, A. 2005
  • CP-31398 Teanner S and Barberis A., 2004; Ho C K and Li G., 2005.
  • a p53 reactivation agent can be one that facilitates DNA binding of the mutant p53 thus enabling the mutant p53 to function again as an activator of transcription.
  • An example of such a p53 reactivation agent is described in Roth, J. et. al., 2003, where a chimeric adaptor protein made of the DNA-binding and tetramerizing portions of the p53-homologue p73 (i.e. having tumor suppressive effects) fused to the oligomerization domain of p53 enables the mutant p53 to bind to its respective p53 response elements and initiate apoptosis.
  • drugs that mimic p53′ s effects in activating gene transcription are also contemplated.
  • agents that increase the production, expression, and/or stability of p′73, the p53 homologue can also be used in combination with the methods described herein. The increase of p73 production, expression, and/or stability in tumor cells serves to promote apoptosis.
  • the methods described herein are administered in conjunction with therapeutics, physiotherapy and/or behavioral psychotherapy used in the treatment of rheumatoid arthritis, obesity, endometriosis, and Alzheimer's disease.
  • NSAIDS non-steroidal anti-inflammatory drugs
  • corticosteroids such as prednisone or cortisone
  • anti-malarial medications such as hydroxychloroquine
  • gold such as hydroxychloroquine
  • sulfasalazine gold
  • penicillamine a member of the group consisting of hydroxychloroquine
  • cyclophosphamide a member of the group consisting of hydroxychloroquine
  • cyclosporine a member of the group consisting of hydroxychloroquine
  • minocycline such as hydroxychloroquine
  • interleukin receptor antagonist such as interleukin receptor antagonist
  • Treatment for Alzhemier's disease include, but are not be limited to, nonsteroidal anti-inflammatory drugs (NSAIDs), estrogen, steroids such as prednisone, vitamin E, menantine, donepezil, rivastigmine, tacrine, and galantamine.
  • NSAIDs nonsteroidal anti-inflammatory drugs
  • steroids such as prednisone, vitamin E, menantine, donepezil, rivastigmine, tacrine, and galantamine.
  • Holistic medicine include example such as gingko nuts extracts.
  • Treatment of endometrosis include, but should not be construed as limited to, a combination oral contraceptives (estrogen plus a progestin), progestins (such as medroxyprogesterone, danazol (a synthetic hormone related to testosterone, gonadotropin-releasing hormone agonists (GnRH agonists such as buserelin, goserelin, leuprolide and nafarelin), and nonsteroidal anti-inflammatory drugs (NSAIDs) for pain control.
  • a combination oral contraceptives estrogen plus a progestin
  • progestins such as medroxyprogesterone, danazol (a synthetic hormone related to testosterone, gonadotropin-releasing hormone agonists (GnRH agonists such as buserelin, goserelin, leuprolide and nafarelin
  • NSAIDs nonsteroidal anti-inflammatory drugs
  • Examples of treatment options for obesity include dieting and nutritional counseling, exercise regime, gastric-bypass surgery, and drugs such as a combination of fenfluramine and phentermine (often called fen-phen), orlistat, sibutramine, phentermine, benzphetamine, diethylpropion, mazindol, and phendimetrazine.
  • Functional peptides of Psap or saposin A, variants and peptidomimetics thereof can be chemically synthesized and purified by biochemical methods that are well known in the art such as solid phase peptide synthesis using t-Boc (tert-butyloxycarbonyl) or FMOC (9-flourenylmethloxycarbonyl) protection group described in “Peptide synthesis and applications” in Methods in molecular biology Vol. 298, Ed. by John Howl and “Chemistry of Peptide Synthesis” by N. Leo Benoiton, 2005, CRC Press, (ISBN-13: 978-1574444544) and “Chemical Approaches to the Synthesis of Peptides and Proteins” by P.
  • Organic linkers attached to the polymer support activate the resin sites and strengthen the bond between the (-amino acid and the polymer support. Chloromethyl linkers, which were developed first, have been found to be unsatisfactory for longer peptides due to a decrease in step yields.
  • the PAM (phenylacetamidomethyl) resin because of the electron withdrawing power of the acid amide group on the phenylene ring, provides a much more stable bond than the classical resin.
  • Another alternative resin for peptides under typical peptide synthesis conditions is the Wang resin. This resin is generally used with the FMOC labile protecting group.
  • a labile group protects the alpha-amino group of the amino acid. This group should be easily removed after each coupling reaction so that the next alpha-amino protected amino acid may be added.
  • Typical labile protecting groups include t-Boc and FMOC t-Boc is a very satisfactory labile group which is stable at room temperature and easily removed with dilute solutions of trifluoroacetic acid (TFA) and dichloromethane.
  • FMOC is a base labile protecting group which is easily removed by concentrated solutions of amines (usually 20-55% piperidine in N-methylpyrrolidone).
  • an acid labile (or base stable) resin such as an ether resin, is desired.
  • the stable blocking group protects the reactive functional group of an amino acid and prevents formation of complicated secondary chains. This blocking group must remain attached throughout the synthesis and may be removed after completion of synthesis. When choosing a stable blocking group, the labile protecting group and the cleavage procedure to be used should be considered.
  • the stable blocking groups are removed and the peptide is cleaved from the resin to produce a “free” peptide.
  • the stable blocking groups and organic linkers are labile to strong acids such as TFA.
  • the resin is washed away and the peptide is extracted with ether to remove unwanted materials such as the scavengers used in the cleavage reaction.
  • the peptide is then frozen and lyophilized to produce the solid peptide. This is then characterized by HPLC and MALDI before being used.
  • the peptide should be purified by HPLC to higher purity before use.
  • peptide synthesizing machines are available for solid phase peptide synthesis.
  • the Advanced Chemtech Model 396 Multiple Peptide Synthesizer and an Applied Biosystems Model 432A Peptide synthesizer There are commercial companies that make custom synthetic peptide to order, e.g. Abbiotec, Abgent, AnaSpec Global Peptide Services, LLC. Invitrogen and rPeptide, LLC.
  • One basic method of designing a molecule which mimics a known protein or peptide is first to identifies the active region(s) of the known protein (for example in the case of an antibody-antigen interaction one identifies which region(s) of the antibody enable binding to the antigen), and then searches for a mimetic which emulates the active region. Since the active region of the known protein is relatively small, it is hoped that a mimetic will be found which is much smaller (e.g. in molecular weight) than the protein, and correspondingly easier and cheaper to synthesis. Such a mimetic could be used as a convenient substitute for the protein, as an agent for interacting with the target molecule.
  • peptide mimetic to a particular peptide or protein
  • M.O.E. Chemical Computing Group's Molecular Operating Environment
  • European Patent EP1206494 European Patent EP1206494
  • the SuperMimic program is designed to identify compounds that mimic parts of a protein, or positions in proteins that are suitable for inserting mimetics.
  • the application provides libraries that contain peptidomimetic building blocks on the one hand and protein structures on the other.
  • a peptide can be produced in vitro directly or can be expressed from a nucleic acid, which can be produced in vitro. Methods of synthetic peptide and nucleic acid chemistry are well known in the art.
  • a library of peptide molecules also can be produced, for example, by constructing a cDNA expression library from mRNA collected from a tissue of interest. Methods for producing such libraries are well known in the art (see, for example, Sambrook et al., Molecular Cloning: A laboratory manual (Cold Spring Harbor Laboratory Press 1989), which is incorporated herein by reference).
  • a peptide encoded by the cDNA is expressed on the surface of a cell or a virus containing the cDNA.
  • Functional fragments of Psap or saposin A, functional variants and functional peptide mimetics thereof and fusion proteins thereof can also be synthesized and purified by molecular methods that are well known in the art.
  • molecular biology methods and recombinant heterologous protein expression systems be used.
  • recombinant protein may be expressed in bacteria, mammal, insects, yeast, or plant cells.
  • the Psap proteins can be synthesized and purified by protein and molecular methods that are well known in the art. Preferably molecular biology methods and recombinant heterologous eukaryotic protein expression systems are used.
  • An example of expression and purification of the human prosaposin is described in Gopalakrishnan, M. M., et. al., 2004 and in U.S. Pat. No. 5,700,909.
  • the purification of rat prosaposin is described in Morales, C R., 1998. These references are hereby incorporated by reference in their entirety. The approach can be applied to the purification of human Psap proteins by one skilled in the art.
  • the variants encode less than 50 amino acid substitutions, less than 40 amino acid substitutions, less than 30 amino acid substitutions, less than 25 amino acid substitutions, less than 20 amino acid substitutions, less than 15 amino acid substitutions, less than 10 amino acid substitutions, less than 5 amino acid substitutions, less than 4 amino acid substitutions, less than 3 amino acid substitutions, or less than 2 amino acid substitutions relative to the prosaposin protein.
  • a “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a side chain with a similar charge.
  • Families of amino acid residues having side chains with similar charges have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan,
  • mutations can be introduced randomly along all or part of the coding sequence, such as by saturation mutagenesis, error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis, site-specific mutagenesis, gene reassembly, GSSM and any combination thereof.
  • the resultant mutants can be screened for Tsp-1 and p53 expression stimulating activity by the assays described herein to identify mutants that retain or have enhanced Tsp-1 and p53 expression stimulating activity.
  • Functional fragments of Psap are incomplete proteins of Psap and will therefore have less than the 524 amino acids in the polypeptide.
  • the full-length polypeptide can be truncated at the amino terminus or the carboxyl terminus or at both ends.
  • the polypeptide can also have an internal deletion of the amino acids such as the deletion of the SapB or SapA coding regions.
  • the functional fragments has less than 50 amino acid deletion, less than 40 amino acid deletion, less than 30 amino acid deletion, less than 25 amino acid deletion, less than 20 amino acid deletion, less than 15 amino acid deletion, less than 10 amino acid deletion, less than 5 amino acid deletion, less than 4 amino acid deletion, less than 3 amino acid deletion, or less than 2 amino acid deletion, relative to the parent Psap protein.
  • the Tsp-1 and p53 expression stimulating activity refers to Psap protein's ability to induce an increase in the expression levels of Tsp-1 and p53 in surrounding tumor stroma or fibroblast cells.
  • the stimulating activity also include the effects on tumor and non-tumor cells.
  • the introduced mutations can be silent or neutral missense mutations, i.e., have no, or little, effect on Psap protein's Tsp-1 and p53 expression stimulating activity. These types of mutations can be useful to optimize codon usage, or improve recombinant Psap protein expression and production. Alternatively, non-neutral missense mutations can alter Psap protein's ability to stimulate Tsp-1 and p53 expression.
  • One of skill in the art would be able to design and test mutant molecules for desired properties such as no alteration of Psap protein's ability to stimulate Tsp-1 and p53 expression.
  • the encoded protein can routinely be expressed and the functional and/or biological activity of the encoded protein, (e.g., ability to stimulate Tsp-1 and p53 in tumor-derived fibroblasts) can be determined using techniques described herein or by routinely modifying techniques known in the art.
  • Embodied in the invention is a vector carrying a cDNA encoding prosaposin, or coding cDNA fragments of prosaposin.
  • Conventional polymerase chain reaction (PCR) cloning techniques can be used to generate the complete cDNA sequence, using, e.g. the PCR primers:
  • the amplified cDNA of Psap is: 5′ATGTACGCCCTCTTCCTCCTGGCCAGCCTCCTGGGCGCGGCTCTAGCCGGCCCGGT CCTTGGACTGAAAGAATGCACCAGGGGCTCGGCAGTGTGGTGCCAGAATGTGAAGA CGGCGTCCGACTGCGGGGCAGTGAAGCACTGCCTGCAGACCGTTTGGAACAAGCCA ACAGTGAAATCCCTTCCCTGCGACATATGCAAAGACGTTGTCACCGCAGCTGGTGA TATGCTGAAGGACAATGCCACTGAGGAGGAGATCCTTGTTTACTTGGAGAAGACCT GTGACTGGCTTCCGAAACCGAACATGTCTGCTTCATGCAAGGAGATAGTGGACTCC TACCTCCCTGTCATCCTGGACATCATTAAAGGAGAAATGAGCCGTCCTGGGGAGGT GTGCTCTGCTCTCTCAACCTAGCAGAGCTGAATCAATAAGAT
  • cDNAs can be cloned into a general purpose cloning vector such as pUC19, pBR322, pBluescript vectors (Stratagene Inc.) or pCR TOPO® from Invitrogen Inc.
  • a general purpose cloning vector such as pUC19, pBR322, pBluescript vectors (Stratagene Inc.) or pCR TOPO® from Invitrogen Inc.
  • the cDNA is subcloned into the vector pDNR-dual.
  • the resultant recombinant vector carrying cDNA sequence encoding prosaposin can then be used for further molecular biological manipulations such as site-directed mutagenesis to enhance Tsp-1 and/or p53 expression stimulating activity, or can be subcloned into protein expression vectors or viral vectors for protein synthesis in a variety of protein expression systems using host cells selected from the group consisting of mammalian cell lines, insect cell lines, yeast, and plant cells.
  • Cre recombinase to move the cDNA's into pCMVneo for expression.
  • Examples of other expression vectors and host cells are the pET vectors (Novagen), pGEX vectors (Amersham Pharmacia), and pMAL vectors (New England labs. Inc.) for protein expression in E. coli host cell such as BL21, BL21(DE3) and AD494(DE3)pLysS, Rosetta (DE3), and Origami(DE3) (Novagen); the strong CMV promoter-based pcDNA3.1 (Invitrogen) and pClneo vectors (Promega) for expression in mammalian cell lines such as CHO, COS, HEK-293, Jurkat, and MCF-7; replication incompetent adenoviral vector vectors pAdeno X, pAd5F35, pLP-Adeno-X-CMV (Clontech), pAd/CMV/V5-DEST, pAd-DEST vector (Invitrogen) for adenovirus-mediated gene transfer and
  • the chloroplast expression vector p64 carrying the most versatile chloroplast selectable marker aminoglycoside adenyl transferase (aadA), which confer resistance to spectinomycin or streptomycin, can be used to express foreign protein in the chloroplast.
  • Biolistic gene gun method is used to introduce the vector in the algae. Upon its entry into chloroplasts, the foreign DNA is released from the gene gun particles and integrates into the chloroplast genome through homologous recombination.
  • Site-directed mutagenesis of Psap cDNA sequence in a vector can be used to create specific amino acid mutations and substitutions.
  • Site-directed mutagenesis can be carried out using the QuikChange® site-directed mutagenesis kit from Stratagene according to manufacture's instructions or any method known in the art.
  • the invention provides expression vectors carrying the Psap cDNA that encodes prosaposin or fragments, derivatives, or variants thereof for the expression and purification of the recombinant Psap proteins produced from a eukaryotic protein expression system using host cells selected from the group consisting of mammal, insects, yeast, or plant cells.
  • Psap protein can be fused to transferrin, IgG, or albumin, to name a few, to enhance serum half life and pharmacokinetics in the individual being treated.
  • Psap protein can also be fused to a tag protein such as tandem histidine residues (6 ⁇ His), GST, myc, thioredoxin first 105 amino acids or HA tag for the purification and/or enhance solubility of the expressed recombinant protein in heterologous system.
  • Enzymatic digestion with serine proteases such as thrombin and enterokinase cleave and release the Psap protein from the histidine or myc tag, releasing the recombinant Psap protein from the affinity resin while the histidine-tags and myc-tags are left attached to the affinity resin.
  • serine proteases such as thrombin and enterokinase
  • Other reasons for tagging the Psap protein include monitoring the distribution of the protein over time in the individual, since the tagged Psap is distinguishable from the native Psap protein.
  • the recombinant vector that expresses prosaposin is a viral vector.
  • the viral vector can be any viral vector known in the art including but not limited to those derived from adenovirus, adeno-associated virus (AAV), retrovirus, and lentivirus. Recombinant viruses provide a versatile system for gene expression studies and therapeutic applications.
  • a simplified system for generating recombinant adenoviruses is presented by He T C. et. al. Proc. Natl. Acad. Sci. USA 95:2509-2514, 1998.
  • the gene of interest is first cloned into a shuttle vector, e.g. pAdTrack-CMV.
  • the resultant plasmid is linearized by digesting with restriction endonuclease Pme I, and subsequently co-transformed into E. coli .
  • Recombinant adenovirus vectors are selected for kanamycin resistance, and recombination confirmed by restriction endonuclease analyses. Finally, the linearized recombinant plasmid is transfected into adenovirus packaging cell lines, for example HEK 293 cells (E1-transformed human embryonic kidney cells) or 911 (E1-transformed human embryonic retinal cells) (Human Gene Therapy 7:215-222, 1996). Recombinant adenovirus are generated within the HEK 293 cells.
  • HEK 293 cells E1-transformed human embryonic kidney cells
  • 911 E1-transformed human embryonic retinal cells
  • the invention provides a recombinant lentivirus for the delivery and expression of prosaposin protein in either dividing or non-dividing mammalian cells.
  • the HIV-1 based lentivirus can effectively transduce a broader host range than the Moloney Leukemia Virus (MoMLV)-base retroviral systems.
  • Preparation of the recombinant lentivirus can be achieved using the pLenti4/V5-DESTTM, pLenti6/V5-DESTTM or pLenti vectors together with ViraPowerTM Lentiviral Expression systems from Invitrogen.
  • the invention provides a recombinant adeno-associated virus (rAAV) vector for the expression of a prosaposin protein.
  • the rAAV vector encoding a prosaposin protein is administered to slow, inhibit, or prevent the growth of cancer and tumors such as glioma.
  • genes can be delivered into a wide range of host cells including many different human and non-human cell lines or tissues. Because AAV is non-pathogenic and does not elicit an immune response, a multitude of pre-clinical studies have reported excellent safety profiles.
  • rAAVs are capable of transducing a broad range of cell types, and transduction is not dependent on active host cell division. High titers, >10 8 viral particles/ml, are easily obtained in the supernatant and 10 11 -10 12 viral particles/ml can be obtained with further concentration.
  • the transgene is integrated into the host genome so expression is long term and stable.
  • AAV vectors Large scale preparation of AAV vectors is made by a three-plasmid cotransfection of a packaging cell line: AAV vector carrying the Psap DNA coding sequence, AAV RC vector containing AAV rep and cap genes, and adenovirus helper plasmid pDF6, into 50 ⁇ 150 mm plates of subconfluent 293 cells. Cells are harvested three days after transfection, and viruses are released by three freeze-thaw cycles or by sonication.
  • AAV vectors are then purified by two different methods depending on the serotype of the vector.
  • AAV2 vector is purified by the single-step gravity-flow column purification method based on its affinity for heparin (Auricchio, A., et. al., 2001, Human Gene therapy 12; 71-6; Summerford, C. and R. Samulski, 1998, J. Virol. 72:1438-45; Summerford, C. and R. Samulski, 1999, Nat. Med. 5: 587-88).
  • AAV2/1 and AAV2/5 vectors are currently purified by three sequential CsCl gradients.
  • the invention provides for a pharmaceutical composition comprising prosaposin, functional fragments or variants thereof and a pharmaceutically acceptable carrier.
  • the invention also provides for a pharmaceutical composition comprising the expression vector carrying the cDNA that encodes prosaposin, functional fragments or variants thereof and a pharmaceutically acceptable carrier.
  • the term “pharmaceutical composition” refers to the Psap proteins in combination with a pharmaceutically acceptable carrier.
  • the pharmaceutical composition does not include tissue culture media, water, and serum.
  • the therapeutic composition of the invention can be administered in any convenient vehicle that is physiologically acceptable.
  • the compounds can be formulated for a variety of modes of administration, including systemic, topical or localized administration. Techniques and formulations generally can be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., latest edition.
  • a therapeutically effective amount of Psap, functional fragments or variants, or vector comprising the cDNA encoding Psap or fragments or variants thereof is administered in order to prevent or inhibit the progression of the angiogenesis-dependent disease or disorder.
  • the Psap, functional fragments or variants, or vector comprising a cDNA encoding Psap or fragments or variants thereof are generally combined with a carrier such as a diluent or excipient which can include fillers, extenders, binding, wetting agents, disintegrants, surface-active agents, or lubricants, depending on the nature of the mode of administration and dosage forms.
  • a carrier such as a diluent or excipient which can include fillers, extenders, binding, wetting agents, disintegrants, surface-active agents, or lubricants, depending on the nature of the mode of administration and dosage forms.
  • Typical dosage forms include tablets, powders, liquid preparations including suspensions, emulsions and solutions, granules, capsules and suppositories, as well as liquid preparations for injections.
  • gene therapy virus for angiogenesis-dependent diseases or disorders that are accessible externally on the skin, such as dermal hemangiomas and skin cancer lesions (melanoma), gene therapy virus, expression vectors, or Psap, fragments or variants can be preferably applied topically to the hemangioma or cancer lesion site in a therapeutically effective amount in admixture with pharmaceutical carriers, in the form of topical pharmaceutical compositions.
  • the gene therapy virus can be in the form of an adenovirus, adeno-associated virus or lentivirus.
  • Such compositions include solutions, suspensions, lotions, gels, creams, ointments, emulsions, skin patches, etc. All of these dosage forms, along with methods for their preparation, are well known in the pharmaceutical and cosmetic art.
  • topical formulations typically contain the active ingredient in a concentration range of 0.1 to 100 mg/ml, in admixture with suitable vehicles.
  • suitable vehicles For gene therapy viruses, the dosage ranges from 10 6 to 10 14 particle per application.
  • Other desirable ingredients for use in such preparations include preservatives, co-solvents, viscosity building agents, carriers, etc.
  • the carrier itself or a component dissolved in the carrier can have palliative or therapeutic properties of its own, including moisturizing, cleansing, or anti-inflammatory/anti-itching properties.
  • Penetration enhancers can, for example, be surface active agents; certain organic solvents, such as di-methylsulfoxide and other sulfoxides, dimethyl-acetamide and pyrrolidone; certain amides of heterocyclic amines, glycols (e.g. propylene glycol); propylene carbonate; oleic acid; alkyl amines and derivatives; various cationic, anionic, nonionic, and amphoteric surface active agents; and the like.
  • organic solvents such as di-methylsulfoxide and other sulfoxides, dimethyl-acetamide and pyrrolidone
  • certain amides of heterocyclic amines such as glycols (e.g. propylene glycol); propylene carbonate; oleic acid; alkyl amines and derivatives; various cationic, anionic, nonionic, and amphoteric surface active agents; and the like.
  • Topical administration of a pharmacologically effective amount can utilize transdermal delivery systems well known in the art.
  • An example is a dermal patch.
  • the biolistic gene gun method of delivery can be used.
  • the gene gun is a device for injecting cells with genetic information, originally designed for plant transformation.
  • the payload is an elemental particle of a heavy metal coated with plasmid DNA. This technique is often simply referred to as biolistics.
  • Another instrument that uses biolistics technology is the PDS-1000/He particle delivery system.
  • the Psap, functional fragments, or variants, expression vector, and/or gene therapy virus can be coated on minute gold particles, and these coated particles are “shot” into biological tissues such as hemangiomas and melanoma under high pressure.
  • An example of gene gun-based method is described for DNA based vaccination of cattle by Loehr B. I. et. al. J. Virol. 2000, 74:6077-86.
  • compositions described herein can be administered directly by intratumoral injection. If the solid tumors and hemangiomas are accessible by injection, the Psap, functional fragments, or variants, expression vector, and/or viral vector can be administered by injection directly to the tumor mass as a pharmaceutical formulation.
  • the preferred formulation is also sterile saline or Lactated Ringer's solution. Lactated Ringer's solution is a solution that is isotonic with blood and intended for intravenous administration.
  • pharmaceutical formulation of the present invention can be applied to the eye by intra-vitral or intraocular injection.
  • the invention can be formulated as an eye drop solution for direct application on the eyes.
  • compositions described herein can also be administered systemically as a pharmaceutical formulation.
  • Systemic routes include but are not limited to oral, parenteral, nasal inhalation, intratracheal, intrathecal, intracranial, and intrarectal.
  • the pharmaceutical formulation is a liquid, preferably in sterile saline, lactated Ringer's or Hank's solution.
  • the pharmaceutical formulation can be in solid forms and re-dissolved or suspended immediately prior to use. Lyophilized forms are also included.
  • compositions described herein are administered to a mammal, preferably a human, in a pharmaceutically acceptable dosage form, including those that can be administered to a human intravenously as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-arterial, intrasynovial, intrathecal, oral, topical, or inhalation routes.
  • the pharmaceutical formulation can be infused upstream from the site of the cells whose activity is to be modulated.
  • Implantable drug pumps as for example Infusaid® pumps (Infusaid, Inc.), are useful for delayed-release intraarterial administration.
  • the preferred embodiment is the intramuscular injection of AAV viral vectors encoding the cDNA of Psap, functional fragments or variants thereof.
  • compositions described herein are also suitably administered by intratumoral, peritumoral, intralesional or perilesional routes, to exert local as well as systemic effects.
  • the intraperitoneal route is expected to be particularly useful, for example, in the treatment of ovarian tumors.
  • additional conventional pharmaceutical preparations such as tablets, granules, powders, capsules, and sprays can be preferentially required.
  • further conventional additives such as binding-agents, wetting agents, propellants, lubricants, and stabilizers can also be required.
  • the composition described herein takes the form of a cationic liposome formulation such as those described for intratracheal gene therapy treatment of early lung cancer treatment (Zou Y. et. al., Cancer Gene Ther. 2000 Can;7(5):683-96).
  • the liposome formulations are especially suitable for aerosol use in lung cancer patients.
  • the pharmaceutical formulation can be contained within a lipid particle or vesicle, such as a liposome or microcrystal, which is also suitable for parenteral administration.
  • the particles can be of any suitable structure, such as unilamellar or plurilamellar, so long as Psap, fragments, variants thereof, or vector carrying the cDNA of Psap fragments, variants thereof are contained therein.
  • Vector DNA and/or virus can be entrapped in ‘stabilized plasmid-lipid particles’ (SPLP) containing the fusogenic lipid dioleoylphosphatidylethanolamine (DOPE), low levels (5-10 mol %) of cationic lipid, and stabilized by a polyethyleneglycol (PEG) coating (Zhang Y. P. et. al. Gene Ther. 1999, 6:1438-47).
  • Positively charged lipids such as N-[1-(2,3-dioleoyloxi)propyl]-N,N,N-trimethyl-amoniummethylsulfate, or “DOTAP,” are particularly preferred for such particles and vesicles.
  • DOTAP N-[1-(2,3-dioleoyloxi)propyl]-N,N,N-trimethyl-amoniummethylsulfate
  • DOTAP DOTAP
  • the dosage for viral vectors is 10 6 to 1 ⁇ 10 14 viral vector particles per application per patient.
  • Systemic administration can also be by transmucosal or transdermal means, or the compounds can be administered orally.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, bile salts and fusidic acid derivatives for transmucosal administration.
  • detergents can be used to facilitate permeation.
  • Transmucosal administration can be through use of nasal sprays, for example, as well as formulations suitable for administration by inhalation, or suppositories.
  • the Psap proteins or vector are formulated into conventional as well as delayed release oral administration forms such as capsules, tablets, and tonics.
  • Topical formulations can be administered up to four-times a day.
  • dosage forms of the compositions described herein include pharmaceutically acceptable carriers that are inherently non-toxic and non-therapeutic.
  • carriers include ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts, or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, and polyethylene glycol.
  • Carriers for topical or gel-based forms of Psap proteins include polysaccharides such as sodium carboxymethylcellulose or methylcellulose, polyvinylpyrrolidone, polyacrylates, polyoxyethylene-polyoxypropylene-block polymers, polyethylene glycol and wood wax alcohols.
  • conventional depot forms are suitably used.
  • Such forms include, for example, microcapsules, nano-capsules, liposomes, plasters, inhalation forms, nose sprays, sublingual tablets, and sustained release preparations.
  • sustained release compositions see U.S. Pat. No. 3,773,919, EP 58,481A, U.S. Pat. No. 3,887,699, EP 158,277A, Canadian Patent No.
  • the Psap proteins will usually be formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml and the vector should be in the range of 10 6 to 1 ⁇ 10 14 viral vector particles per application per patient.
  • ingredients can be added to the pharmaceutical formulations as described herein, such as anti-oxidants, e.g., ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose, or dextrins; chelating agents such as EDTA; and sugar alcohols such as mannitol or sorbitol.
  • anti-oxidants e.g., ascorbic acid
  • polypeptides e.g., polyarginine or tripeptides
  • proteins such as serum albumin, gelatin, or immunoglobulins
  • hydrophilic polymers such as
  • the pharmaceutical formulation used for therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes).
  • preservatives can be used to prevent the growth or action of microorganisms.
  • Various preservatives are well known and include, for example, phenol and ascorbic acid.
  • the Psap proteins ordinarily will be stored in lyophilized form or as an aqueous solution if it is highly stable to thermal and oxidative denaturation.
  • the pH of the Psap proteins preparations typically will be about from 6 to 8, although higher or lower pH values can also be appropriate in certain instances.
  • the localized concentration or amount administered to a subject can be determined empirically and will depend upon the purpose of the administration, the area to be treated, the effectiveness of the composition, and the manner of administration.
  • the localized concentration at the site of the targeted cells will desirably be in the range of about 0.05 to 50 ⁇ M, or more particularly 0.2 to 5 ⁇ M, although higher or lower dosages can be employed as appropriate.
  • a dosage of from about 0.01, 0.1, or 1 mg/kg up to 50, 100, or 150 mg/kg or more can typically be employed.
  • the invention described herein provides a method of screening and identifying tumor secreted factors such as proteins that promote angiogenesis and metastasis, the method comprises: (a) contacting fibroblasts and/or endothelial cells with a cancer cell derived factor; and (b) determining the levels of angiogenic growth factors and/or angiogenesis inhibitors and comparing with reference levels of angiogenic growth factors and/or angiogenesis inhibitors, wherein a decrease in the level of an angiogenesis inhibitor and/or an increase in the level of an angiogenic growth factors indicates that the cancer cell derived factor contains factors (e.g. proteins, peptides, carbohydrates, sugars, lipids, inorganic and organic compounds) that promote angiogenesis and metastasis.
  • factors e.g. proteins, peptides, carbohydrates, sugars, lipids, inorganic and organic compounds
  • Cancer cell derived factor as used herein include, but are not limited to conditioned media from cultured cancer cells obtained from an individual diagnosed with cancer, lysate of cancer cells, homogenates of cancer cells, blood plasma from an individual diagnosed with cancer, whole blood from an individual diagnosed with cancer, biopsy tissue samples from an individual diagnosed with cancer and fractionated samples thereof. Fractionation of cancer cell derived factors can be performed, for example, with size-exclusion gel chromatography and copper-heparin affinity chromatography, although other fractionation approaches can be used.
  • the cultured cancer cells can be non-angiogenic, angiogenic, non-metastatic, or metastatic cancer. Methods of determining whether a cancer is metastatic or angiogenic are well known to one skilled in the art, e.g. measurement of biomarkers such as metalloproteinase pump-1 (U.S. Pat. No. 5,726,015), CA125, or CEA.
  • the fibroblasts and/or endothelial cells can also be co-cultured with cancer cells obtained from the individual diagnosed with cancer.
  • the screening method comprises co-culturing fibroblasts and/or endothelial cells with cancer cells, determining the levels of angiogenic growth factors and/or angiogenesis inhibitors in the tested fibroblasts and/or endothelial cells, and comparing with reference levels of angiogenic growth factors and/or angiogenesis inhibitors, wherein a decrease in the level of an angiogenesis inhibitor and/or an increase in the level of an angiogenic growth factors in the tested fibroblasts and/or endothelial cells indicates that the tested cancer secretes factors that promote angiogenesis and metastasis.
  • Reference levels of angiogenic growth factors and angiogenesis inhibitors are those obtained from fibroblasts and/or endothelial cells not in contact with the tested cancer cell derived factor, e.g. fibroblasts and/or endothelial cells in culture media only.
  • the reference levels are normalized to 100%.
  • a decrease in the level of an angiogenesis inhibitor compared with a reference level of the same angiogenesis inhibitor is at least 95% to 0% of the reference angiogenesis inhibitor level, including all percentages between 95% and 0%, i.e. at least 95%, 80%, 70% . . . , 20%, . . . , 10%, . . . 5%, . . . 2% . . . 0% of the reference angiogenesis inhibitor level.
  • An increase in the level of an angiogenic growth factor compared with a reference level of the same angiogenic growth factor is at least 105% or more of the reference angiogenic growth factor level.
  • Angiogenic growth factors are any factors that promote, bring about, facilitate and lead to angiogenesis.
  • Angiogenic growth factors include, but are not limited to EGFR, E-cadherin, VEGF, angiogenin, angiopoietin-1, del-1, fibroblast growth factors: acidic (aFGF) and basic (bFGF), follistatin, granulocyte colony-stimulating factor (G-CSF), hepatocyte growth factor (HGF), scatter factor (SF), interleukin-8 (IL-8), leptin, midkine, placental growth factor, platelet-derived endothelial cell growth factor (PD-ECGF), platelet-derived growth factor-BB (PDGF-BB), pleiotrophin (PTN), progranulin, proliferin, transforming growth factor-alpha (TGF-alpha), transforming growth factor-beta (TGF-beta), tumor necrosis factor-alpha (TNF-alpha) and c
  • the angiogenesis inhibitors are any factors that inhibit, impede, arrest, block, stop, prevent the onset and progression of angiogenesis.
  • Angiogenesis inhibitors include, but are not limited to Tsp-1, Psap, p53, angioarrestin, angiostatin (plasminogen fragment), antiangiogenic antithrombin III, cartilage-derived inhibitor (CDI), CD59 complement fragment, endostatin (collagen XVIII fragment), fibronectin fragment, gro-beta, heparinases heparin hexasaccharide fragment, human chorionic gonadotropin (hCG), interferon alpha/beta/gamma, interferon inducible protein (IP-10), interleukin-12, kringle 5 (plasminogen fragment), metalloproteinase inhibitors (TIMPs), 2-Methoxyestradiol, placental ribonuclease inhibitor, plasminogen activator inhibitor, platelet factor-4 (PF4), pro
  • fractions that contained secreted factors that promote angiogenesis and metastasis can then be further analyzed by tandem LC/MS to identify the factors.
  • the invention described herein provides a method of screening and identifying compounds, drugs, and/or small molecules that inhibit, prevent, arrest, impede, stop, and/or block angiogenesis and metastasis comprising: (a) contacting fibroblasts and/or endothelial cells with a cancer cell derived factor in the presence of compounds, drugs, and/or small molecules; and (b) determining the levels of angiogenic growth factors and angiogenesis inhibitors, and comparing with reference levels of angiogenic growth factors and angiogenesis inhibitors, wherein an increase in the level of an angiogenesis inhibitor and/or a decrease in the level of an angiogenic growth factor indicate that the said compounds, drugs, and/or small molecules can inhibit, prevent, arrest, stop, and/or block the angiogenesis and metastasis.
  • Cancer cell derived factor as used herein include, but are not limited to conditioned media from cultured cancer cells obtained from an individual diagnosed with cancer, lysate of cancer cells, homogenates of cancer cells, blood plasma from an individual diagnosed with cancer, whole blood from an individual diagnosed with cancer, biopsy tissue samples from an individual diagnosed with cancer and fractionated samples thereof.
  • the cancer cell derived factor is metastatic cancer or tumors. Fractionation of cancer cell derived factors can be performed, for example, with copper-heparin affinity chromatography, although other fractionation approaches scan be used.
  • the cultured cancer cells can be non-angiogenic, angiogenic, non-metastatic, or metastatic cancer.
  • Methods of determining whether a cancer is metastatic or angiogenic are well known to one skilled in the art, e.g. measurement of biomarkers such as metalloproteinase pump-1 (U.S. Pat. No. 5,726,015), CA125, or CEA.
  • biomarkers such as metalloproteinase pump-1 (U.S. Pat. No. 5,726,015), CA125, or CEA.
  • the fibroblasts and/or endothelial cells can also be co-cultured with cancer cells obtained from the individual diagnosed with cancer.
  • Reference levels of angiogenic growth factors and angiogenesis inhibitors are those obtained from fibroblasts and/or endothelial cells not treated with the cancer cell derived factor, e.g. fibroblasts and/or endothelial cells in culture media.
  • the reference levels are normalized to 100%.
  • a decrease in the level of an angiogenic growth factor compared with a reference level of the same angiogenic growth factor is at least 95% to 0% of the reference angiogenic growth factor level, including all percentages between 95% and 0%, i.e. at least 95%, 80%, 70% . . . , 20%, . . . , 10%, . . . . 5%, . . . 2% . . . 0% of the reference angiogenesis inhibitor level.
  • An increase in the level of an angiogenesis inhibitor compared with a reference level of the same angiogenesis inhibitor is at least 105% or more of the reference angiogenesis inhibitor level.
  • the invention described herein provides a method of screening and identifying compounds, drugs, and/or small molecules that promote anti-angiogenic and anti-metastatic activities comprising (a) contacting fibroblasts and/or endothelial cells with a compound; and (b) determining the expression levels of p53 and Tsp-1 comparing with reference levels of p53 and Tsp-1, wherein increases in the levels of p53 and Tsp-1 expression in the treated cells indicate that the tested compound have anti-angiogenesis and anti-metastatic activity.
  • the method further comprises determining the amount of secreted Psap protein in the treated cells and comparing with a reference level of secreted Psap protein wherein an increase in the secreted Psap protein from the treated cells further indicates that the tested compound have anti-angiogenesis and anti-metastatic activity.
  • Reference levels of p53 and Tsp-1 expression and secreted Psap protein are those obtained from fibroblasts and/or endothelial not treated with any compound, drug, and/or small molecules. The reference levels are normalized to 100%.
  • An increase in the level of p53 and Tsp-1 expression and secreted Psap protein compared with a reference level of the respective p53 and Tsp-1 expression and secreted Psap protein is at least 105% or more of the reference respective p53 and Tsp-1 expression and secreted Psap protein.
  • a variety of different fibroblasts can be used for the screening method described herein, each fibroblast originating from a different organ or tissue type in the body, such as bone-marrow derived fibroblast or lung-derived fibroblast.
  • Other types of cells include but are not limited to, stromal cells, immune inflammatory cells, and endothelial cells. These cells can be derived from a various tissues such as the brain, lung, liver, bone, breast, prostate, pancreas, kidney, skin, and colon. Different compound, drugs, and/or small molecules can have different effects on different cells types, depending on the origin of the cells. It is specifically contemplated that a small molecule that has demonstrated anti-angiogenic and anti-metastatic activity in pancreas-derived fibroblast can be useful in treating pancreatic cancer.
  • the libraries of compounds, drugs, and/or small molecules used for screening can be obtained from commercial sources such as Biomol Inc. which a variety of compound libraries: bioactive lipid library, endocannabinoid library, fatty acid library, Harvard Institute of Chemistry and Cell Biology (ICCB) known bioactives library, ion channel ligand library, kinase inhibitor library, kinase/phosphatase inhibitor library neurotransmitter library, LOPAC 1280 compound library, natural products library, nuclear receptor ligand library, orphan ligand library, protease inhibitor library, phosphatase inhibitor library, and rare natural products library; TimTec, Inc, and many others in the Molecular Libraries Screening Centers Network (MLSCN).
  • custom libraries can be made using services of companies such as AsisChem, Inc. Existing screening library are also available among the community of academic researchers at Harvard University, Cambridge, USA and Whitehead Institute for Biomedical Research at MIT, Cambridge, USA.
  • the invention described herein provides a method of predicting the metastatic tissue specificity of cancer cells in an individual diagnosed with cancer comprising: (a) contacting fibroblasts and/or endothelial cells with a cancer cell derived factor; (b) determining the levels of Tsp-1, Psap, and/or c-Myc in the fibroblasts and/or endothelial cells and comparing to the reference levels of Tsp-1, Psap, and c-Myc of fibroblasts and/or endothelial cells not treated with cancer cell derived factors, wherein repression of Tsp-1 and Psap expressions, and/or an activation of c-Myc expression in the treated fibroblasts and/or endothelial cells indicate that cancer is likely to metastasize to the type of tissue from which the test fibroblast and/or endothelial cells had originated.
  • Cancer cell derived factors as used herein include, but are not limited to conditioned media from cultured cancer cells obtained from an individual diagnosed with cancer, preferably a metastatic form of cancer, lysates of cancer cell, homogenates of cancer cells, blood plasma from individual diagnosed with cancer, whole blood from an individual diagnosed with cancer, and biopsy tissue samples from an individual diagnosed with cancer.
  • conditioned media from cultured cancer cells obtained from an individual diagnosed with cancer, preferably a metastatic form of cancer, lysates of cancer cell, homogenates of cancer cells, blood plasma from individual diagnosed with cancer, whole blood from an individual diagnosed with cancer, and biopsy tissue samples from an individual diagnosed with cancer.
  • a sample of liver cancer cells is obtained from said individual and cultured in vitro.
  • the blood plasma from the individual can be used.
  • the conditioned media of the cultured liver cancer cells are collected and added to a variety of different fibroblast tissue cultures.
  • fibroblasts A variety of different fibroblasts are used, each fibroblast originating from a different organ or tissue type in the body, such as bone-marrow derived fibroblast or lung-derived fibroblast.
  • the fibroblasts and/or endothelial cells can be co-cultured with the liver cancer cells in transwell apparati. The fibroblasts and/or endothelial cells are then analyzed for the levels of Tsp-1, Psap, or c-Myc expression.
  • Tsp-1 and Psap or a higher level of c-Myc in a treated fibroblast and/or endothelial cells, for example, bone marrow derived fibroblast, compared to the reference levels of Tsp-1, Psap, and c-Myc indicate that said fibroblasts and/or endothelial cells are responsive to factors from said liver cancer cells and are conducive to the establishment of said liver cancer cells once the cancer cells have metastasized to the bone marrow. Therefore, liver cancer in the individual is likely to metastasize to the bone marrow. A skilled clinician can then proceed to screen the bone marrow of that individual for cancer.
  • Reference levels of Tsp-1, Psap, and c-Myc are those obtained from a control sample of non-treated fibroblasts with any cancer cells derived factors.
  • the reference Tsp-1, Psap, and c-Myc levels are normalized to 100%.
  • Lower levels of Tsp-1 and Psap determined in the fibroblasts and/or endothelial cells treated with cancer cells derived factors compared to reference Tsp-1 and Psap levels are at least 95% to 0% of the reference Tsp-1 and Psap levels, including all percentages between 95% and 0%, i.e. at least 95%, 80%, 70% . . . , 20%, . . . , 10%, . . .
  • a higher level of c-Myc in the fibroblasts treated with cancer cells derived factors compared to the reference c-Myc level is at least 105% or more of the reference c-myc level.
  • the screening assays used are according to those described herein for the in vitro conditioned media assays and co-culture assays in the Example section. A skilled artisan would be able to make adjustments to the method for various agents being screened. Basically, the assay screens for elevated Tsp-1 level in the stroma of non-metastatic tumors in the presence of an agent, condition media or fractions thereof as compared to in the absence of that agent, condition media or fractions thereof.
  • conditioned media from non-metastatic cells was fractionated over a heparin-Cu-column and the fractions were used to treated fibroblasts derived from the primary site of tumors (prostate and breast) as well as sites of metastasis (lung and bone). After a period of incubation, aliquots of the culture media were taken and analyzed for Tsp-1 and prosaposin levels. The analyses can be performed by Western blots or by ELISA. After identifying the fraction(s) that contained Tsp-1 stimulating activity, that “active” fraction is then sent for mass spectrometry sequencing to identify the protein(s) within the active fraction.
  • the candidates are validated by silencing their expression in non-metastatic cells using shRNA and by ectopically expressing them in metastatic cells.
  • this same screening platform can be used to identify tumor secreted proteins that repress VEGF expression or stimulate the expression of other anti-angiogenic proteins such as endostatin (collagen 18), semaphorin 3F, prolyl hydroxylase, etc.
  • the method described herein is not restricted to the analyses of Tsp-1, Psap, and c-Myc.
  • the levels of a variety of angiogenic growth factors and angiogenesis inhibitors are known to one skilled in the art.
  • the invention provides a method for prognostic evaluation of an individual diagnosed with cancer comprising determining the level of Psap expression in a tumor sample from an individual diagnosed with cancer, wherein when the level of Psap in the tumor sample is lower than a reference Psap level, there is an increased likelihood of cancer metastasis and/or recurrence of neoplastic disease, and thus a poor prognosis.
  • the invention provides a method for prognostic evaluation in an individual diagnosed with cancer comprising: (a) determining the level of Psap expression in a sample from an individual diagnosed with cancer at a first time point; (b) determining the level of Psap expression in a sample from an individual diagnosed with cancer at a second time point, the first time point being before the second time point; and (c) comparing the levels of Psap from the time points with a reference Psap level; wherein when the level of Psap at the second time point becomes lower than the reference Psap level, the cancer has likely metastased.
  • the sample is blood, platelet, serum or plasma.
  • the method described herein makes a prediction on the likelihood of cancer metastasis, recurrence, and relapse of neoplastic disease in a subject diagnosed with cancer by comparing the level of Psap in the tumor to a reference level of Psap.
  • a reference level of Psap is that obtained from a control sample of non-tumor, healthy cells in the same tissue type or organ type from which a tumor sample was excised.
  • the reference Psap level is normalized to 100%.
  • a lower level of Psap determined in a tumor sample compared to a reference Psap level is at least 95% to 0% of the reference Psap level, including all percentages between 95% and 0%, i.e. at least 95%, 80%, 70% .
  • the reference Psap level is determined using healthy breast tissue from a female subject. This reference breast Psap level is compared with a level of Psap determined in a breast cancer tissue sample.
  • the prognosis is an increased likelihood of cancer metastasis and/or recurrence of neoplastic disease, and thus a poor prognosis.
  • the method for prognostic evaluation of an individual diagnosed with cancer further comprises: (a) determining the level of Psap expression in the tumor stroma; and (b) determining the level of Tsp-1 expression in the tumor stroma, wherein when the levels of Psap and Tsp-1 in the tumor stroma are lower than a reference Psap level and a reference Tsp-1 level respectively, there is an increased likelihood of cancer metastasis and/or recurrence of neoplastic disease, and thus a poor prognosis.
  • the method described herein makes a prediction on the likelihood of cancer metastasis, recurrence, and relapse of neoplastic disease in a subject diagnosed with cancer by comparing the levels of Psap and Tsp-1 in the tumor stroma with reference levels of Psap and Tsp-1.
  • Reference levels of Psap and Tsp-1 are those obtained from a control sample of non-tumor, healthy cells in the same tissue type or organ type from which a tumor sample was excised.
  • the reference Psap and Tsp-1 levels are normalized to 100%.
  • Lower levels of Psap and Tsp-1 in a tumor sample compared to the reference Psap and Tsp-1 levels are at least 95% to 0% of the reference Psap level, including all percentages between 95% and 0%, i.e. at least 95%, 80%, 70% . . . , 20%, . . . , 10%, . . . 5%, . . . 2% . . . 0% of the reference Psap or Tsp-1 levels.
  • the reference Psap and Tsp-1 levels are determined using healthy lung tissue from a male subject.
  • lung Psap and Tsp-1 levels are then compared with levels of Psap and Tsp-1 determined in a lung cancer tissue sample. If the lung cancer tissue sample has a Psap level of 25% and a Tsp-1 level of 5% compared to the respective reference Psap and Tsp-1 levels found in healthy lung tissue, the prognosis is an increased likelihood of cancer metastasis and/or recurrence of neoplastic disease, and thus a poor prognosis. Since highly metastatic tumors have virtually no detectable Tsp-1 and Psap, extremely low levels (i.e.
  • the treatment plan can include administering Psap protein and/or vector expressing Psap protein in conjunction with surgical removal of tumors or tissue with cancerous lesions, chemotherapy, radiation therapy, a cytostatic agent, an anti-VEGF agent, an anti-angiogenesis factor and/or a p53 reactivation agent.
  • Administering a composition comprising of Psap protein and or vector expressing Psap protein systemically raises the level of Psap and consequently the Tsp-1 and p53 in the cancer cells, surrounding tissue, and potential metastatic sites to which metastatic cancer cell can target. This can prevent future metastasis and also establishment of secondary tumors.
  • Compositions comprising of Psap proteins and/or vector expressing Psap proteins can also be injected intratumorly.
  • the methods described herein provide a method of treating an individual diagnosed with cancer comprising making a prognosis evaluation based on the levels of Psap in the tumor sample and tumor stroma, and administering a therapeutically effective amount of Psap protein or a vector comprising a nucleic acid encoding Psap protein and a pharmaceutically acceptable carrier if the Psap level is lower than 95% of a reference Psap level and the prognosis is poor.
  • the invention provides a method for diagnosing metastasis an individual diagnosed with cancer comprising determining the level of Psap expression in a sample from an individual diagnosed with cancer, wherein when the level of Psap in the sample is same or lower than a reference Psap level, there is an increased likelihood of cancer metastasis and/or recurrence of neoplastic disease, and thus a poor prognosis.
  • the sample can be blood, preferably platelet, serum or plasma. Methods of collecting and isolating platelet, serum or plasma are well known in the art.
  • the reference Psap level is the average Psap level in the corresponding platelet, serum or plasma of normal healthy individuals not diagnosed with any cancer.
  • the reference Psap levels are normalized to 100%.
  • the Psap levels in the platelet, serum or plasma of patients having non-metastatic cancer are higher than the reference Psap levels, at least 5% higher.
  • the Psap levels in platelet, serum or plasma of patients having metastatic cancer tend to be comparable, and can even be lower than the reference Psap levels.
  • the invention provides a method for monitoring or surveillance for the development of metastasis in an individual diagnosed with cancer comprising determining the level of Psap expression in a sample from an individual at a first time point, determining the level of Psap expression in a sample from an individual at a second time point, the first time point being before the second time point; comparing the levels of Psap from the time points with a reference Psap level, wherein the levels of Psap at the second time point become the lower than the reference Psap level, the cancer is deemed likely to have developed into a metastasis cancer and thus a poor prognosis.
  • the sample can be blood, preferably platelet, serum or plasma.
  • the reference Psap level is the average Psap levels in the corresponding platelet, serum or plasma of normal healthy individuals not diagnosed with any cancer.
  • the reference Psap levels are normalized to 100%.
  • the Psap levels in the platelet, serum or plasma of patients diagnosed having non-metastatic cancer are higher than the reference Psap levels, at least 5% higher.
  • the Psap levels in platelet, serum or plasma of patients having metastatic cancer can be the same, and/or lower than the reference Psap levels.
  • the Psap level in the sample can be used as a biomarker for the progression of the disease into the metastatic form. For example, a patient has been newly diagnosed with breast cancer. A single tumor mass was found and excised.
  • a sample of her plasma is collected at this initial diagnosis and the Psap level in her plasma is determined and compared to the reference Psap level. Over the next few years, periodic sampling of her plasma Psap level can be performed, e.g. every three months initially for the first two years, then every six months for the next five years thereafter if she remains cancer free in the first two years. These samplings of plasma Psap level can be compared to the reference Psap level and charted over time. When there is a drop in her plasma Psap level compared to the reference Psap level, at least 5%, this is an indication that possibly the cancer has recurred and is of the metastatic form. Her physician can then perform a thorough screening for the cancer recurrence.
  • the method described herein provides a method of prognosis evaluation in an individual diagnosed with cancer.
  • the methods described herein provide a method of treating an individual diagnosed with cancer comprising: (a) determining a level of Psap in a tumor sample from said individual; (b) comparing the Psap level determined in (a) with a reference Psap level; and (c) when said Psap level determined in (a) is lower than 95% of said reference Psap level, administering a therapeutically effective amount of Psap protein or a vector comprising a nucleic acid encoding Psap protein and a pharmaceutically acceptable carrier.
  • Reference levels of Psap is that obtained from a control sample of non-tumor, healthy cells in the same tissue type or organ type from which a tumor sample was excised. The reference Psap level is normalized to 100%.
  • the reference Psap level is the average of the Psap levels obtained from a population of healthy individuals and the reference Psap level is normalized to 100%.
  • the average Psap level from a population of healthy individuals is for a specific tissue type or organ type, e.g. the liver or lungs.
  • the average Psap level is from obtained from the liver Psap levels of a population of healthy individuals.
  • the reference Psap level is normalized to 100%.
  • prognosis is intended to encompass predictions and likelihood analyses of disease progression, particularly tumor recurrence, metastatic spread and disease relapse.
  • the prognostic methods of the invention are intended to be used clinically in making decisions concerning treatment modalities, including therapeutic intervention, diagnostic criteria such as disease staging, and disease monitoring and surveillance for metastasis or recurrence of neoplastic disease.
  • the method for prognosis evaluation is carried out on tissue samples removed from a subject in a surgical procedure, for example, in a biopsy.
  • the method is carried out using human cancer patient tumor samples, or samples from human patients suspected of having cancer or having abnormal growth or lesions.
  • Various methods of harvesting a tissue sample are known to those skilled in the art and include, for example, fine needle aspiration, image-guided needle core aspiration, liposuction, laser capture microdissection, and ultrasound guided needle core aspiration, to name a few.
  • the samples are preserved, for example, in paraffin, and prepared for histological and immunohistochemical analysis.
  • the samples can be prepared for other methods of determining and quantifying protein expression levels that are well known in the art.
  • Tissues samples are often dissolved in TrizolTM reagent to prevent the breakdown and to preserve the integrity of the nucleic acids and proteins.
  • Nucleic acid molecules can then be extracted and isolated from the TrizolTM dissolved sample using any of a number of procedures, which are well-known in the art. For example, the most common approach is the alcohol salt precipitation of nucleic acids.
  • the patient's blood can be drawn directly into anti-coagulants containing citrate, EDTA, PGE, and theophylline.
  • the whole blood should be separated into the plasma portion, the cells, and platelets portion by refrigerated centrifugation at 3500 g, 2 minutes. Since platelets have a tendency to adhere to glass, it is preferred that the collection tube be siliconized. After centrifugation, the supernatant is the plasma.
  • the plasma is filtered though a 0.2 ⁇ m filter to remove residual platelets and is kept at ⁇ 20° C. before measurements are performed.
  • the serum can be collected from the whole blood. Collect the blood in a hard plastic or glass tube; blood will not clot in soft plastic. Draw 15 mL of whole blood for 6 mL of serum. The whole blood is allowed to stand at room temperature for 30 minutes to 2 hours until a clot has formed. Carefully separate clot from the sides of the container using a glass rod or wooden applicator stick and leave overnight at 4° C. After which, decant serum, centrifuge, and/or using a Pasteur pipette, remove serum into a clean tube. Clarify the serum by centrifugation at 2000-3000 rpm for 10 minutes. The serum is stored at ⁇ 20° or ⁇ 80° C. measurement is performed. Detailed described of obtaining serum using collection tubes can be found in U.S. Pat. No. 3,837,376 and is incorporated by reference. Blood collection tubes can also be purchased from BD Diagnostic Systems, Greiner Bio-One, and Kendall Company.
  • Platelets can be separated from whole blood.
  • whole blood is centrifuged as described herein to separate the blood cells from the plasma, a pellet is formed at the end of the centrifugation, with the plasma above it.
  • Centrifugation separates out the blood components (red blood cells, white blood cells, and platelets) by their various densities.
  • the red blood cells (RBCs) are denser and will be the first to move to the bottom of the collection/centrifugation tube, followed by the smaller white blood cells, and finally the platelets.
  • the plasma fraction is the least dense and is found on top of the pellet.
  • the “buffy coat” which contains the majority of platelets will be sandwiched between the plasma and above the RBCs. Centrifugation of whole blood (with anti-coagulant, PGE and theophylline) can produce an isolated a platelet rich “buffy coat” that lies just above the buoy.
  • the “buffy” coat contains the concentrated platelets and white blood cells.
  • Platelets can be separated from blood according to methods described in U.S. Pat. No. 4,656,035 using lectin to agglutinate the platelets in whole blood.
  • the methods and apparatus described in U.S. Pat. No. 7,223,346 can be used involving a platelet collection device comprising a centrifugal spin-separator container with a cavity having a longitudinal inner surface in order to collect the “buffy coat” enriched with platelets after centrifugation.
  • the methods and apparatus as described in WO/2001/066172 can be used. Each of these are incorporated by reference herein in their entirety.
  • Platelets can be isolated by the two methods described in A. L. Copley and R. B. Houlihan, Blood, 1947, 2:170-181, which is incorporated by reference herein in its entirety. Both methods are based on the principle that the platelet layer can be obtained by repeated fractional centrifugation.
  • the whole blood can be first separated into platelet-rich plasma and cells (white and red blood cells).
  • Platelet rich plasma (PRP) can be isolated from the blood centrifugation of citrated whole blood at 200 ⁇ G for 20 minutes. The platelet rich plasma is then transferred to a fresh polyethylene tube. This PRP is then centrifuged at 800 ⁇ G to pellet the platelets and the supernatant (platelet poor plasma [PPP]) can be saved for analysis by ELIZA at a later stage. Platelets can be then gently re-suspended in a buffer such as Tyrodes buffer containing 1 U/ml PGE2 and pelleted by centrifugation again.
  • a buffer such as Tyrodes buffer containing 1 U/ml PGE2
  • the wash can be repeated twice in this manner before removing the membrane fraction of platelets by centrifugation with Triton X, and lysing the pellet of platelet for Psap analyses.
  • Platelets can be lysed using 50 mM Tris HCL, 100-120 mM NaCl, 5 mM EDTA, 1% Igepal and Protease Inhibitor Tablet (complete TM mixture, Boehringer Manheim, Indianopolis, Ind.).
  • the pellet of platelets can be dissolved in Trizol® immediately after separation from the plasma.
  • Real time PCR is an amplification technique that can be used to determine levels of mRNA expression.
  • Real-time PCR evaluates the level of PCR product accumulation during amplification. This technique permits quantitative evaluation of mRNA levels in multiple samples.
  • mRNA levels mRNA is extracted from a biological sample, e.g. a tumor and normal tissue, and cDNA is prepared using standard techniques.
  • Real-time PCR can be performed, for example, using a Perkin Elmer/Applied Biosystems (Foster City, Calif.) 7700 Prism instrument.
  • Matching primers and fluorescent probes can be designed for genes of interest using, for example, the primer express program provided by Perkin Elmer/Applied Biosystems (Foster City, Calif.). Optimal concentrations of primers and probes can be initially determined by those of ordinary skill in the art, and control (for example, beta-actin) primers and probes can be obtained commercially from, for example, Perkin Elmer/Applied Biosystems (Foster City, Calif.). To quantitate the amount of the specific nucleic acid of interest in a sample, a standard curve is generated using a control. Standard curves can be generated using the Ct values determined in the real-time PCR, which are related to the initial concentration of the nucleic acid of interest used in the assay.
  • Standard dilutions ranging from 10 1 -10 6 copies of the gene of interest are generally sufficient.
  • a standard curve is generated for the control sequence. This permits standardization of initial content of the nucleic acid of interest in a tissue sample to the amount of control for comparison purposes.
  • the TaqMan based assays use a fluorogenic oligonucleotide probe that contains a 5′ fluorescent dye and a 3′ quenching agent.
  • the probe hybridizes to a PCR product, but cannot itself be extended due to a blocking agent at the 3′ end.
  • the 5′ nuclease activity of the polymerase for example, AmpliTaq
  • RNA transcripts can be achieved by Northern blotting, wherein a preparation of RNA is run on a denaturing agarose gel, and transferred to a suitable support, such as activated cellulose, nitrocellulose or glass or nylon membranes. Labeled (e.g., radiolabeled) cDNA or RNA is then hybridized to the preparation, washed and analyzed by methods such as autoradiography.
  • a suitable support such as activated cellulose, nitrocellulose or glass or nylon membranes.
  • Labeled (e.g., radiolabeled) cDNA or RNA is then hybridized to the preparation, washed and analyzed by methods such as autoradiography.
  • RNA transcripts can further be accomplished using known amplification methods. For example, it is within the scope of the present invention to reverse transcribe mRNA into cDNA followed by polymerase chain reaction (RT-PCR); or, to use a single enzyme for both steps as described in U.S. Pat. No. 5,322,770, or reverse transcribe mRNA into cDNA followed by symmetric gap lipase chain reaction (RT-AGLCR) as described by R. L. Marshall, et al., PCR Methods and Applications 4: 80-84 (1994).
  • RT-PCR polymerase chain reaction
  • RT-AGLCR symmetric gap lipase chain reaction
  • amplification methods which can be utilized herein include but are not limited to the so-called “NASBA” or “3SR” technique described in PNAS USA 87: 1874-1878 (1990) and also described in Nature 350 (No. 6313): 91-92 (1991); Q-beta amplification as described in published European Patent Application (EPA) No. 454-4610; strand displacement amplification (as described in G. T. Walker et al., Clin. Chem. 42: 9-13 (1996) and European Patent Application No. 684315; and target mediated amplification, as described by PCT Publication WO 9322461.
  • NASBA so-called “NASBA” or “3SR” technique described in PNAS USA 87: 1874-1878 (1990) and also described in Nature 350 (No. 6313): 91-92 (1991); Q-beta amplification as described in published European Patent Application (EPA) No. 454-4610; strand displacement amplification (as described in G. T. Walker e
  • In situ hybridization visualization can also be employed, wherein a radioactively labeled antisense RNA probe is hybridized with a thin section of a biopsy sample, washed, cleaved with RNase and exposed to a sensitive emulsion for autoradiography.
  • the samples can be stained with haematoxylin to demonstrate the histological composition of the sample, and dark field imaging with a suitable light filter shows the developed emulsion.
  • Non-radioactive labels such as digoxigenin can also be used.
  • mRNA expression can be detected on a DNA array, chip or a microarray.
  • Oligonucleotides corresponding to enzyme are immobilized on a chip which is then hybridized with labeled nucleic acids of a test sample obtained from a patient. Positive hybridization signal is obtained with the sample containing enzyme transcripts.
  • Methods of preparing DNA arrays and their use are well known in the art. (See, for example U.S. Pat. Nos. 6,618,6796; 6,379,897; 6,664,377; 6,451,536; 548,257; U.S. 20030157485 and Schena et al. 1995 Science 20:467-470; Gerhold et al. 1999 Trends in Biochem. Sci.
  • Serial Analysis of Gene Expression can also be performed (See for example U.S. Patent Application 20030215858).
  • mRNA is extracted from the tissue sample to be tested, reverse transcribed, and fluorescent-labeled cDNA probes are generated.
  • the microarrays capable of hybridizing to enzyme cDNA are then probed with the labeled cDNA probes, the slides scanned and fluorescence intensity measured. This intensity correlates with the hybridization intensity and expression levels.
  • Quantitative amplification involves simultaneously co-amplifying a known quantity of a control sequence using the same primers. This provides an internal standard that can be used to calibrate the PCR reaction. Detailed protocols for quantitative PCR are provided, for example, in Innis et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, Inc. N.Y.
  • the levels of Psap and Tsp-1 proteins are measured by contacting the tissue sample with an antibody-based binding moiety that specifically binds to Psap or Tsp-1, or to a fragment of Psap or Tsp-1. Formation of the antibody-protein complex is then detected by a variety of methods known in the art.
  • antibody-based binding moiety or “antibody” includes immunoglobulin molecules and immunologically active determinants of immunoglobulin molecules, e.g., molecules that contain an antigen binding site which specifically binds (immunoreacts with) to the Psap proteins.
  • antibody-based binding moiety is intended to include whole antibodies, e.g., of any isotype (IgG, IgA, IgM, IgE, etc), and includes fragments thereof which are also specifically reactive with the Psap proteins. Antibodies can be fragmented using conventional techniques.
  • the term includes segments of proteolytically-cleaved or recombinantly-prepared portions of an antibody molecule that are capable of selectively reacting with a certain protein.
  • proteolytic and/or recombinant fragments include Fab, F(ab') 2 , Fab', Fv, dAbs and single chain antibodies (scFv) containing a VL and VH domain joined by a peptide linker.
  • the scFv's can be covalently or non-covalently linked to form antibodies having two or more binding sites.
  • antibody-base binding moiety includes polyclonal, monoclonal, or other purified preparations of antibodies and recombinant antibodies.
  • antibody-base binding moiety is further intended to include humanized antibodies, bispecific antibodies, and chimeric molecules having at least one antigen binding determinant derived from an antibody molecule.
  • the antibody-based binding moiety detectably labeled.
  • Labeled antibody includes antibodies that are labeled by a detectable means and include, but are not limited to, antibodies that are enzymatically, radioactively, fluorescently, and chemiluminescently labeled. Antibodies can also be labeled with a detectable tag, such as c-Myc, HA, VSV-G, HSV, FLAG, V5, or HIS. The detection and quantification of Psap or Tsp-1 present in the tissuel samples correlate to the intensity of the signal emitted from the detectably labeled antibody.
  • a detectable tag such as c-Myc, HA, VSV-G, HSV, FLAG, V5, or HIS.
  • the antibody-based binding moiety is detectably labeled by linking the antibody to an enzyme.
  • the enzyme when exposed to it's substrate, will react with the substrate in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorometric or by visual means.
  • Enzymes which can be used to detectably label the antibodies of the present invention include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-V-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-VI-phosphate dehydrogenase, glucoamylase and acetylcholinesterase.
  • Detection can also be accomplished using any of a variety of other immunoassays.
  • radioactively labeling an antibody it is possible to detect the antibody through the use of radioimmune assays.
  • the radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by audioradiography.
  • Isotopes which are particularly useful for the purpose of the present invention are 3 H, 131 I, 35 S, 14 C, and preferably 125 I.
  • fluorescent labeling compounds include CYE dyes, fluorescein isothiocyanate, rhodamine, phycoerytherin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.
  • An antibody can also be detectably labeled using fluorescence emitting metals such as 152Eu, or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriaminepentaacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).
  • DTPA diethylenetriaminepentaacetic acid
  • EDTA ethylenediaminetetraacetic acid
  • An antibody also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction.
  • chemiluminescent labeling compounds are luminol, luciferin, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.
  • levels of enzyme protein can be detected by immunoassays, such as enzyme linked immunoabsorbant assay (ELISA), radioimmunoassay (RIA), Immunoradiometric assay (IRMA), Western blotting, immunocytochemistry or immunohistochemistry, each of which are described in more detail below.
  • Immunoassays such as ELISA or RIA, which can be extremely rapid, are more generally preferred.
  • Antibody arrays or protein chips can also be employed, see for example U.S. Patent Application Nos: 20030013208A1; 20020155493A1; 20030017515 and U.S. Pat. Nos. 6,329,209; 6,365,418, which are herein incorporated by reference in their entirety.
  • ELISA Enzyme-Linked Immunosorbent Assay
  • an antibody e.g. anti-enzyme
  • a solid phase i.e. a microtiter plate
  • antigen e.g. enzyme
  • a labeled antibody e.g. enzyme linked
  • enzymes that can be linked to the antibody are alkaline phosphatase, horseradish peroxidase, luciferase, urease, and B-galactosidase.
  • the enzyme linked antibody reacts with a substrate to generate a colored reaction product that can be measured.
  • antibody is incubated with a sample containing antigen (i.e. enzyme).
  • antigen i.e. enzyme
  • the antigen-antibody mixture is then contacted with a solid phase (e.g. a microtiter plate) that is coated with antigen (i.e., enzyme).
  • a solid phase e.g. a microtiter plate
  • antigen i.e., enzyme
  • a labeled (e.g., enzyme linked) secondary antibody is then added to the solid phase to determine the amount of primary antibody bound to the solid phase.
  • an “immunohistochemistry assay” a section of tissue is tested for specific proteins by exposing the tissue to antibodies that are specific for the protein that is being assayed.
  • the antibodies are then visualized by any of a number of methods to determine the presence and amount of the protein present. Examples of methods used to visualize antibodies are, for example, through enzymes linked to the antibodies (e.g., luciferase, alkaline phosphatase, horseradish peroxidase, or beta-galactosidase), or chemical methods (e.g., DAB/Substrate chromagen).
  • the sample is then analysed microscopically, most preferably by light microscopy of a sample stained with a stain that is detected in the visible spectrum, using any of a variety of such staining methods and reagents known to those skilled in the art.
  • Radioimmunoassays can be employed.
  • a radioimmunoassay is a technique for detecting and measuring the concentration of an antigen using a labeled (e.g. radioactively or fluorescently labeled) form of the antigen.
  • radioactive labels for antigens include 3H, 14C, and 125I.
  • the concentration of antigen enzyme in a biological sample is measured by having the antigen in the biological sample compete with the labeled (e.g. radioactively) antigen for binding to an antibody to the antigen.
  • the labeled antigen is present in a concentration sufficient to saturate the binding sites of the antibody. The higher the concentration of antigen in the sample, the lower the concentration of labeled antigen that will bind to the antibody.
  • the antigen-antibody complex In a radioimmunoassay, to determine the concentration of labeled antigen bound to antibody, the antigen-antibody complex must be separated from the free antigen.
  • One method for separating the antigen-antibody complex from the free antigen is by precipitating the antigen-antibody complex with an anti-isotype antiserum.
  • Another method for separating the antigen-antibody complex from the free antigen is by precipitating the antigen-antibody complex with formalin-killed S. aureus .
  • Yet another method for separating the antigen-antibody complex from the free antigen is by performing a “solid-phase radioimmunoassay” where the antibody is linked (e.g., covalently) to Sepharose beads, polystyrene wells, polyvinylchloride wells, or microtiter wells.
  • a “solid-phase radioimmunoassay” where the antibody is linked (e.g., covalently) to Sepharose beads, polystyrene wells, polyvinylchloride wells, or microtiter wells.
  • An “Immunoradiometric assay” is an immunoassay in which the antibody reagent is radioactively labeled.
  • An IRMA requires the production of a multivalent antigen conjugate, by techniques such as conjugation to a protein e.g., rabbit serum albumin (RSA).
  • the multivalent antigen conjugate must have at least 2 antigen residues per molecule and the antigen residues must be of sufficient distance apart to allow binding by at least two antibodies to the antigen.
  • the multivalent antigen conjugate can be attached to a solid surface such as a plastic sphere.
  • sample antigen and antibody to antigen which is radioactively labeled are added to a test tube containing the multivalent antigen conjugate coated sphere.
  • the antigen in the sample competes with the multivalent antigen conjugate for antigen antibody binding sites.
  • the unbound reactants are removed by washing and the amount of radioactivity on the solid phase is determined.
  • the amount of bound radioactive antibody is inversely proportional to the concentration of antigen in the sample.
  • Detectably labeled anti-enzyme antibodies can then be used to assess enzyme levels, where the intensity of the signal from the detectable label corresponds to the amount of enzyme present. Levels can be quantified, for example by densitometry.
  • Psap and Tsp-1, and/or their mRNA levels in the tissue sample can be determined by mass spectrometry such as MALDI/TOF (time-of-flight), SELDI/TOF, liquid chromatography-mass spectrometry (LC-MS), gas chromatography-mass spectrometry (GC-MS), high performance liquid chromatography-mass spectrometry (HPLC-MS), capillary electrophoresis-mass spectrometry, nuclear magnetic resonance spectrometry, or tandem mass spectrometry (e.g., MS/MS, MS/MS/MS, ESI-MS/MS, etc.).
  • mass spectrometry such as MALDI/TOF (time-of-flight), SELDI/TOF, liquid chromatography-mass spectrometry (LC-MS), gas chromatography-mass spectrometry (GC-MS), high performance liquid chromatography-mass spectrometry (HPLC-MS), capillary electrophoresis-mas
  • Mass spectrometry methods are well known in the art and have been used to quantify and/or identify biomolecules, such as proteins (see, e.g., Li et al. (2000) Tibtech 18:151-160; Rowley et al. (2000) Methods 20: 383-397; and Kuster and Mann (1998) Curr. Opin. Structural Biol. 8: 393-400). Further, mass spectrometric techniques have been developed that permit at least partial de novo sequencing of isolated proteins. Chait et al., Science 262:89-92 (1993); Keough et al., Proc. Natl. Acad. Sci. USA. 96:7131-6 (1999); reviewed in Bergman, EXS 88:133-44 (2000).
  • a gas phase ion spectrophotometer is used.
  • laser-desorption/ionization mass spectrometry is used to analyze the sample.
  • Modern laser desorption/ionization mass spectrometry (“LDI-MS”) can be practiced in two main variations: matrix assisted laser desorption/ionization (“MALDI”) mass spectrometry and surface-enhanced laser desorption/ionization (“SELDI”).
  • MALDI matrix assisted laser desorption/ionization
  • SELDI surface-enhanced laser desorption/ionization
  • Laser energy is directed to the substrate surface where it desorbs and ionizes the biological molecules without significantly fragmenting them. See, e.g., U.S. Pat. No. 5,118,937 (Hillenkamp et al.), and U.S. Pat. No. 5,045,694 (Beavis & Chait).
  • the substrate surface is modified so that it is an active participant in the desorption process.
  • the surface is derivatized with adsorbent and/or capture reagents that selectively bind the protein of interest.
  • the surface is derivatized with energy absorbing molecules that are not desorbed when struck with the laser.
  • the surface is derivatized with molecules that bind the protein of interest and that contain a photolytic bond that is broken upon application of the laser.
  • the derivatizing agent generally is localized to a specific location on the substrate surface where the sample is applied. See, e.g., U.S. Pat. No. 5,719,060 and WO 98/59361.
  • the two methods can be combined by, for example, using a SELDI affinity surface to capture an analyte and adding matrix-containing liquid to the captured analyte to provide the energy absorbing material.
  • Detection of the presence of Psap or Tsp-1 mRNA or protein will typically depend on the detection of signal intensity. This, in turn, can reflect the quantity and character of a polypeptide bound to the substrate. For example, in certain embodiments, the signal strength of peak values from spectra of a first sample and a second sample can be compared (e.g., visually, by computer analysis etc.), to determine the relative amounts of particular biomolecules.
  • Software programs such as the Biomarker Wizard program (Ciphergen Biosystems, Inc., Fremont, Calif.) can be used to aid in analyzing mass spectra. The mass spectrometers and their techniques are well known to those of skill in the art.
  • the diagnostic method of the invention uses antibodies or anti-sera for determining the expression levels of Psap and Tsp-1.
  • the antibodies for use in the present invention can be obtained from a commercial source such as Novus Biologicals (anti-prosaposin, Clone 1D1-C12, catalog #H00005660-M01), Santa Cruz Biotechnology (Anti-saposin B (E-15), catalog #sc-27014; anti-Tsp-1, Clone CSI 002-65, catalog #sc-59888), and Labvision (anti-Tsp-1, clone Ab-2, catalog #MS-419-B).
  • the antibodies can be polyclonal or monoclonal antibodies. Alternatively, antibodies can be raised against Psap protein (Genbank Accession No.
  • Antibodies for use in the present invention can be produced using standard methods to produce antibodies, for example, by monoclonal antibody production (Campbell, A. M., Monoclonal Antibodies Technology: Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers, Amsterdam, the Netherlands (1984); St. Groth et al., J. Immunology, (1990) 35: 1-21; and Kozbor et al., Immunology Today (1983) 4:72).
  • Antibodies can also be readily obtained by using antigenic portions of the protein to screen an antibody library, such as a phage display library by methods well known in the art.
  • U.S. Pat. No. 5,702,892 U.S.A. Health & Human Services
  • WO 01/18058 Novopharm Biotech Inc.
  • Detection of Psap and Tsp-1 antibodies can be achieved by direct labeling of the antibodies themselves, with labels including a radioactive label such as 3 H, 14 C, 35 S, 125 I, or 131 I, a fluorescent label, a hapten label such as biotin, or an enzyme such as horse radish peroxidase or alkaline phosphatase.
  • a radioactive label such as 3 H, 14 C, 35 S, 125 I, or 131 I
  • a fluorescent label such as 3 H, 14 C, 35 S, 125 I, or 131 I
  • a fluorescent label such as 3 H, 14 C, 35 S, 125 I, or 131 I
  • a fluorescent label such as 3 H, 14 C, 35 S, 125 I, or 131 I
  • a fluorescent label such as 3 H, 14 C, 35 S, 125 I, or 131 I
  • a fluorescent label such as 3 H, 14 C, 35 S, 125 I, or 131 I
  • PC3 and MDA-MB-231 were obtained from the American Type Culture Collection (ATCC, Manassas, Va.).
  • PC3M-LN4 was the generous gift of Dr. Judith Fidler (MD Anderson Cancer Center, Houston, Tex.)
  • MDA-MET was the generous gift of Dr. Larry Suva (University of Arkansas for Medical Sciences, Little Rock, Ark.)
  • MDA-MB-231-LM2 and 1833 were generously provided by Dr. Joan Massague (Memorial Sloan-Kettering Cancer Center, New York, N.Y.) and have been previously described (Bendre et al., 2002; Kang et al., 2003; Minn et al., 2005; Pettaway et al., 1996).
  • the prostate cancer cell lines were grown in RPMI medium containing 10% fetal bovine serum (FBS).
  • FBS fetal bovine serum
  • the prostate fibroblasts and MDA-MB-231 and MDA-MET cells were grown in DMEM medium with 10% FBS.
  • the WI 38 and MRC 5 lung fibroblasts were also obtained from the ATCC and were grown in MEM medium with 10% FBS.
  • the bone marrow derived stromal cells were the generous gift of Dr. Michael Rosenblatt (Tufts Medical School, Boston, Mass.) and were grown in high-glucose DMEM with 10% heat-inactivated FBS, 250 ⁇ M L-ascorbic acid and 1% penicillin/streptomycin.
  • PC3MycER cells were generated by retroviral infection of PC3 cells with pBabepuro-MycER (Littlewood et al., 1995; Watnick et al., 2003) using the previously described protocol.
  • PC3-shPsap and PC3M-LN4-shMyc cells were generated by lentiviral infection of PC3 cells with shRNA-Psap and PC3M-LN4 cells with shRNA-Myc respectively (Sigma, St. Louis, Mo.).
  • Human Prostate Fibroblast (PrF) and lung fibroblasts (MRCS) were also infected with pLKO-shRNAp53 (Sigma, St. Louis, Mo.) to silence expression of p53 in these fibroblast cells.
  • PC3M-LN4-Psap cells were generated by PCR cloning the Prosaposin cDNA sequence from total cDNA generated from PC3 cells using the following primers: 5′-CGGGCTACGTAATGTACGCCCTCTTCCTCCTGG (SEQ. ID. No. 7) and 3′-GGCGGGGTCGACCTAGTTCCACACATGGCG (SEQ. ID. No. 8).
  • the resultant PCR product was digested with gel purified and digested with SnaB1 and Sal1 and ligated into the pBabePuro retroviral vector.
  • PC3M-LN4 cells were then transduced with pBabePuro-Psap as described previously (Elenbaas et al., 2001) to generate PC3M-LN4-Psap. Cre-lox site-specific recombination cloning of the pDNR-Dual Prosaposin cDNA into pLP-LNCX vector (Clontech, Moutainview, Calif.) was also performed to generate an independent line of PC3M-LN4-Psap cells.
  • mice Male SCID mice 6-8 weeks old were injected with 2 ⁇ 10 6 viable cells in the prostate gland. The cells were washed and harvested in PBS prior to injection into the prostate glands of anaesthetized mice (2% avertin, 0.5 ml per mouse) in a volume of 0.8 ml. Endpoint assays were conducted at 5 weeks after injection unless significant morbidity required that the mouse be euthanized earlier.
  • conditioned media assay 1.5 ⁇ 10 6 tumor cells and fibroblasts cells were grown in the tumor cell media containing 0.1% FBS for 12 hours at which point the conditioned media from the tumor cells was centrifuged to remove any cells or cell debris and transferred to the fibroblasts subsequent to removal of the low serum fibroblast growth media. All assays were performed a minimum of five times and representative samples depicted. The fibroblasts and media were harvested after 12 to 16 hours after addition of the tumor cell conditioned media and lysed for the western blot analysis while the conditioned media was collected for ELISA analysis.
  • fibroblasts were seeded in the bottom chamber of transwell tissue culture plates (Corning Inc., Corning, N.Y.) and 1 ⁇ 10 6 tumor cells were seeded on the membrane in the top chamber of the plates.
  • the two cell types were co-cultured for 40 to 44 hours in tumor cell media containing 0.1% FBS before harvesting and lysing the fibroblasts for western blot analysis and collecting the media for ELISA analysis.
  • VEGF levels were normalized against total protein from the cells used in the assay.
  • Xenograft tumors and tissue samples were homogenized and suspended in PBS and murine VEGF levels were determined using an ELISA kit that was specific for murine VEGF (R & D, Minneapolis, Minn.) results were normalized against the mass of the tumors. All error bars included in the graphical depiction of ELISA data represent SEM (Standard Error of Mean).
  • TSP-Ab-4 mouse monoclonal thrombospondin antibody
  • p53 sections were stained with a mouse monoclonal antibody (p53-PAB1802; Santa Cruz Biotechnology, CA, USA), incubated overnight (4° C.), dilution 1:10, after heat induced microwave epitope retrieval in TRS (pH 6.0) for 15 minutes.
  • p53 only nuclear staining was considered, and staining intensity was recorded as either negative/weak or moderate/strong.
  • immunostaining of tissue sections was performed on the DAKO Autostainer with the DAKO ARK (animal research kit) peroxidase (Dako Cytomation, Copenhagen, Denmark) as detection system. Antigen localization was achieved using the DAB diaminobenzidine peroxidase reaction, counterstained with hematoxylin.
  • the column was subsequently washed with 50 mL 10 mM NaPO 4 , 2M NaCl, pH 7.4; 50 mL 10 mM NaPO 4 , 150 mM NaCl, pH 7.4; 50 mM 10 mM NaPO 4 , 150 mL NaCl, 10 mM imidazole, pH 7.4, and finally 50 mL 10 mM NaPO 4 , 150 mM NaCl, pH 7.4.
  • the remaining bound proteins were eluted at 1 mL/min in 10 mM NaPO 4 , 10 mM imidazole, pH 7.4 with a linear gradient of NaCl ranging from 0.3M to 2M with fractions collected in 0.05M NaCl increments.
  • the fractions were then dialyzed against 10 mM NaPO 4 , 150 mL NaCl, pH 7.4 to remove excess NaCl and imidazole.
  • the fractions were then tested for activity by adding 1 mL to serum starved prostate or lung fibroblasts in 9 mL of DMEM containing 0.1% FBS for 12 hours. The fibroblasts were then prepped for western blot analysis as described above. Fractions containing Tsp-1 stimulating activity were concentrated using centriplus-10 columns (Millipore, Mass., USA) and submitted to the Children's Hospital Proteomics Center for tandem liquid chromatography/mass spectroscopy analysis. The lists of proteins present in all the active fractions was then cross compared to identify proteins present in all active fractions.
  • Prosaposin was cloned into pLNCX acceptor vector (Clontech) including a C-terminal 6X-HN tag.
  • PC3M-LN4 cells were then retrovirally transduced with this construct and subsequent to selection using G418 were serum starved cells for 12 hours and collected 500 mL of conditioned media.
  • the conditioned media was then incubated with 5 mL Talon metal affinity resin (Clontech) for 1 hr at 4° C. The solution was then centrifuged at 2,000 ⁇ G in an SS-34 rotor for 10 minutes and the supernatant removed.
  • the beads were then resuspended in 10 mM NaPO 4 , 150 mM NaCl, pH8.0 and loaded into a 10 mL Econo-column (Bio-Rad).
  • the column was then washed first with 100 mL 10 mM NaPO 4 , 150 mM NaCl, pH8.0 and subsequently with 10 mM NaPO 4 , 150 mM NaCl, 25 mM imidazole pH8.0.
  • the remaining bound proteins were then eluted from the column with a step gradient of 50-500 mM imidazole in 10 mM NaPO 4 , 150 mM NaCl, pH 7.4.
  • Wild-type and Tsp-1 ⁇ / ⁇ C57BL/6J mice were pretreated with 500 ⁇ L of serum-free conditioned media from PC3 or PC3shPsap cells or serum-free RPMI media for 10 days via intraperitoneal (i.p.) injection. On the 10th day mice were injected via tail vein, with 1 ⁇ 10 6 Lewis Lung Carcinoma cells. Subsequently, i.p. injections of serum-free tumor cell conditioned media or control RPMI were performed for 19 additional days, at which point the animals were sacrificed. The lungs were photographed and the number of visible metastatic nodules were counted by eye.
  • Tsp-1 Expression is Inversely Related to Metastatic Potential
  • the initial step of metastasis is dependent on access to the vasculature or lymphatic system.
  • Metastatic human tumors may differ in the relative of expression of pro- and anti-angiogenic proteins compared to non-metastatic tumors.
  • the level of VEGF secretion by the weakly metastatic prostate cancer cell line PC3 and a metastatic derivative PC3M-LN4 as well as by the breast cancer cell line MDA-MB-231 and a bone-specific metastatic derivative MDA-MET were measured.
  • PC3M-LN4 cells have been documented to metastasize to multiple organs, including lymph node, liver, lung and bone, while MDA-MET was derived to metastasize only to bone via intra-cardiac injection (Bendre et al., 2002; Pettaway et al., 1996).
  • Tsp-1 an endogenous inhibitor of angiogenesis, Tsp-1, was determined to ascertain whether metastatic tumor cells express lower levels of Tsp-1 than their non-metastatic counterparts.
  • Tsp-1 levels decreased as the metastatic potential of the cell lines increased ( FIG. 1B ).
  • the non-metastatic PC3 cells expressed high levels of Tsp-1 while their metastatic PC3M-LN4 derivatives expressed no detectable Tsp-1.
  • This analysis was extended to the breast cancer cell lines MDA-MB-231 and MDA-MET. Consistent with the expression levels in the prostate cancer cells, the weakly metastatic MDA-MB-231 breast cancer cell line also expressed higher levels of Tsp-1 than its bone-specific metastatic derivative MDA-MET ( FIG. 1B ). This indicated an inverse relationship between metastatic potential and Tsp-1 expression.
  • c-myc is often amplified or overexpressed in several types of human cancer, including prostate and breast cancer (Escot et al., 1986; Nag and Smith, 1989). Furthermore, c-Myc represses the expression of Tsp-1 (Janz et al., 2000; Ngo et al., 2000; Tikhonenko et al., 1996; Watnick et al., 2003). Therefore, the levels of c-Myc was analyzed to determine whether the levels of c-Myc increase as tumors progress to the metastatic phenotype. The levels of c-Myc increase with the metastatic potential of both prostate and breast cancer cells were examined.
  • Protein expression of c-Myc was significantly increased in the highly metastatic PC3M-LN4 and MDA-MET cells as compared to the parental PC3 and MDA-MB-231 cells ( FIG. 1B ). Furthermore, levels of phosphorylated c-Myc, which have been shown to be directly involved in Tsp-1 repression (Watnick et al., 2003), were also significantly increased in the metastatic cell lines ( FIG. 1C ). Hence, the levels of Tsp-1 could be attributable to the effects of Myc protein expression.
  • PC3M-LN4 cells In order to determine whether levels of Tsp-1 observed in in vitro culture conditions were representative of their expression levels in vivo, 2 ⁇ 10 6 PC3 and their metastatic derivatives, PC3M-LN4 cells, were injected orthotopically into the prostate glands of SCID mice. Five weeks after injection the tumors and surrounding tissue were analyzed for Tsp-1 expression via western blot analysis and immunohistochemistry.
  • the prostate tumors formed by both PC3 and PC3M-LN4 cells were histologically characterized by significant nuclear atypia and a diffuse infiltrating growth pattern, i.e. poorly differentiated, often surrounding benign prostate glands.
  • VEGF secreted by the host stroma in these tumors was analyzed using a murine specific VEGF ELISA that does not recognize the human form of the protein secreted by the tumor cells themselves.
  • 4 out of 5 PC3 tumors sampled contained higher levels of stromal (murine) VEGF than the 4 sampled tumors formed by the PC3M-LN4 cells ( FIG. 1E ).
  • the one metastatic PC3 tumor that did not express higher levels of VEGF also expressed low levels of Tsp-1 as determined by immunohistochemistry and western blot ( FIG. 1D ), thus indicating that repression of Tsp-1 obviates the requirements for high levels of VEGF in tumor metastasis.
  • Tsp-1 in distant tissue sites was determined to ascertain if similar reduction of expression of Tsp-1 in distant tissue sites was correlated with the growth of metastases.
  • the lungs from mice injected orthotopically with PC3 and PC3M-LN4 cells was analyzed.
  • the lung metastases were distributed in both central and peripheral lung tissues, and in a few cases as small subpleural tumor cell clusters.
  • the lung metastases harbored only a minimal amount of stroma compared with corresponding prostate tumors, but scattered stromal cells were identified within the metastases.
  • stromal Tsp-1 The regulation of stromal Tsp-1 by human tumor cells could be the result of a unidirectional paracrine signaling event or a reciprocal signaling system involving both tumor cells and nearby stromal fibroblasts.
  • stromal Tsp-1 The regulation of stromal Tsp-1 by human tumor cells could be the result of a unidirectional paracrine signaling event or a reciprocal signaling system involving both tumor cells and nearby stromal fibroblasts.
  • in vitro tissue culture system that recapitulate the in vivo observations.
  • human prostate (PrF) and mammary fibroblasts (a gift of Dr. Kornelia Polyak, Dana Farber Cancer Institute, Boston, Mass.) was treated with conditioned media from metastatic and non-metastatic prostate and breast cancer cell lines, respectively.
  • FIGS. 2A and B Treatment of fibroblasts with conditioned media from non-metastatic PC3 prostate and MDA-MB-231 breast cancer cell lines stimulated Tsp-1 expression 4-fold (as determined by band volume density) ( FIGS. 2A and B). Conversely, treatment of prostate fibroblasts with conditioned media from the metastastic PC3M-LN4 line resulted in a 3-fold suppression of Tsp-1 protein expression ( FIG. 2A ). Hence, non-metastatic PC-3 cells actively induced Tsp-1 expression above its normal basal levels, while metastatic PC3M-LN4 actively suppressed Tsp-1 below its normal levels.
  • the conditioned media from MDA-MET cells stimulated Tsp-1 expression in mammary fibroblasts. Furthermore, when these tumor cells were co-cultured with mammary fibroblasts in a transwell apparatus, the level of Tsp-1 expression in the fibroblasts was still not repressed by MDA-MET cells ( FIG. 2B ). While the MDA-MET cells are portrayed as being metastatic, in fact they do not metastasize from orthotopic sites of injection and instead do so only following intracardiac injection. Thus, in consonance with the fact that MDA-MET cells do not metastasize when injected into the mammary fat pad, these cells are unable to repress Tsp-1 expression in mammary fibroblasts.
  • Tsp-1 expression was also suppressed in sites of pulmonary metastasis formation.
  • the ability of metastasizing cancer cells to also repress Tsp-1 production in the fibroblasts forming the stroma was determined in two favored sites of metastasis—the lungs and the bone marrow.
  • Human lung and bone marrow derived fibroblasts were treated with conditioned media from PC3, PC3M-LN4, MDA-MB-231 and MDA-MET cells. Consistent with their ability to metastasize to both lung and bone, western blot analysis revealed that PC3M-LN4 cells repressed Tsp-1 expression in both types of fibroblasts ( FIG.
  • cancer cells can successfully repress Tsp-1 expression in the stromal fibroblasts of tissues in which they succeed in forming metastases.
  • the fibroblasts in different tissues are biologically heterogeneous, in that some are and some are not responsive to these Tsp-1-repressing signals.
  • the Tsp-1-inducing fractions were concentrated and submitted them for tandem liquid chromatography/mass spectrometry (LC/MS) analysis.
  • the LC/MS analysis revealed that only two proteins were present in all of the active fractions, Prosaposin and Fetuin A (Table 3).
  • Western blot analysis of cell lysates and conditioned media from both PC3 and PC3M-LN4 cells revealed that Prosaposin (Psap), was expressed at ⁇ 10-fold higher levels in PC3 cells than in PC3M-LN4 cells ( FIG. 3C ), while there was no significant difference between the two cell populations in Fetuin A expression (data not shown).
  • Psap Prosaposin
  • FIG. 3C shows that metastatic derivatives of the MDA-MB-231 cell line also expressed significantly lower levels of Psap ( FIG. 3D ) than the parental, weakly metastatic, MDA-MB-231 cells
  • PC3 cells were transduced with lentiviral constructs specifying five different shRNAs targeted to Psap. It was confirmed via western blot analysis that four of these hairpin sequences suppressed the expression of Psap expressed by PC3 cells ( FIG. 3E , #1, 2, 4, and 5). Significantly, suppression of Psap expression had no effect on the expression of Tsp-1 by PC3 cells themselves ( FIG. 3E ).
  • Normal human prostate and WI-38 lung fibroblasts were subsequently treated with the conditioned media from the five cell populations expressing the various Psap shRNA sequences and assessed Tsp-1 expression.
  • the tumor suppressor p53 was studied. It has been demonstrated that the tumor suppressor p53 is a transcriptional activator of Tsp-1 in human fibroblasts (Dameron et al., 1994). Thus, the relative p53 expression levels in the stroma of PC3 and PC3M-LN4 tumors were determined via western blot analysis. Both PC3 and PC3M-LN4 contain deletion mutations in the p53 gene (Isaacs et al., 1991), resulting in the absence of detectable p53 protein in both cell types. The immunohistochemical analysis of p53 tumor expression is therefore simplified by the lack of contribution from the tumor cells themselves.
  • lymph nodes from mice bearing PC3M-LN4 tumors expressed p53 at levels similar to normal lymph nodes ( FIG. 4B ).
  • the inventors determined if p53 stimulation could be responsible for the increased expression of Tsp-1.
  • Cultured prostate fibroblasts (PrFs) were treated with conditioned media from either the PC3 or PC3M-LN4 cells and assessed the change in p53 protein levels via western blot analysis. Consistent with the immunohistochemical and western blot results of the tumor-associated stroma, PC3-conditioned media stimulated p53 protein levels in PrFs, while PC3M-LN4-conditioned media induced a modest repression of p53 in PrF's ( FIG. 4C ). Hence, in parallel with earlier analyses of Tsp-1 expression, non-metastatic cells induced p53 levels while metastatic cells caused their repression.
  • the p53 expression was silenced in both prostate and lung fibroblasts via lentiviral transduction of a short-hairpin RNA (shRNA) sequence targeted to p53 (Brummelkamp et al., 2002).
  • shRNA short-hairpin RNA
  • FIGS. 4D and E More significantly conditioned media from PC3 cells failed to stimulate Tsp-1 expression in fibroblasts in which p53 had been silenced.
  • Prostate and lung fibroblasts were treated with conditioned media from the five populations of PC3shPsap cells described above.
  • silencing of Psap also reversed the ability of PC3 cells to stimulate p53 expression ( FIGS. 4F and G).
  • the one shRNA sequence that did not suppress Psap in PC3 cells (#3) still stimulated p53 in both prostate and lung fibroblasts ( FIGS. 4F and G).
  • overexpression of Psap in PC3M-LN4 cells reversed the ability to repress p53 in prostate fibroblasts ( FIG.
  • the metastatic PC3M-LN4 cells express lower levels of Psap than the non-metastatic parental PC3 cells.
  • the PC3 cells express lower levels of Myc than their metastatic derivative PC3M-LN4, indicating that Psap expression might be negatively regulated by Myc.
  • PC3 cells were transduced with a retroviral construct specifying a Myc-Estrogen Receptor (ER) fusion protein, which is activated upon administration of 4-hydroxy-tamoxifen (4-HT) (Littlewood et al., 1995).
  • ER Myc-Estrogen Receptor
  • conditioned media from the 4-HT-treated PC3MycER cells failed to stimulate the expression of either p53 or Tsp-1 in lung or prostate fibroblasts, while conditioned media from untreated PC3MycER cells stimulated both p53 and Tsp-1 expression in these two cell types ( FIG. 5B ).
  • Myc expression in PC3M-LN4 cells were silenced via lentiviral transduction of an shRNA construct that specifically antagonizes c-Myc expression.
  • Two shRNA sequences directed against Myc that were able to achieve significant knockdown of Myc protein expression were identified (4- and 8-fold, respectively) ( FIG. 5C ). Indeed, these two cell lines expressed higher levels (>3- and 6-fold, respectively) of Psap than PC3M-LN4 cells, as determined via western blot analysis ( FIG. 5D ).
  • PC3shPsap cells that demonstrated the greatest knockdown of Psap expression ( FIG. 3E : #4) and PC3pLKO control cells were injected, independently, into the prostate glands of SCID mice. It was observed that six of seven tumors formed by PC3shPsap cells gave rise to large lymph node metastases whereas none of the eight tumors generated from PC3pLKO vector controls cells gave rise to metastases (data not shown).
  • Tsp-1 ⁇ / ⁇ mice (Lawler et al., 1998) were used to answer this question. Earlier observations have shown that Prosaposin could act systemically to influence the levels of both Tsp-1 and p53 in distant organs ( FIGS. 6C and D). Both wild-type C57BL/6J and Tsp-1 ⁇ / ⁇ mice from the same genetic background were pretreated with RPMI media or conditioned media from PC3pLKO or PC3shPsap cells for 10 days; these serum-free media were injected at daily intervals into the peritoneal space of these animals.
  • LLC Lewis Lung Carcinoma
  • Prosaposin is differentially expressed in metastatic and localized human prostate cancer.
  • a microarray gene expression data set was gathered from 55 patient samples consisting of normal prostate, benign prostatic hyperplasia (BPH), localized primary prostate tumors and metastatic prostate tumors (Dhanasekaran et al., 2001) and the data were analyzed. Consistent with the xenograft experiments, it was discovered that relative psap mRNA expression (normalized to normal, benign prostate tissue) was ⁇ 40% lower, on average, in the metastatic tumors as compared with localized primary tumors with a p value ⁇ 0.0001 ( FIG. 7B ).
  • Truncation mutants of Prosaposin comprised of SaposinA, SaposinAB, and SaposinABC downstream of the native signal sequence of Prosaposin that mediates secretion of the protein. These mutants were created by PCR of Prosaposin using the following primers: Saposin A: 5′ Primer: 5′-ggcggcTCAGTCGACGGTACCGG-3′ (SEQ. ID. No. 9) which primes at the 5′ region of the pDNR-Dual MCS, the vector where the cDNA of Psap is subcloned into, 3′ Primer:5′-ggcgcctctagaAGAGACTCGCAGAGGTTGAG-3′ (SEQ. ID. No. 10).
  • Saposin AB 5′ Primer: 5′-ggcggcTCAGTCGACGGTACCGG-3′(SEQ. ID. No. 9) and 3′ Primer:5′-ggcgcctctagaACCTCATCACAGAACCC-3′(SEQ. ID. No. 11).
  • Saposin ABC 5′ Primer: 5′-ggcggcTCAGTCGACGGTACCGG-3′ (SEQ. ID. No. 9) and 3′ Primer:5′-ggcgcctctagaGCCAGAGCAGAGGTGCAGC-3′(SEQ. ID. No. 12).
  • the resulting PCR products were cloned into the SalI and XbaI sites of pDNR-dual.
  • the Saposin constructs were then transferred via Cre-recombinase mediated cloning into pCMVneo for transient expression.
  • These pCMVneoSaposin constructs were transiently transfected into the PC3M-LN4 prostate cancer cells. After 48 hours the conditioned media from these cells as well as cells infected with pCMVneo alone were transferred to prostate and lung fibroblasts. After 12 hours the treated fibroblasts were harvested and lysed and Tsp-1 expression assessed by western blot analysis.
  • the Psap in platelets and plasma were determined for patients with either tumor type. There was also a strong correlation between metastasis and the Psap level in the plasma and/or platelets of patients with non-metastatic and metastatic cancers. Both plasma and platelets of patients with non-metastatic cancers contained elevated levels of Psap compared to normal individuals with no diagnosed cancers. Conversely, the plasma and platelets of patients with metastatic cancers contain Psap levels that are comparable to normal individuals with no diagnosed cancers ( FIG. 13 ).
  • tissue microarray Representative tumor areas from a tissue microarray were identified on HE slides, and three tissue cylinders (diameter of 0.6 mm) were punched from the donor block and mounted into a recipient paraffin block. Sections were stained for expression of Prosaposin using the antibody from Santa Cruz Biotechnology described above.
  • the tissue microarray was assembled from a consecutive series of 104 men treated by radical prostatectomy for clinically localized prostate cancer during 1988-1994, with long and complete follow-up, was included.
  • Clinical stage T1/T2 disease, negative bone scan and generally good health were the prerequisites for radical retropubic prostatectomy. The majority of cancers in this series is clinical stage T2 and presented before the PSA era started in Norway in the mid-1990s.
  • s-PSA posteriorly, s-PSA, loco-regional tumor recurrences, distant metastases, and patient survival were recorded.
  • Time from surgery until biochemical failure (defined as persistent or rising s-PSA level of >0.5 ng/ml in two consecutive blood samples) was noted.
  • the last time of follow-up was December 2001.
  • Median follow-up time was 95 months (7.9 yrs). No patients were lost because of insufficient data. 67 patients experienced biochemical failure, 31 patients had clinical recurrence, and 9 patients died of prostate cancer.
  • Tsp-1 expressed by the epithelial tumor cells
  • Metastatic human tumor cells should be more angiogenic than their non/weakly metastatic counterparts in the primary site, so as to have better access to their conduit, the vasculature and lymphatics, as well as at metastatic sites to allow their growth beyond the microscopic size. Described herein 14 of 17 tumors formed by the weakly metastatic PC3 cell line expressed high levels of Tsp-1. Of the three PC3 tumors that expressed low levels of Tsp-1 two formed lung metastases.
  • Described herein is a novel suppressor of tumor metastasis. It was demonstrated that secretion of Psap by tumor cells inhibits metastasis by stimulating the expression of p53 and, consequently, Tsp-1 in stromal fibroblasts. Significantly, Psap, secreted by the primary tumor, also was able to stimulate the expression of p53 in distal tissues, such as lymph node and lung. Furthermore, the Psap-mediated stimulation of Tsp-1 was a direct function of p53 activation as shRNA knockdown of p53 abolishes this stimulation. Additionally, it was determined that expression of Psap was not only repressed in metastatic prostate cancer cells, but in several independently derived metastatic versions of the MDA-MB-231 cell line.
  • MDA-MET cells which were selected to metastasize solely to the bone (Bendre et al., 2002), are only able to repress Tsp-1 in bone marrow-derived stromal cells.
  • escape from the primary site and growth at the metastatic site is not only a function of tumor-secreted Tsp-1 but also of the level of Tsp-1 secreted by the tumor-associated stromal fibroblasts.
  • the investigators analyzed the prosaposin protein levels in the serum of normal subjects and colon cancer patients of varying stages.
  • the prosaposin levels increased with grade T1-T4 and then decreased back to normal levels in patients with metastasis ( FIG. 15 ).
  • patient H3 was originally diagnosed as stage T4 with no mets (N 0 M 0 ) yet subsequently developed both lymph node and lung metastases and was reclassified as N 2 M 1 , which is consistent with the hypothesis that prosaposin levels inversely correlate with metastatic progression.
  • colon cancer is not a hormone responsive cancer, like breast and prostate, strongly indicates that repression of prosaposin is a more widespread event in metastatic disease.
  • LRP Low Density Lipoprotein Receptor Related Protein
  • LRP1 and LRP2 were then silenced, independently in WI-38 lung fibroblasts, to determine the requirement for LRP1 in mediating prosaposin functions and whether the closely related protein LRP2 could substitute. As shown in FIG. 18 , over 95% suppression of LRP1 and LRP2 mRNA with 2 different shRNA sequences were obtained and, importantly, knockdown of one did not affect expression of the other.
  • a Peptide within Saposin A is Sufficient to Stimulate Tsp-1
  • PC3M-LN4 cells were transduced with retroviral vectors expressing truncated mutants of prosaposin containing saposin A, saposin AB, saposin ABC, or saposin BCD.
  • the lung fibroblasts were then treated with the CM from these cells and it was observed that all of the constructs containing saposin A, including the construct that only expressed saposin A, were sufficient to stimulate Tsp-1 expression in lung fibroblasts, while the construct specifying saposin BCD was unable to stimulate Tsp-1 ( FIG. 20 ).
  • saposin A is sufficient to stimulate Tsp-1 in fibroblasts.
  • a cyclic 13 amino acid peptide was synthesized and tested.
  • the cyclic 13-mer comprises amino acid residues 35-47 of saposin A and is flanked at the N- and C-terminus by cysteines which form a disulfide bond (CDWLPKPNMSASC, SEQ. ID. No. 37). It was determined that this peptide was sufficient to stimulate Tsp-1 and p53 ( FIG. 22 ). It has been demonstrated that PKC can phosphorylate ck1 (casein kinase 1) and that ck1 can regulate the interaction of p53 with MDM2 by phosphorylating MDM2.
  • WI-38 fibroblasts were treated with the cyclic 13-mer in the presence and absence of the casein kinase inhibitor D4476.
  • Western blot analysis revealed that the 13-mer induced the stimulation of p53 and Tsp-1 and the concomitant down regulation of MDM2, and inhibition of CKI by D4476 resulted in the reduction of Tsp-1 and p53 and increase in MDM2 protein levels ( FIG. 22 ).
  • the data indicate that saposin A binds to LRP1 through this 13 amino acid motif resulting in activation of a signal transduction pathway leading from PKC to CKI culminating in a reduction of MDM2 levels and resultant increase in p53 and Tsp-1 protein levels.
  • lymphatic endothelial cells LEC
  • PC3M-LN4 PC3M-LN4-Psap cells
  • PC3 cells inhibited the migration of LECs by 2-fold, while silencing of Psap in these cells resulted in a 1.5-fold increase in LEC migration.
  • PC3M-LN4 cells induced the migration of 2-fold more LECs/field, while ectopic expression of Prosaposin in these cells virtually abolished the stimulation of migration in a p53-dependent manner ( FIG. 23 ).
  • prosaposin stimulates the expression of semaphorin 3F, a transcriptional target of p53 and an inhibitor of metastasis and lymphangiogenesis, at the mRNA level ( FIG. 25 ).
  • Bone Stromal cells Prostate Lung Marrow Breast Skin Tumor cells PC3 ⁇ ⁇ ⁇ ⁇ ⁇ PC3M-LN4 ⁇ ⁇ ⁇ ⁇ ⁇ MDA-MB-231 ⁇ ⁇ ⁇ ⁇ ⁇ MDA-MET — ⁇ ⁇ — ⁇
  • Tsp-1 stimulating fractions of Heparin/Cu 2+ fractionated PC3 or LN4 conditioned media are the salt elution fractions at 0.7 M and 0.9 M NaCl respectively. Proteins present in all active fractions are highlighted in bold.
  • NP_002769 (SEQ. ID. No. 1) MYALFLLASLLGAALAGPVLGLKCTRGSAVWCQNVKTASDCGAVKHCLQT VWNKPTVKSLPCDICKDVVTAAGDMLKDNATILVYLKTCDWLPKPNMSAS CKIVDSYLPVILDIIKGMSRPGVCSALNLCSLQKHLALNHQKQLSNKIPL DMTVVAPFMANIPLLLYPQDGPRSKPQPKDNGDVCQDCIQMVTDIQTAVR TNSTFVQALVHVKCDRLGPGMADICKNYISQYSIAIQMMMHMQPKICALV GFCDVKMPMQTLVPAKVASKNVIPALLVPIKKHVPAKSDVYCVCFLVKVT KLIDNNKTKILDAFDKMCSKLPKSLSCQVVDTYGSSILSILLVSPLVCSM LHLCSGTRLPALTVHVTQPKDGGFCVCKKLVGYLDRNLKNSTKQILAALK GCSFLPDPYQKQCDQFVA
US12/640,788 2007-06-22 2009-12-17 Methods and uses thereof of prosaposin Abandoned US20100144603A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
US12/640,788 US20100144603A1 (en) 2007-06-22 2009-12-17 Methods and uses thereof of prosaposin
EP18153550.1A EP3366695B1 (fr) 2009-12-17 2010-12-17 Peptides dérivés de la saposine-a et leurs utilisations
CA2822026A CA2822026C (fr) 2009-12-17 2010-12-17 Peptides derives de saposine a et utilisations de ceux-ci
PCT/US2010/061007 WO2011084685A2 (fr) 2009-12-17 2010-12-17 Peptides dérivés de saposine a et utilisations de ceux-ci
AU2010339794A AU2010339794B2 (en) 2009-12-17 2010-12-17 Saposin-A derived peptides and uses thereof
US13/516,511 US10267799B2 (en) 2007-06-22 2010-12-17 Saposin-A derived peptides and uses thereof
EP21170894.6A EP3925670A1 (fr) 2009-12-17 2010-12-17 Peptides dérivés de la saposine-a et leurs utilisations
EP10842644.6A EP2513137B1 (fr) 2009-12-17 2010-12-17 Peptides dérivés de saposine a et utilisations de ceux-ci
AU2016222333A AU2016222333B2 (en) 2009-12-17 2016-08-30 Saposin-a derived peptides and uses thereof
AU2018201649A AU2018201649B2 (en) 2009-12-17 2018-03-07 Saposin-a derived peptides and uses thereof
US16/379,193 US10670600B2 (en) 2007-06-22 2019-04-09 Saposin-A derived peptides and uses thereof
AU2020200165A AU2020200165B2 (en) 2009-12-17 2020-01-09 Saposin-a derived peptides and uses thereof
US16/867,560 US20210102945A1 (en) 2007-06-22 2020-05-05 Saposin-a derived peptides and uses thereof
AU2021261975A AU2021261975B2 (en) 2009-12-17 2021-11-05 Saposin-a derived peptides and uses thereof
AU2023219929A AU2023219929A1 (en) 2009-12-17 2023-08-24 Saposin-a derived peptides and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93679207P 2007-06-22 2007-06-22
PCT/US2008/067899 WO2009002931A2 (fr) 2007-06-22 2008-06-23 Procédés et utilisations de prosaposine
US12/640,788 US20100144603A1 (en) 2007-06-22 2009-12-17 Methods and uses thereof of prosaposin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/067899 Continuation-In-Part WO2009002931A2 (fr) 2007-06-22 2008-06-23 Procédés et utilisations de prosaposine

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2010/061007 Continuation WO2011084685A2 (fr) 2007-06-22 2010-12-17 Peptides dérivés de saposine a et utilisations de ceux-ci
US13/516,511 Continuation US10267799B2 (en) 2007-06-22 2010-12-17 Saposin-A derived peptides and uses thereof

Publications (1)

Publication Number Publication Date
US20100144603A1 true US20100144603A1 (en) 2010-06-10

Family

ID=40186257

Family Applications (4)

Application Number Title Priority Date Filing Date
US12/640,788 Abandoned US20100144603A1 (en) 2007-06-22 2009-12-17 Methods and uses thereof of prosaposin
US13/516,511 Active US10267799B2 (en) 2007-06-22 2010-12-17 Saposin-A derived peptides and uses thereof
US16/379,193 Active US10670600B2 (en) 2007-06-22 2019-04-09 Saposin-A derived peptides and uses thereof
US16/867,560 Pending US20210102945A1 (en) 2007-06-22 2020-05-05 Saposin-a derived peptides and uses thereof

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13/516,511 Active US10267799B2 (en) 2007-06-22 2010-12-17 Saposin-A derived peptides and uses thereof
US16/379,193 Active US10670600B2 (en) 2007-06-22 2019-04-09 Saposin-A derived peptides and uses thereof
US16/867,560 Pending US20210102945A1 (en) 2007-06-22 2020-05-05 Saposin-a derived peptides and uses thereof

Country Status (5)

Country Link
US (4) US20100144603A1 (fr)
EP (3) EP3666284A1 (fr)
AU (1) AU2008268461B2 (fr)
CA (2) CA3056116A1 (fr)
WO (1) WO2009002931A2 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053224A1 (en) * 2007-08-02 2009-02-26 Arresto Biosciences Lox and loxl2 inhibitors and uses thereof
US20100209415A1 (en) * 2009-01-06 2010-08-19 Victoria Smith Chemotherapeutic methods and compositions
US20110044981A1 (en) * 2009-08-21 2011-02-24 Spangler Rhyannon Methods and compositions for treatment of pulmonary fibrotic disorders
US20110044907A1 (en) * 2009-08-21 2011-02-24 Derek Marshall In vivo screening assays
US20110076272A1 (en) * 2009-08-21 2011-03-31 Victoria Smith Therapeutic methods and compositions
US20110076739A1 (en) * 2009-08-21 2011-03-31 Mccauley Scott Catalytic domains from lysyl oxidase and loxl2
US20110207144A1 (en) * 2009-08-21 2011-08-25 Derek Marshall In vitro screening assays
US8680246B2 (en) 2010-02-04 2014-03-25 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
US20140086845A1 (en) * 2011-05-09 2014-03-27 Children's Hospital Medical Center Method for imaging a site of arthritis in an animal
US8815823B2 (en) 2002-11-27 2014-08-26 Technion Research & Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
WO2014151840A1 (fr) 2013-03-14 2014-09-25 Children's Medical Center Corporation Utilisation de cd36 pour identifier des sujets atteints de cancer à des fins de traitement
CN106659764A (zh) * 2014-03-26 2017-05-10 儿童医学中心公司 环状鞘脂激活蛋白原肽及其用途
US10267799B2 (en) 2007-06-22 2019-04-23 Children's Medical Center Corporation Saposin-A derived peptides and uses thereof
CN110650751A (zh) * 2017-03-22 2020-01-03 儿童医学中心公司 Lrp1结合剂及其用途
US10736935B2 (en) 2011-12-22 2020-08-11 Children's Medical Center Corporation Saposin-A derived peptides and uses thereof
US11840563B2 (en) 2017-03-22 2023-12-12 Children's Medical Center Corporation Methods of treating cancer by administering inhibitory RNA molecules targeting protease serine 2 (PRSS2) expression

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3399450A1 (fr) 2006-05-18 2018-11-07 Caris MPI, Inc. Système et procédé permettant de déterminer une intervention médicale individualisée pour un état pathologique
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CA2716055A1 (fr) * 2008-02-21 2009-11-19 Shahriar Koochekpour Saposine c et psap humaines recombinantes biologiquement actives
CA2743211A1 (fr) 2008-11-12 2010-05-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Procedes et systemes d'utilisation d'exosomes pour determiner des phenotypes
AU2010339794B2 (en) * 2009-12-17 2016-09-22 Children's Medical Center Corporation Saposin-A derived peptides and uses thereof
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
MX2020003965A (es) * 2017-10-03 2020-10-05 Prevail Therapeutics Inc Terapias genicas para los trastornos lisosomales.
WO2023114169A1 (fr) * 2021-12-13 2023-06-22 Hessian Labs, Inc. Méthodes de détermination du pronostic et du stade d'une maladie ou d'une affection

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696080A (en) * 1993-07-30 1997-12-09 Myelos Neurosciences Corporation Pharmaceutical compositions comprising neurotrophic peptides derived from prosaposin
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
US20020177551A1 (en) * 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US6500431B1 (en) * 1998-07-13 2002-12-31 University Of Southern California Inhibitors of angiogenesis and tumor growth
US20040120961A1 (en) * 2002-12-20 2004-06-24 Shahriar Koochekpour Saposin C and receptors as targets for treatment of benign and malignant disorders
US20040229799A1 (en) * 2003-04-28 2004-11-18 Xiaoyang Qi Saposin C-DOPS: a novel anti-tumor agent
US20060275274A1 (en) * 2003-03-26 2006-12-07 Daria Onichtchouk Use of saposin-related proteins for preventing and treating obesity, diabetes and/or metabolic syndrome
US20070099251A1 (en) * 2005-10-17 2007-05-03 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20130072425A1 (en) * 2007-06-22 2013-03-21 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US548257A (en) 1895-10-22 Hay rake and loader
US684780A (en) 1901-02-28 1901-10-22 Newton S Beale Corn-crib.
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3837376A (en) 1971-06-01 1974-09-24 Metropolitan Pathology Labor I Blood serum collection tube and method
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3413608A1 (de) 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4656035A (en) 1984-12-21 1987-04-07 University Of Tennessee Research Corporation Method of separating blood platelets
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US5180816A (en) 1988-08-24 1993-01-19 Centocor One vial method for labeling protein/linker conjugates with technetium-99M
GB2236186B (en) 1989-08-22 1994-01-05 Finnigan Mat Gmbh Process and device for laser desorption of analyte molecular ions, especially of biomolecules
US5045694A (en) 1989-09-27 1991-09-03 The Rockefeller University Instrument and method for the laser desorption of ions in mass spectrometry
EP0834576B1 (fr) 1990-12-06 2002-01-16 Affymetrix, Inc. (a Delaware Corporation) Détection de séquences d'acides nucléiques
WO1992020820A1 (fr) 1991-05-15 1992-11-26 Vanderbilt University Methode de determination du potentiel metastatique des cellules tumorales
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
AU681082B2 (en) 1992-05-06 1997-08-21 Gen-Probe Incorporated Nucleic acid sequence amplification method, composition and kit
PT700521E (pt) 1993-05-28 2003-10-31 Baylor College Medicine Metodo e espectrometro de massa para dessorcao e ionizacao de analitos
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
US6379897B1 (en) 2000-11-09 2002-04-30 Nanogen, Inc. Methods for gene expression monitoring on electronic microarrays
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
GB9608130D0 (en) 1996-04-19 1996-06-26 Univ Sheffield Adam proteins and uses thereof
US5817752A (en) * 1996-06-06 1998-10-06 La Jolla Pharmaceutical Company Cyclic polypeptides comprising a thioether linkage and methods for their preparation
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
EP1011709A4 (fr) * 1997-09-09 2003-06-18 Univ California Inhibition de l'apoptose au moyen d'agonistes du recepteur de la prosaposine
WO1999045026A1 (fr) 1998-03-05 1999-09-10 Chiron Corporation Procede d'augmentation de la demi-vie serique d'une molecule biologiquement active
US6638911B1 (en) 1998-05-05 2003-10-28 Adherex Technologies Inc. Compounds and methods for modulating desmosomal cadherin-mediated functions
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
CA2255430C (fr) 1998-12-10 2003-08-26 P. Wedge Co. Ltd. Dispositif articule pour pylone de manche a vent
US20020182702A1 (en) 1999-05-27 2002-12-05 Ruben Steven M. ADAM polynucleotides, polypeptides, and antibodies
CA2377244A1 (fr) 1999-08-02 2001-02-08 Synt:Em S.A. Methodes de conception par ordinateur destinees a la production de mimetiques moleculaires
AU7262700A (en) 1999-09-07 2001-04-10 Viventia Biotech Inc. Enhanced phage display library of human vh fragments and methods for producing same
US7429466B2 (en) 2000-01-24 2008-09-30 Hypromatrix, Inc Methods and arrays for detecting biological molecules
JP4382322B2 (ja) 2000-03-09 2009-12-09 カリディアンビーシーティ、インコーポレイテッド 体外血液処理装置
US20020168639A1 (en) * 2000-09-22 2002-11-14 Muraca Patrick J. Profile array substrates
CN1463291A (zh) 2001-04-19 2003-12-24 赛弗根生物系统股份有限公司 用质谱法和亲和标记物鉴定生物分子的特性
IL159015A0 (en) 2001-05-25 2004-05-12 Genset Sa Polypeptides, their preparation and use
US7112408B2 (en) 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
US8068987B2 (en) 2001-08-13 2011-11-29 Bg Medicine, Inc. Method and system for profiling biological systems
US20030215858A1 (en) 2002-04-08 2003-11-20 Baylor College Of Medicine Enhanced gene expression system
AU2003239152A1 (en) 2002-04-23 2003-11-10 Millipore Corporation Sample preparation of biological fluids for proteomic applications
US20030205538A1 (en) 2002-05-03 2003-11-06 Randel Dorian Methods and apparatus for isolating platelets from blood
US20040219609A1 (en) * 2002-07-12 2004-11-04 Day Anthony G. Methods for modulating proteins not previously known as proteases
AU2010339794B2 (en) 2009-12-17 2016-09-22 Children's Medical Center Corporation Saposin-A derived peptides and uses thereof
EP4306123A3 (fr) 2011-12-22 2024-04-17 Children's Medical Center Corporation Peptides dérivés de la saposine-a et leurs utilisations
ES2872403T3 (es) 2013-03-14 2021-11-02 Childrens Medical Center Péptido Psap para el tratamiento de cánceres que expresan CD36

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
US5714459A (en) * 1993-07-30 1998-02-03 Myelos Neurosciences Corp. Use of prosaposin and neurotrophic peptides derived therefrom
US5696080A (en) * 1993-07-30 1997-12-09 Myelos Neurosciences Corporation Pharmaceutical compositions comprising neurotrophic peptides derived from prosaposin
US7341730B1 (en) * 1998-07-13 2008-03-11 University Of Southern California Inhibitors of angiogenesis and tumor growth
US6500431B1 (en) * 1998-07-13 2002-12-31 University Of Southern California Inhibitors of angiogenesis and tumor growth
US20020177551A1 (en) * 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US20040120961A1 (en) * 2002-12-20 2004-06-24 Shahriar Koochekpour Saposin C and receptors as targets for treatment of benign and malignant disorders
US7166691B2 (en) * 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
US20060275274A1 (en) * 2003-03-26 2006-12-07 Daria Onichtchouk Use of saposin-related proteins for preventing and treating obesity, diabetes and/or metabolic syndrome
US20040229799A1 (en) * 2003-04-28 2004-11-18 Xiaoyang Qi Saposin C-DOPS: a novel anti-tumor agent
US20090269373A1 (en) * 2003-04-28 2009-10-29 Children's Hospital Medical Center Saposin C-DOPS: A Novel Anti-Tumor Agent
US20070099251A1 (en) * 2005-10-17 2007-05-03 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20130072425A1 (en) * 2007-06-22 2013-03-21 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Morimoto (Proc Natl Acad Sci 86, 3389-93, 1989) *
O'Brien (FASEB J. 5: 301-308, 1991) *
O'Brien (Science 241, 1098-1101, 1988) *

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815823B2 (en) 2002-11-27 2014-08-26 Technion Research & Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
US10670600B2 (en) 2007-06-22 2020-06-02 Children's Medical Center Corporation Saposin-A derived peptides and uses thereof
US10267799B2 (en) 2007-06-22 2019-04-23 Children's Medical Center Corporation Saposin-A derived peptides and uses thereof
US10494443B2 (en) 2007-08-02 2019-12-03 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
US20090053224A1 (en) * 2007-08-02 2009-02-26 Arresto Biosciences Lox and loxl2 inhibitors and uses thereof
US8461303B2 (en) 2007-08-02 2013-06-11 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
US9176139B2 (en) 2007-08-02 2015-11-03 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
US20090104201A1 (en) * 2007-08-02 2009-04-23 Victoria Smith Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US8658167B2 (en) 2007-08-02 2014-02-25 Gilead Biologics, Inc. Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US8679485B2 (en) 2007-08-02 2014-03-25 Gilead Biologics, Inc. Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US9289447B2 (en) 2009-01-06 2016-03-22 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US20100209415A1 (en) * 2009-01-06 2010-08-19 Victoria Smith Chemotherapeutic methods and compositions
US20110044907A1 (en) * 2009-08-21 2011-02-24 Derek Marshall In vivo screening assays
US20110044981A1 (en) * 2009-08-21 2011-02-24 Spangler Rhyannon Methods and compositions for treatment of pulmonary fibrotic disorders
US20110076739A1 (en) * 2009-08-21 2011-03-31 Mccauley Scott Catalytic domains from lysyl oxidase and loxl2
US8927700B2 (en) 2009-08-21 2015-01-06 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2
US8512990B2 (en) 2009-08-21 2013-08-20 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2
US20110207144A1 (en) * 2009-08-21 2011-08-25 Derek Marshall In vitro screening assays
US20110076272A1 (en) * 2009-08-21 2011-03-31 Victoria Smith Therapeutic methods and compositions
US8680246B2 (en) 2010-02-04 2014-03-25 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
US20140086845A1 (en) * 2011-05-09 2014-03-27 Children's Hospital Medical Center Method for imaging a site of arthritis in an animal
US9585972B2 (en) * 2011-05-09 2017-03-07 Sherry L. Thornton Method for imaging a site of arthritis in an animal
US11590196B2 (en) 2011-12-22 2023-02-28 Children's Medical Center Corporation Saposin-A derived peptides and uses thereof
US10736935B2 (en) 2011-12-22 2020-08-11 Children's Medical Center Corporation Saposin-A derived peptides and uses thereof
EP3919070A1 (fr) * 2013-03-14 2021-12-08 Children's Medical Center, Corp. Utilisation de cd36 pour identifier des sujets atteints de cancer pour le traitement
WO2014151840A1 (fr) 2013-03-14 2014-09-25 Children's Medical Center Corporation Utilisation de cd36 pour identifier des sujets atteints de cancer à des fins de traitement
US10175243B2 (en) 2013-03-14 2019-01-08 Children's Medical Center Corporation Use of CD36 to identify cancer subjects for treatment
EP2971166A4 (fr) * 2013-03-14 2016-12-07 Children's Medical Center Corp Utilisation de cd36 pour identifier des sujets atteints de cancer à des fins de traitement
US9921224B2 (en) 2013-03-14 2018-03-20 Children's Medical Center Corporation Use of CD36 to identify cancer subjects for treatment
CN105358708A (zh) * 2013-03-14 2016-02-24 儿童医学中心公司 Cd36鉴定癌症对象以用于治疗的用途
US10646541B2 (en) 2014-03-26 2020-05-12 Children's Medical Center Corporation Cyclic prosaposin peptides and uses thereof
US11191805B2 (en) 2014-03-26 2021-12-07 Children's Medical Center Corporation Cyclic prosaposin peptides and uses thereof
US11654178B2 (en) 2014-03-26 2023-05-23 Children's Medical Center Corporation Cyclic prosaposin peptides and uses thereof
CN113908253A (zh) * 2014-03-26 2022-01-11 儿童医学中心公司 环状鞘脂激活蛋白原肽及其用途
CN106659764A (zh) * 2014-03-26 2017-05-10 儿童医学中心公司 环状鞘脂激活蛋白原肽及其用途
CN110650751A (zh) * 2017-03-22 2020-01-03 儿童医学中心公司 Lrp1结合剂及其用途
US11840563B2 (en) 2017-03-22 2023-12-12 Children's Medical Center Corporation Methods of treating cancer by administering inhibitory RNA molecules targeting protease serine 2 (PRSS2) expression

Also Published As

Publication number Publication date
US20130072425A1 (en) 2013-03-21
US20200081007A1 (en) 2020-03-12
US10267799B2 (en) 2019-04-23
CA2692171C (fr) 2019-10-22
CA3056116A1 (fr) 2008-12-31
WO2009002931A3 (fr) 2011-03-03
EP3127549A1 (fr) 2017-02-08
US10670600B2 (en) 2020-06-02
EP3666284A1 (fr) 2020-06-17
EP3127549B1 (fr) 2019-12-18
US20210102945A1 (en) 2021-04-08
AU2008268461A1 (en) 2008-12-31
EP2190448B1 (fr) 2016-04-20
AU2008268461B2 (en) 2015-04-09
EP2190448A2 (fr) 2010-06-02
CA2692171A1 (fr) 2008-12-31
WO2009002931A2 (fr) 2008-12-31

Similar Documents

Publication Publication Date Title
US10670600B2 (en) Saposin-A derived peptides and uses thereof
AU2021261975B2 (en) Saposin-a derived peptides and uses thereof
US11590196B2 (en) Saposin-A derived peptides and uses thereof
AU2017201638B2 (en) Methods and uses thereof of prosaposin
Class et al. Patent application title: SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF Inventors: Randolph Watnick (Newton, MA, US) Assignees: CHILDREN'S MEDICAL CENTER CORPORATION

Legal Events

Date Code Title Description
AS Assignment

Owner name: CHILDREN'S MEDICAL CENTER CORPORATION,MASSACHUSETT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WATNICK, RANDOLPH;REEL/FRAME:023723/0462

Effective date: 20080728

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION